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PREAMBLE
The American College of Cardiology (ACC) and the
American Heart Association (AHA) are committed to the
prevention and management of cardiovascular diseases
through professional education and research for clini-
cians, providers, and patients. Since 1980, the ACC and
AHA have shared a responsibility to translate scientiﬁc
evidence into clinical practice guidelines (CPGs) with
recommendations to standardize and improve car-
diovascular health. These CPGs, based on systematic
methods to evaluate and classify evidence, provide a
cornerstone of quality cardiovascular care.
In response to published reports from the Institute of
Medicine (1,2) and the ACC/AHA’s mandate to evaluate
new knowledge and maintain relevance at the point of
care, the ACC/AHA Task Force on Practice Guidelines
(Task Force) began modifying its methodology. This
modernization effort is published in the 2012 Methodol-
ogy Summit Report (3) and 2014 perspective article (4).
The latter recounts the history of the collaboration,
changes over time, current policies, and planned initia-
tives to meet the needs of an evolving healthcare envi-
ronment. Recommendations on value in proportion to
resource utilization will be incorporated as high-qualitycomparative-effectiveness data become available (5).
The relationships between CPGs and data standards,
appropriate use criteria, and performance measures are
addressed elsewhere (4).
Intended Use—CPGs provide recommendations applicable
to patients with or at risk of developing cardiovascular
disease. The focus is on medical practice in the United
States, but CPGs developed in collaboration with other
organizations may have a broader target. Although CPGs
may be used to inform regulatory or payer decisions, the
intent is to improve the quality of care and be aligned
with the patient’s best interest.
Evidence Review—Guideline writing committee (GWC)
members are charged with reviewing the literature;
weighing the strength and quality of evidence for or
against particular tests, treatments, or procedures; and
estimating expected health outcomes when data exist. In
analyzing the data and developing CPGs, the GWC uses
evidence-based methodologies developed by the Task
Force (6). A key component of the ACC/AHA CPG meth-
odology is the development of recommendations on the
basis of all available evidence. Literature searches focus
on randomized controlled trials (RCTs) but also include
registries, nonrandomized comparative and descriptive
studies, case series, cohort studies, systematic reviews,
and expert opinion. Only selected references are cited in
the CPG. To ensure that CPGs remain current, new data
are reviewed biannually by the GWCs and the Task Force
to determine if recommendations should be updated or
modiﬁed. In general, a target cycle of 5 years is planned
for full revisions (1).
Guideline-Directed Medical Therapy—Recognizing ad-
vances in medical therapy across the spectrum of car-
diovascular diseases, the Task Force designated the term
“guideline-directed medical therapy” (GDMT) to repre-
sent recommended medical therapy as deﬁned mainly by
Class I measures, generally a combination of lifestyle
modiﬁcation and drug- and device-based therapeutics. As
medical science advances, GDMT evolves, and hence
GDMT is preferred to “optimal medical therapy.” For
GDMT and all other recommended drug treatment regi-
mens, the reader should conﬁrm the dosage with product
insert material and carefully evaluate for contraindica-
tions and possible drug interactions. Recommendations
are limited to treatments, drugs, and devices approved for
clinical use in the United States.
Class of Recommendation and Level of Evidence—Once
recommendations are written, the Class of Recommendation
(COR; i.e., the strength the GWC assigns to the recommenda-
tion, which encompasses the anticipated magnitude and
judged certainty of beneﬁt in proportion to risk) is assigned by
the GWC. Concurrently, the Level of Evidence (LOE) rates the
scientiﬁc evidence supporting the effect of the intervention on
the basis on the type, quality, quantity, and consistency of data
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the clinical practice guidelines do not
lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons
of the treatments or strategies being evaluated.
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e143from clinical trials and other reports (Table 1) (4). Unless
otherwise stated, recommendations are presented in order by
the COR and then the LOE. Where comparative data exist,
preferred strategies take precedence. When more than 1 drug,
strategy, or therapy exists within the same COR and LOE and
there arenocomparativedata, optionsare listedalphabetically.
Relationships With Industry and Other Entities—The ACC
and AHA exclusively sponsor the work of GWCs without
commercial support, and members volunteer their time
for this activity. The Task Force makes every effort to
avoid actual, potential, or perceived conﬂicts of interest
that might arise through relationships with industry orother entities (RWI). All GWC members and reviewers are
required to fully disclose current industry relationships
or personal interests from 12 months before initiation
of the writing effort. Management of RWI involves
selecting a balanced GWC and requires that both the chair
and a majority of GWC members have no relevant RWI
(see Appendix 1 for the deﬁnition of relevance). GWC
members are restricted with regard to writing or voting
on sections to which their RWI apply. In addition, for
transparency, GWC members’ comprehensive disclosure
information is available as an online supplement. Com-
prehensive disclosure information for the Task Force is
*Estimate includes secondary discharge diagnoses.
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e144available as an additional supplement. The Task Force
strives to avoid bias by selecting experts from a broad
array of backgrounds representing different geographic
regions, sexes, ethnicities, races, intellectual perspec-
tives/biases, and scopes of clinical practice. Selected or-
ganizations and professional societies with related
interests and expertise are invited to participate as part-
ners or collaborators.
Individualizing Care in Patients With Associated Conditions
and Comorbidities—The ACC and AHA recognize the
complexity of managing patients with multiple condi-
tions, compared with managing patients with a single
disease, and the challenge is compounded when CPGs
for evaluation or treatment of several coexisting illnesses
are discordant or interacting (7). CPGs attempt to deﬁne
practices that meet the needs of patients in most, but not
all, circumstances and do not replace clinical judgment.
Clinical Implementation—Management in accordance
with CPG recommendations is effective only when fol-
lowed; therefore, to enhance their commitment to treat-
ment and compliance with lifestyle adjustment, clinicians
should engage the patient to participate in selecting
interventions on the basis of the patient’s individual
values and preferences, taking associated conditions and
comorbidities into consideration (e.g., shared decision
making). Consequently, there are circumstances in which
deviations from these guidelines are appropriate.
The recommendations in this CPG are the ofﬁcial policy of
the ACC and AHA until they are superseded by a published
addendum, focused update, or revised full-text CPG.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this CPG are, whenever
possible, evidence based. An extensive evidence review was
conducted through October 2012, and other selected refer-
ences published through April 2014 were reviewed by the
GWC. Literature included was derived from research
involving human subjects, published in English, and indexed
in MEDLINE (through PubMed), EMBASE, the Cochrane
Library, Agency for Healthcare Research and Quality Reports,
and other selected databases relevant to this CPG. The rele-
vant data are included in evidence tables in the Online Data
Supplement. Key search words included but were not
limited to the following: acute coronary syndrome, anticoag-
ulant therapy, antihypertensives, anti-ischemic therapy, anti-
platelet therapy, antithrombotic therapy, beta blockers,
biomarkers, calcium channel blockers, cardiac rehabilitation,
conservative management, diabetes mellitus, glycoprotein IIb/
IIIa inhibitors, heart failure, invasive strategy, lifestyle modiﬁ-
cation,myocardial infarction, nitrates, non–ST-elevation, P2Y12receptor inhibitor, percutaneous coronary intervention, renin-
angiotensin-aldosterone inhibitors, secondary prevention,
smoking cessation, statins, stent, thienopyridines, troponins,
unstable angina, and weight management. Additionally, the
GWC reviewed documents related to non–ST-elevation acute
coronary syndrome (NSTE-ACS) previously published by the
ACC and AHA. References selected and published in this
document are representative and not all-inclusive.
1.2. Organization of the GWC
TheGWCwas composed of clinicians, cardiologists, internists,
interventionists, surgeons, emergency medicine specialists,
family practitioners, and geriatricians. The GWC included
representatives from the ACC andAHA, American Academy of
Family Physicians, American College of Emergency Physi-
cians, American College of Physicians, Society for Cardiovas-
cular Angiography and Interventions (SCAI), and Society of
Thoracic Surgeons (STS).
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by the ACC and AHA; 1 reviewer each from the
American Academy of Family Physicians, American Col-
lege of Emergency Physicians, SCAI, and STS; and 37
individual content reviewers (including members of the
American Association of Clinical Chemistry, ACC Heart
Failure and Transplant Section Leadership Council, ACC
Cardiovascular Imaging Section Leadership Council, ACC
Interventional Section Leadership Council, ACC Preven-
tion of Cardiovascular Disease Committee, ACC Surgeons’
Council, Association of International Governors, and
Department of Health and Human Services). Reviewers’
RWI information was distributed to the GWC and is pub-
lished in this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and the AHA and endorsed
by the American Association for Clinical Chemistry, SCAI,
and the STS.
1.4. Scope of the CPG
The 2014 NSTE-ACS CPG is a full revision of the 2007 ACCF/
AHACPGfor themanagementofpatientswithunstableangina
(UA) and non–ST-elevation myocardial infarction (NSTEMI)
and the 2012 focused update (8). The new title, “Non–ST-
Elevation Acute Coronary Syndromes,” emphasizes the con-
tinuum between UA and NSTEMI. At presentation, patients
with UA and NSTEMI can be indistinguishable and are there-
fore considered together in this CPG.
In the United States, NSTE-ACS affects >625,000
patients annually,* or almost three fourths of all patients
with acute coronary syndrome (ACS) (9). In selecting the
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strategy” has replaced the previous descriptor, “initial
conservative management,” to more clearly convey the
physiological rationale of this approach.
The task of the 2014 GWC was to establish a contem-
porary CPG for the optimal management of patients with
NSTE-ACS. It incorporates both established and new evi-
dence from published clinical trials, as well as informa-
tion from basic science and comprehensive review
articles. These recommendations were developed toTABLE 2 Associated CPGs and Statements
Title
CPGs
Stable ischemic heart disease
Atrial ﬁbrillation
Assessment of cardiovascular risk
Heart failure
Lifestyle management to reduce cardiovascular risk
Management of overweight and obesity in adults
ST-elevation myocardial infarction
Treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults
Acute myocardial infarction in patients presenting with ST-segment elevation
Device-based therapy
Third universal deﬁnition of myocardial infarction
Acute coronary syndromes in patients presenting without persistent ST-segment elev
Coronary artery bypass graft surgery
Hypertrophic cardiomyopathy
Effectiveness-based guidelines for the prevention of cardiovascular disease in women
Percutaneous coronary intervention
Secondary prevention and risk reduction therapy for patients with coronary and othe
atherosclerotic vascular disease
Assessment of cardiovascular risk in asymptomatic adults
Myocardial revascularization
Unstable angina and non–ST-elevation myocardial infarction
Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care—par
postcardiac arrest care
Seventh report of the joint national committee on prevention, detection, evaluation,
treatment of high blood pressure
Statements
Key data elements and deﬁnitions for measuring the clinical management and outcom
patients with acute coronary syndromes and coronary artery disease
Practical clinical considerations in the interpretation of troponin elevations
Testing of low-risk patients presenting to the emergency department with chest pain
Primary prevention of cardiovascular diseases in people with diabetes mellitus
Prevention and control of inﬂuenza
*The full-text SIHD CPG is from 2012 (11). A focused update was published in 2014 (10).
†Minor modiﬁcations were made in 2013. For a full explanation of the changes, see http://p
AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiolo
for Disease Control and Prevention; CPG, clinical practice guideline; ESC, European Society of C
NICE, National Institute for Health and Clinical Excellence; PCNA, Preventive Cardiovascular N
stable ischemic heart disease; STS, Society of Thoracic Surgeons; TOS, The Obesity Society; aguide the clinician in improving outcomes for patients
with NSTE-ACS. Table 2 lists documents deemed per-
tinent to this effort and is intended for use as a re-
source, thus obviating the need to repeat extant CPG
recommendations.
The GWC abbreviated the discussion sections to
include an explanation of salient information related to
the recommendations. In contrast to textbook declaratory
presentations, explanations were supplemented with
evidence tables. The GWC also provided a brief summaryOrganization
Publication Year
(Reference)
ACC/AHA/AATS/PCNA/SCAI/STS 2014 (10)*
2012 (11)
AHA/ACC/HRS 2014 (12)
ACC/AHA 2013 (13)
ACC/AHA 2013 (14)
AHA/ACC 2013 (15)
AHA/ACC/TOS 2013 (16)
ACC/AHA 2013 (17)
ACC/AHA 2013 (18)
ESC 2012 (19)
ACC/AHA/HRS 2013 (20)
ESC/ACC/AHA/WHF 2012 (21)
ation ESC 2011 (22)
ACC/AHA 2011 (23)
ACC/AHA 2011 (24)
AHA/ACC 2011 (25)
ACC/AHA/SCAI 2011 (26)
r AHA/ACC 2011 (27)
ACC/AHA 2010 (28)
ESC 2010 (29)
NICE 2010 (30)†
t 9: AHA 2010 (31)
and NHLBI 2003 (32)
es of ACC/AHA 2013 (33)
ACC 2012 (34)
AHA 2010 (35)
AHA/ADA 2007 (36)
CDC 2005 (37)
ublications.nice.org.uk/unstable-angina-and-nstemi-cg94/changes-after-publication.
gy; ADA, American Diabetes Association; AHA, American Heart Association; CDC, Centers
ardiology; HRS, Heart Rhythm Society; NHLBI, National Heart, Lung, and Blood Institute;
urses Association; SCAI, Society for Cardiovascular Angiography and Interventions; SIHD,
nd WHF, World Heart Federation.
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to secondary prevention rather than detailed reiteration.
Throughout, the goal was to provide the clinician with
concise, evidence-based contemporary recommendations
and the supporting documentation to encourage their
application.
2. OVERVIEW OF ACS
2.1. Deﬁnition of Terms
ACS has evolved as a useful operational term that refers to
a spectrum of conditions compatible with acute myocar-
dial ischemia and/or infarction that are usually due to an
abrupt reduction in coronary blood ﬂow (Figure 1). A key
branch point is ST-segment elevation (ST-elevation) or
new left bundle-branch block on the electrocardiogram
(ECG), which is an indication for immediate coronary
angiography to determine if there is an indication for
reperfusion therapy to open a likely completely occluded
coronary artery. Separate CPGs have been developed for
ST-elevation myocardial infarction (STEMI) (17).
The absence of persistent ST-elevation is suggestive
of NSTE-ACS (except in patients with true posterior
myocardial infarction [MI], Sections 3.3.2.4, 4.3.2, and
7.2.2). NSTE-ACS can be further subdivided on the basis of
cardiac biomarkers of necrosis (e.g., cardiac troponin,
Sections 3.2.4 and 3.4). If cardiac biomarkers are elevated
and the clinical context is appropriate, the patient is
considered to have NSTEMI (34); otherwise, the patient
is deemed to have UA. ST depression, transient ST-
elevation, and/or prominent T-wave inversions may be
present but are not required for a diagnosis of NSTEMI.
Abnormalities on the ECG and elevated troponins in
isolation are insufﬁcient to make the diagnosis of ACS but
must be interpreted in the appropriate clinical context.
Thus, UA and NSTEMI are closely related conditions
whose pathogenesis and clinical presentations are similar
but vary in severity. The conditions differ primarily by
whether the ischemia is severe enough to cause myocar-
dial damage leading to detectable quantities of myocar-
dial injury biomarkers. The term “possible ACS” is often
assigned during initial evaluation if the ECG is unreveal-
ing and troponin data are not yet available. UA can pre-
sent without any objective data of myocardial ischemic
injury (normal ECG and normal troponin), in which case
the initial diagnosis depends solely on the patient’s clin-
ical history and the clinician’s interpretation and judg-
ment. However, with the increasing sensitivity of
troponin assays, biomarker-negative ACS (i.e., UA) is
becoming rarer (39). The pathogenesis of ACS is consid-
ered in the “Third Universal Deﬁnition of Myocardial
Infarction” (21). This statement deﬁnes MI caused by a
primary coronary artery process such as spontaneous
plaque rupture as MI type 1 and one related to reducedmyocardial oxygen supply and/or increased myocardial
oxygen demand (in the absence of a direct coronary artery
process) as a MI type 2 (Appendix 4, Table A and Section
3.4 for an additional discussion on the diagnosis of MI).
2.2. Epidemiology and Pathogenesis
2.2.1. Epidemiology
In the United States, the median age at ACS presentation
is 68 years (interquartile range 56 to 79), and the male-to-
female ratio is approximately 3:2 (40). Some patients have
a history of stable angina, whereas in others, ACS is the
initial presentation of coronary artery disease (CAD). It is
estimated that in the United States, each year, >780,000
persons will experience an ACS. Approximately 70% of
these will have NSTE-ACS (9). Patients with NSTE-ACS
typically have more comorbidities, both cardiac and
noncardiac, than patients with STEMI.
2.2.2. Pathogenesis
The hallmark of ACS is the sudden imbalance between
myocardial oxygen consumption (MVO2) and demand,
which is usually the result of coronary artery obstruction.
The imbalance may also be caused by other conditions,
including excessive myocardial oxygen demand in the
setting of a stable ﬂow-limiting lesion; acute coronary
insufﬁciency due to other causes (e.g., vasospastic
[Prinzmetal] angina [Section 7.11], coronary embolism,
coronary arteritis); noncoronary causes of myocardial
oxygen supply-demand mismatch (e.g., hypotension,
severe anemia, hypertension, tachycardia, hypertrophic
cardiomyopathy, severe aortic stenosis); nonischemic
myocardial injury (e.g., myocarditis, cardiac contusion,
cardiotoxic drugs); and multifactorial causes that are not
mutually exclusive (e.g., stress [Takotsubo] cardiomyop-
athy [Section 7.13], pulmonary embolism, severe heart
failure [HF], sepsis) (41).
3. INITIAL EVALUATION AND MANAGEMENT
3.1. Clinical Assessment and Initial Evaluation:
Recommendation
CLASS I
1. Patients with suspected ACS should be risk stratiﬁed based
on the likelihood of ACS and adverse outcome(s) to decide on
the need for hospitalization and assist in the selection of
treatment options (42–44). (Level of Evidence: B)
Patients with suspected ACS must be evaluated rapidly to
identify those with a life-threatening emergency versus
those with a more benign condition. The goal of the initial
evaluation focuses on answering 2 questions:
1. What is the likelihood that the symptoms and signs
represent ACS?
2. What is the likelihood of adverse clinical outcome(s)?
FIGURE 1 Acute Coronary Syndromes
The top half of the ﬁgure illustrates the progression of plaque formation and onset and complications of NSTE-ACS, with management at each stage. The
numbered section of an artery depicts the process of atherogenesis from 1) normal artery to 2) extracellular lipid in the subintima to 3) ﬁbrofatty stage to 4)
procoagulant expression and weakening of the ﬁbrous cap. ACS develops with 5) disruption of the ﬁbrous cap, which is the stimulus for thrombogenesis. 6)
Thrombus resorption may be followed by collagen accumulation and smooth muscle cell growth. Thrombus formation and possible coronary vasospasm
reduce blood ﬂow in the affected coronary artery and cause ischemic chest pain. The bottom half of the ﬁgure illustrates the clinical, pathological, elec-
trocardiographic, and biomarker correlates in ACS and the general approach to management. Flow reduction may be related to a completely occlusive
thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Most patients with ST-elevation (thick white arrow in bottom
panel) develop QwMI, and a few (thin white arrow) develop NQMI. Those without ST-elevation have either UA or NSTEMI (thick red arrows), a distinction
based on cardiac biomarkers. Most patients presenting with NSTEMI develop NQMI; a few may develop QwMI. The spectrum of clinical presentations
including UA, NSTEMI, and STEMI is referred to as ACS. This NSTE-ACS CPG includes sections on initial management before NSTE-ACS, at the onset of NSTE-
ACS, and during the hospital phase. Secondary prevention and plans for long-term management begin early during the hospital phase. Patients with
noncardiac etiologies make up the largest group presenting to the ED with chest pain (dashed arrow).
*Elevated cardiac biomarker (e.g., troponin), Section 3.4.
ACS indicates acute coronary syndrome; CPG, clinical practice guideline; Dx, diagnosis; ECG, electrocardiogram; ED, emergency department; MI, myocardial
infarction; NQMI, non–Q-wave myocardial infarction; NSTE-ACS, non–ST-elevation acute coronary syndromes; NSTEMI, non–ST-elevation myocardial
infarction; QwMI, Q-wave myocardial infarction; STEMI, ST-elevation myocardial infarction; and UA, unstable angina.
Modiﬁed with permission from Libby et al. (38).
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using clinical history, physical examination, ECG, and
cardiac troponins have been developed to help identify
patients with ACS at increased risk of adverse outcome(s).
Common risk assessment tools include the TIMI (Throm-
bolysis In Myocardial Infarction) risk score (42), the PUR-
SUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrilin Therapy) risk score
(43), the GRACE (Global Registry of Acute Coronary
Events) risk score (44), and the NCDR-ACTION (National
Cardiovascular Data Registry-Acute Coronary Treatment
and Intervention Outcomes Network) registry (https://
www.ncdr.com/webncdr/action/). These assessment tools
have been applied with variable efﬁcacy to predict out-
comes in patients presenting to the emergency depart-
ment (ED) with undifferentiated chest pain (“pain”
encompasses not only pain, but also symptoms such as
discomfort, pressure, and squeezing) (45–48). The Sanchis
score (49), Vancouver rule (50), Heart (History, ECG, Age,
Risk Factors, and Troponin) score (51), HEARTS3 score (52),
and Hess prediction rule (53) were developed speciﬁcally
for patients in the ED with chest pain. Although no
deﬁnitive study has demonstrated the superiority of risk
assessment scores or clinical prediction rules over clinician
judgment, determination of the level of risk on initial
evaluation is imperative to guide patient management,
including the need for additional diagnostic testing and
treatment. See Section 3.2.2 for a discussion of risk strat-
iﬁcation variables.
See Online Data Supplement 1 for additional information
on clinical assessment and initial evaluation.
3.1.1. ED or Outpatient Facility Presentation: Recommendations
CLASS I
1. Patients with suspected ACS and high-risk features such as
continuing chest pain, severe dyspnea, syncope/presyncope,
or palpitations should be referred immediately to the ED and
transported by emergency medical services when available.
(Level of Evidence: C)
CLASS IIb
1. Patients with less severe symptoms may be considered for
referral to the ED, a chest pain unit, or a facility capable of
performing adequate evaluation depending on clinical
circumstances. (Level of Evidence: C)
Patients with suspected ACS and high-risk features should be
transported to the ED by emergency medical services when
available. Hospitals and outpatient facilities should provide
clearly visible signage directing patients transported by
private vehicle to the appropriate triage area. Outpatient
facilities should have the capacity for ECG and cardiac
troponin measurements with immediate ED referral for
those considered to have ACS.3.2. Diagnosis of NSTE-ACS
Differential diagnosis of NSTE-ACS includes (41):
 Nonischemic cardiovascular causes of chest pain
(e.g., aortic dissection, expanding aortic aneurysm,
pericarditis, pulmonary embolism)
 Noncardiovascular causes of chest, back, or upper
abdominal discomfort include:
o Pulmonary causes (e.g., pneumonia, pleuritis,
pneumothorax)
o Gastrointestinal causes (e.g., gastroesophageal re-
ﬂux, esophageal spasm, peptic ulcer, pancreatitis,
biliary disease)
o Musculoskeletal causes (e.g., costochondritis, cervi-
cal radiculopathy)
o Psychiatric disorders
o Other etiologies (e.g., sickle cell crisis, herpes zoster)
In addition, the clinician should differentiate NSTE-ACS from
acute coronary insufﬁciency due to a nonatherosclerotic
cause and noncoronary causes of myocardial oxygen supply-
demand mismatch (41) (Section 2.2.2).
3.2.1. History
NSTE-ACS most commonly presents as a pressure-type
chest pain that typically occurs at rest or with minimal
exertion lasting $10 minutes (41). The pain most
frequently starts in the retrosternal area and can radiate
to either or both arms, the neck, or the jaw. Pain may also
occur in these areas independent of chest pain. Patients
with NSTE-ACS may also present with diaphoresis, dys-
pnea, nausea, abdominal pain, or syncope. Unexplained
new-onset or increased exertional dyspnea is the most
common angina equivalent. Less common presentations
include nausea and vomiting, diaphoresis, unexplained
fatigue, and syncope. Factors that increase the probability
of NSTE-ACS are older age, male sex, positive family his-
tory of CAD, and the presence of peripheral arterial
disease, diabetes mellitus, renal insufﬁciency, prior MI,
and prior coronary revascularization. Although older pa-
tients ($75 years of age) and women usually present with
typical symptoms of ACS, the frequency of atypical pre-
sentations is increased in these groups aswell as in patients
with diabetes mellitus, impaired renal function, and
dementia (54,55). Atypical symptoms, including epigastric
pain, indigestion, stabbing or pleuritic pain, and increasing
dyspnea in the absence of chest pain should raise concern
for NSTE-ACS (56). Psychiatric disorders (e.g., somatoform
disorders, panic attack, anxiety disorders) are noncardiac
causes of chest pain that can mimic ACS (57).
3.2.2. Physical Examination
The physical examination in NSTE-ACS can be normal, but
signs of HF should expedite the diagnosis and treatment
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S4, a paradoxical splitting of S2, or a new murmur of mitral
regurgitation due to papillary muscle dysfunction. How-
ever, these signs may also exist without NSTE-ACS and
thus are nonspeciﬁc. The coupling of pain on palpation
suggesting musculoskeletal disease or inﬂammation with
a pulsatile abdominal mass suggesting abdominal aortic
aneurysm raises concern for nonischemic causes of NSTE-
ACS. The physical examination can indicate alternative
diagnoses in patients with chest pain, several of which are
life threatening. Aortic dissection is suggested by back
pain, unequal palpated pulse volume, a difference of $15
mm Hg between both arms in systolic blood pressure (BP),
or a murmur of aortic regurgitation. Acute pericarditis is
suggested by a pericardial friction rub. Cardiac tampo-
nade can be reﬂected by pulsus paradoxus. Pneumo-
thorax is suspected when acute dyspnea, pleuritic chest
pain, and differential breath sounds are present. A pleural
friction rub may indicate pneumonitis or pleuritis.
3.2.3. Electrocardiogram
A 12-lead ECG should be performed and interpreted within
10 minutes of the patient’s arrival at an emergency facility
to assess for cardiac ischemia or injury (21). Changes on
ECG in patients with NSTE-ACS include ST depression,
transient ST-elevation, or new T-wave inversion (21,58).
Persistent ST-elevation or anterior ST depression indica-
tive of true posterior MI should be treated according to the
STEMI CPG (17). The ECG can be relatively normal or
initially nondiagnostic; if this is the case, the ECG should
be repeated (e.g., at 15- to 30-minute intervals during the
ﬁrst hour), especially if symptoms recur (21). A normal ECG
does not exclude ACS and occurs in 1% to 6% of such pa-
tients (59–61). A normal ECG may also be associated with
left circumﬂex or right coronary artery occlusions, which
can be electrically silent (in which case posterior electro-
cardiographic leads [V7 to V9] may be helpful). Right-sided
leads (V3R to V4R) are typically performed in the case of
inferior STEMI to detect evidence of right ventricular
infarction. Left ventricular (LV) hypertrophy, bundle-
branch blocks with repolarization abnormalities, and
ventricular pacing may mask signs of ischemia/injury (62).
3.2.4. Biomarkers of Myocardial Necrosis
Cardiac troponins are the most sensitive and speciﬁc
biomarkers for NSTE-ACS. They rise within a few hours of
symptom onset and typically remain elevated for several
days (but may remain elevated for up to 2 weeks with a
large infarction). A negative cardiac troponin obtained
with more sensitive cardiac troponin assays on admission
confers a >95% negative predictive value for MI compared
with high-sensitivity assays that confer a negative pre-
dictive value $99% (63–65). See Section 3.4 for a detailed
review of biomarkers for the diagnosis of MI.3.2.5. Imaging
A chest roentgenogram is useful to identify potential
pulmonary causes of chest pain and may show a widened
mediastinum in patients with aortic dissection. Com-
puted tomography (CT) of the chest with intravenous
contrast can help exclude pulmonary embolism and aortic
dissection. Transthoracic echocardiography can identify a
pericardial effusion and tamponade physiology and may
also be useful to detect regional wall motion abnormal-
ities. Transesophageal echocardiography can identify a
proximal aortic dissection. In low-risk patients with chest
pain, coronary CT angiography can result in a more rapid,
more cost-effective diagnosis than stress myocardial
perfusion imaging (66).
3.3. Prognosis—Early Risk Stratiﬁcation: Recommendations
See Table 4 for a summary of recommendations from this
section.
CLASS I
1. In patients with chest pain or other symptoms suggestive of
ACS, a 12-lead ECG should be performed and evaluated for
ischemic changes within 10 minutes of the patient’s arrival at
an emergency facility (21). (Level of Evidence: C)
2. If the initial ECG is not diagnostic but the patient remains
symptomatic and there is a high clinical suspicion for ACS,
serial ECGs (e.g., 15- to 30-minute intervals during the ﬁrst
hour) should be performed to detect ischemic changes.
(Level of Evidence: C)
3. Serial cardiac troponin I or T levels (when a contemporary
assay is used) should be obtained at presentation and 3 to 6
hours after symptom onset (see Section 3.4, Class I, #3
recommendation if time of symptom onset is unclear) in
all patients who present with symptoms consistent with
ACS to identify a rising and/or falling pattern of values
(21,64,67–71). (Level of Evidence: A)
4. Additional troponin levels should be obtained beyond
6 hours after symptom onset (see Section 3.4, Class I, #3
recommendation if time of symptom onset is unclear) in
patients with normal troponin levels on serial examination
when changes on ECG and/or clinical presentation confer an
intermediate or high index of suspicion for ACS (21,72–74).
(Level of Evidence: A)
5. Risk scores should be used to assess prognosis in patients
with NSTE-ACS (42–44,75–80). (Level of Evidence: A)
CLASS IIa
1. Risk-stratiﬁcation models can be useful in management
(42–44,75–81). (Level of Evidence: B)
2. It is reasonable to obtain supplemental electrocardiographic
leads V7 to V9 in patients whose initial ECG is nondiagnostic
and who are at intermediate/high risk of ACS (82–84). (Level
of Evidence: B)
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1. Continuous monitoring with 12-lead ECG may be a reason-
able alternative in patients whose initial ECG is non-
diagnostic and who are at intermediate/high risk of ACS
(85,86). (Level of Evidence: B)
2. Measurement of B-type natriuretic peptide or N-terminal pro–
B-type natriuretic peptide may be considered to assess risk in
patients with suspected ACS (87–91). (Level of Evidence: B)3.3.1. Rationale for Risk Stratiﬁcation and Spectrum of Risk:
High, Intermediate, and Low
Assessment of prognosis guides initial clinical evaluation
and treatment and is useful for selecting the site of
care (coronary care unit, monitored step-down unit, or
outpatient monitored unit), antithrombotic therapies
(e.g., P2Y12 inhibitors, platelet glycoprotein [GP] IIb/IIIa
inhibitors [Sections 4.3.1.2 and 5.1.2.2]), and invasive
management (Sections 4.4.2.1, 4.3.1, 4.4, 4.4.4, 4.4.5).
There is a strong relationship between indicators of
ischemia due to CAD and prognosis (Table 3 and Figure 2).
Patients with a high likelihood of ischemia due to CAD are
at greater risk of a major adverse cardiac event (MACE)
than patients with a lower likelihood of ischemia due to
CAD. Risk is highest at the time of presentation but re-
mains elevated past the acute phase. By 6 months, NSTE-
ACS mortality rates may equal or exceed those of STEMI
(58). By 12 months, rates of death, MI, and recurrent
instability in contemporary registries are >10%. Early
events are related to the ruptured coronary plaque and
thrombosis, and later events are more closely associated
with the pathophysiology of chronic atherosclerosis and
LV systolic function (92–98).
3.3.2. Estimation of Level of Risk
At initial presentation, the clinical history, anginal
symptoms and equivalents, physical examination, ECG,TABLE 3 TIMI Risk Score* for NSTE-ACS
TIMI Risk
Score
All-Cause Mortality, New or Recurrent MI, or Severe
Recurrent Ischemia Requiring Urgent Revascularization
Through 14 d After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
*The TIMI risk score is determined by the sum of the presence of 7 variables at
admission; 1 point is given for each of the following variables: $65 y of age; $3 risk
factors for CAD; prior coronary stenosis $50%; ST deviation on ECG; $2 anginal events
in prior 24 h; use of aspirin in prior 7 d; and elevated cardiac biomarkers.
CAD indicates coronary artery disease; ECG, electrocardiogram; MI, myocardial
infarction; NSTE-ACS, non–ST-elevation acute coronary syndromes; and TIMI, Throm-
bolysis In Myocardial Infarction.
Modiﬁed with permission from Antman et al. (42).renal function, and cardiac troponin measurements can
be integrated into an estimation of the risk of death and
nonfatal cardiac ischemic events (Table 3 and Figure 2)
(42,78).
3.3.2.1. History: Angina Symptoms and Angina Equivalents
In patients with or without known CAD, clinicians must
determine whether the presentation is consistent with
acute ischemia, stable ischemic heart disease, or an
alternative etiology. Factors in the initial clinical history
related to the likelihood of acute ischemia include age,
sex, symptoms, prior history of CAD, and the number of
traditional risk factors (99–105).
The characteristics of angina include deep, poorly
localized chest or arm pain that is reproducibly associated
with exertion or emotional stress (106). Angina is relieved
promptly (i.e., in <5 minutes) with rest and/or short-
acting nitroglycerin. Patients with NSTE-ACS may have
typical or atypical anginal symptoms, but episodes are
more severe and prolonged, may occur at rest, or may be
precipitated by less exertion than the patient previously
experienced. Some patients have no chest pain but pre-
sent solely with dyspnea or with arm, shoulder, back, jaw,
neck, epigastric, or ear discomfort (107–109).
Features not characteristic of myocardial ischemia
include:
 Pleuritic pain (sharp or knifelike pain provoked by
respiration or cough);
 Primary or sole location of discomfort in the middle or
lower abdomen;
 Pain localized by the tip of 1 ﬁnger, particularly at the
LV apex or costochondral junction;
 Pain reproduced with movement or palpation of the
chest wall or arms;
 Brief episodes of pain lasting a few seconds or less;
 Pain that is of maximal intensity at onset; and
 Pain that radiates into the lower extremities.
Evaluation should include the clinician’s impression of
whether the pain represents a high, intermediate, or low
likelihood of acute ischemia.
Although typical characteristics increase the probability
of CAD, atypical features do not exclude ACS. In the
Multicenter Chest Pain Study, acute ischemia was diag-
nosed in 22% of patients who presented to the ED with
sharp or stabbing pain and in 13% of those with pleuritic
pain (110). Seven percent of patients whose pain was
reproduced with palpation had ACS. The ACI-TIPI (Acute
Cardiac Ischemia Time-Insensitive Predictive Instrument)
project found that older age, male sex, chest or left arm
pain, and chest pain or pressure were the most important
ﬁndings, and each increased the likelihood of ACS (111,112).
The relief of chest pain with nitroglycerin is not pre-
dictive of ACS. One study reported that sublingual
TABLE 4 Summary of Recommendations for Prognosis: Early Risk Stratiﬁcation
Recommendations COR LOE References
Perform rapid determination of likelihood of ACS, including a 12-lead ECG within 10 min of arrival at an
emergency facility, in patients whose symptoms suggest ACS
I C (21)
Perform serial ECGs at 15- to 30-min intervals during the ﬁrst hour in symptomatic patients with initial
nondiagnostic ECG
I C N/A
Measure cardiac troponin (cTnI or cTnT) in all patients with symptoms consistent with ACS* I A (21,64,67–71)
Measure serial cardiac troponin I or T at presentation and 3–6 h after symptom onset* in all patients with
symptoms consistent with ACS
I A (21,72–74)
Use risk scores to assess prognosis in patients with NSTE-ACS I A (42–44,75–80)
Risk-stratiﬁcation models can be useful in management IIa B (42–44,75–81)
Obtain supplemental electrocardiographic leads V7 to V9 in patients with initial nondiagnostic ECG at
intermediate/high risk for ACS
IIa B (82–84)
Continuous monitoring with 12-lead ECG may be a reasonable alternative with initial nondiagnostic ECG
in patients at intermediate/high risk for ACS
IIb B (85,86)
BNP or NT–pro-BNP may be considered to assess risk in patients with suspected ACS IIb B (87–91)
*See Section 3.4, Class I, #3 recommendation if time of symptom onset is unclear.
ACS indicates acute coronary syndromes; BNP, B-type natriuretic peptide; COR, Class of Recommendation; cTnI, cardiac troponin I; cTnT, cardiac troponin T; ECG, electrocardiogram;
LOE, Level of Evidence; N/A, not available; NSTE-ACS, nonST-elevation acute coronary syndromes; and NT–pro-BNP, N-terminal pro–B-type natriuretic peptide.
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documented ACS compared with 41% of patients without
ACS (113). The relief of chest pain by “gastrointestinal
cocktails” (e.g., mixtures of liquid antacids, and/or
viscous lidocaine, and/or anticholinergic agents) does not
predict the absence of ACS (114).
3.3.2.2. Demographics and History in Diagnosis and Risk
Stratiﬁcation
A prior history of MI is associated with a high risk of
obstructive and multivessel CAD (115). Women with sus-
pected ACS are less likely to have obstructive CAD than
men. When obstructive CAD is present in women, it tends
to be less severe than it is in men (116). It has been
suggested that coronary microvascular disease and endo-
thelial dysfunction play a role in the pathophysiology of
NSTE-ACS in patients with nonobstructive CAD (116). Older
adults have increased risks of underlying CAD (117,118),
multivessel CAD, and a worse prognosis (Section 7.1).
A family history of premature CAD is associated with
increased coronary artery calcium scores (119) and
increased risk of 30-day cardiac events in patients with ACS
(120,121). Diabetesmellitus, extracardiac (carotid, aortic, or
peripheral) arterial disease, and hypertension are major
risk factors for poor outcomes in patients with ACS (Section
6.2) with both STEMI (122) and NSTE-ACS (92).
The current or prior use of aspirin at presentation is
associated with increased cardiovascular risk (42), likely
reﬂecting the greater probability that patients who have
been prescribed aspirin have an increased cardiovascular
risk proﬁle and/or prior vascular disease. Smoking is
associated with a lower risk of death in ACS (42,123,124),
primarily because of the younger age of smokers with ACSand less severe CAD. Overweight and/or obesity at ACS
presentation are associated with lower short-term risk of
death. The “obesity paradox” may be a function of
younger age at presentation, referral for angiography at
an earlier stage of disease, and more aggressive manage-
ment of ACS (123). These individuals, especially those
with severe obesity (body mass index >35), have a higher
long-term total mortality risk (124–129).
Cocaine use can cause ACS by inducing coronary
vasospasm, dissection, thrombosis, positive chronotropic
and hypertensive actions, and direct myocardial toxicity
(Section 7.10) (130). Methamphetamines are also associ-
ated with ACS (131). Urine toxicology screening should be
considered when substance abuse is suspected as a cause
of or contributor to ACS, especially in younger patients
(<50 years of age) (132).
3.3.2.3. Early Estimation of Risk
The TIMI risk score is composed of 7, 1-point risk
indicators rated on presentation (Table 3) (42). The com-
posite endpoints increase as the score increases. The TIMI
risk score has been validated internally within the TIMI
11B trial and in 2 separate cohorts of patients from the
ESSENCE (Efﬁcacy and Safety of Subcutaneous Enox-
aparin in Non–Q-Wave Coronary Event) trial (133). The
TIMI risk score calculator is available at www.timi.org.
The TIMI risk index is useful in predicting 30-day
and 1-year mortality in patients with NSTE-ACS (134).
For patients with a TIMI risk score of 0 and normal
high-sensitivity cardiac troponin 2 hours after presenta-
tion, accelerated diagnostic protocols have been devel-
oped that predict a very low rate of 30-day MACE
(Section 3.4.3) (65).
FIGURE 2 Global Registry of Acute Coronary Events Risk Calculator for In-Hospital Mortality for Acute Coronary Syndrome
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discharge mortality or MI (44,78,79,81). The GRACE tool
was developed from 11,389 patients in GRACE and vali-
dated in subsequent GRACE and GUSTO (Global
Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries) IIb cohorts. The
sum of scores is applied to a reference nomogram to
determine all-cause mortality from hospital discharge to
6 months. The GRACE clinical application tool is a
web-based downloadable application available at http://
www.outcomes-umassmed.org/grace/ (Figure 2) (44,135).
Among patients with a higher TIMI risk score (e.g., $3),
there is a greater beneﬁt from therapies such as low-
molecular-weight heparin (LMWH) (133,136), platelet GP
IIb/IIIa inhibitors (137), and an invasive strategy (138).
Similarly, the GRACE risk model can identify patients who
would beneﬁt from an early invasive strategy (139).
Patients with elevated cardiac troponin beneﬁt from more
aggressive therapy, whereas those without elevated
cardiac troponins may not (140). This is especially true for
women in whom some data suggest adverse effects from
invasive therapies in the absence of an elevated cardiac
troponin value (141). Although B-type natriuretic peptide
and N-terminal pro–B-type natriuretic peptide are not
useful for the diagnosis of ACS per se (but rather HF,
which has many etiologies), they add prognostic value
(87–91).
3.3.2.4. Electrocardiogram
The 12-lead ECG is pivotal in the decision pathway for the
evaluation and management of patients presenting with
symptoms suggestive of ACS (58,59,85). Transient ST
changes ($0.5 mm [0.05 mV]) during symptoms at rest
strongly suggest ischemia and underlying severe CAD.
Patients without acute ischemic changes on ECG have a
reduced risk of MI and a very low risk of in-hospital life-
threatening complications, even in the presence of
confounding electrocardiographic patterns such as LV
hypertrophy (143–145). ST depression (especially horizon-
tal or downsloping) is highly suggestive of NSTE-
ACS (21,146,147). Marked symmetrical precordial T-wave
inversion ($2 mm [0.2 mV]) suggests acute ischemia,
particularly due to a critical stenosis of the left anterior
descending coronary artery (148,149); it may also be seen
with acute pulmonary embolism and right-sided ST-T
changes.
Nonspeciﬁc ST-T changes (usually deﬁned as ST devi-
ation of <0.5 mm [0.05 mV] or T-wave inversion of <2 mm
[0.2 mV]) are less helpful diagnostically. Signiﬁcant Q
waves are less helpful, although by suggesting prior MI,
they indicate a high likelihood of signiﬁcant CAD. Isolated
Q waves in lead 3 are a normal ﬁnding. A completely
normal ECG in a patient with chest pain does not exclude
ACS, because 1% to 6% of such patients will have a MI,and at least 4% will have UA (59–61). Fibrinolytic therapy
is contraindicated for patients with ACS without ST-
elevation, except for those with electrocardiographic
evidence of true posterior MI (i.e., ST-elevation in pos-
terior chest leads [V7 to V9]). This can be evaluated when
acute myocardial infarction (AMI) is suspected but elec-
trocardiographic changes are modest or not present
(82–84); a transthoracic echocardiogram to evaluate for
posterior wall motion abnormalities may also be helpful
in this setting.
Alternative causes of ST-T changes include LV aneu-
rysm, pericarditis, myocarditis, bundle-branch block, LV
hypertrophy, hyperkalemia, Prinzmetal angina, early
repolarization, apical LV ballooning syndrome (Takotsubo
cardiomyopathy, Section 7.13), and Wolff-Parkinson-
White conduction. Central nervous system events and
therapy with tricyclic antidepressants or phenothiazines
can cause deep T-wave inversion.
3.3.2.5. Physical Examination
The physical examination is helpful in assessing the
hemodynamic impact of an ischemic event. Patients with
suspected ACS should have vital signs measured (BP in
both arms if dissection is suspected) and should undergo
a thorough cardiovascular examination. Patients with
evidence of LV dysfunction on examination (e.g., rales, S3
gallop) or acute mitral regurgitation have a higher likeli-
hood of severe underlying CAD and are at high risk of a
poor outcome. In the SHOCK (Should we Emergently
Revascularize Occluded Coronaries for Cardiogenic
Shock) study, NSTEMI accounted for approximately 20%
of cardiogenic shock complicating MI (150). Other trials
have reported lower percentages (92,151). The physical
examination may also help identify comorbid conditions
(e.g., occult GI bleeding) that could impact therapeutic
risk and decision making.
See Online Data Supplement 2 for additional information
on risk stratiﬁcation.
3.4. Cardiac Biomarkers and the Universal Deﬁnition of MI:
Recommendations
See Table 5 for a summary of recommendations from this
section and Online Data Supplement 3 for additional in-
formation on cardiac injury markers and the universal
deﬁnition of AMI.
3.4.1. Biomarkers: Diagnosis
CLASS I
1. Cardiac-speciﬁc troponin (troponin I or T when a contem-
porary assay is used) levels should be measured at presen-
tation and 3 to 6 hours after symptom onset in all patients
who present with symptoms consistent with ACS to identify
a rising and/or falling pattern (21,64,67–71,152–156). (Level
of Evidence: A)
TABLE 5 Summary of Recommendations for Cardiac Biomarkers and the Universal Deﬁnition of MI
Recommendations COR LOE References
Diagnosis
Measure cardiac-speciﬁc troponin (troponin I or T) at presentation and 3—6 h after symptom onset in all
patients with suspected ACS to identify pattern of values
I A (21,64,67–71,152–156)
Obtain additional troponin levels beyond 6 h in patients with initial normal serial troponins with
electrocardiographic changes and/or intermediate/high risk clinical features
I A (21,72–74,157)
Consider time of presentation the time of onset with ambiguous symptom onset for assessing troponin values I A (67,68,72)
With contemporary troponin assays, CK-MB and myoglobin are not useful for diagnosis of ACS III: No Beneﬁt A (158–164)
Prognosis
Troponin elevations are useful for short- and long-term prognosis I B (71,73,165,166)
Remeasurement of troponin value once on d 3 or 4 in patients with MI may be reasonable as an index of
infarct size and dynamics of necrosis
IIb B (164,165)
BNP may be reasonable for additional prognostic information IIb B (87,88,167–171)
ACS indicates acute coronary syndromes; BNP, B-type natriuretic peptide; CK-MB, creatine kinase myocardial isoenzyme; COR, Class of Recommendation; LOE, Level of Evidence; and
MI, myocardial infarction.
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6 hours after symptom onset in patients with normal tro-
ponins on serial examination when electrocardiographic
changes and/or clinical presentation confer an intermediate
or high index of suspicion for ACS (21,72–74,157). (Level of
Evidence: A)
3. If the time of symptom onset is ambiguous, the time of
presentation should be considered the time of onset for
assessing troponin values (67,68,72). (Level of Evidence: A)
CLASS III: NO BENEFIT
1. With contemporary troponin assays, creatine kinase myocar-
dial isoenzyme (CK-MB) and myoglobin are not useful for
diagnosis of ACS (158–164). (Level of Evidence: A)3.4.2. Biomarkers: Prognosis
CLASS I
1. The presence and magnitude of troponin elevations are
useful for short- and long-term prognosis (71,73,165,166).
(Level of Evidence: B)
CLASS IIb
1. It may be reasonable to remeasure troponin once on day 3 or
day 4 in patients with MI as an index of infarct size and
dynamics of necrosis (164,165). (Level of Evidence: B)
2. Use of selected newer biomarkers, especially B-type natriuretic
peptide, may be reasonable to provide additional prognostic
information (87,88,167–171). (Level of Evidence: B)
Cardiac troponins are the mainstay for diagnosis of ACS and
for risk stratiﬁcation in patients with ACS. The primary
diagnostic biomarkers of myocardial necrosis are cardiac
troponin I and cardiac troponin T. Features that favor tro-
ponins for detection of ACS include high concentrations of
troponins in the myocardium; virtual absence of troponins innonmyocardial tissue; high-release ratio into the systemic
circulation (amount found in blood relative to amount
depleted from myocardium); rapid release into the blood in
proportion to the extent of myocardial injury; and the ability
to quantify values with reproducible, inexpensive, rapid, and
easily applied assays. The 2012 Third Universal Deﬁnition of
MI provides criteria that classify 5 clinical presentations of MI
on the basis of pathological, clinical, and prognostic factors
(21). In the appropriate clinical context, MI is indicated by a
rising and/or falling pattern of troponin with $1 value above
the 99th percentile of the upper reference level and evidence
for serial increases or decreases in the levels of troponins
(67,68,156). The potential consequences of emerging high-
sensitivity troponin assays include increases in the diag-
nosis of NSTEMI (152,172,173) inﬂuenced by the deﬁnition of
an abnormal troponin (67,153,174,175). The recommenda-
tions in this section are formulated from studies predicated
on both the new European Society of Cardiology/ACC/AHA/
World Health Organization criteria (21) and previous criteria/
redeﬁnitions of MI based on earlier-generation troponin
assays (Appendix 4, Table A).
3.4.3. Cardiac Troponins
See Online Data Supplement 4 for additional information
on cardiac troponins.
Of the 3 troponin subunits, 2 subunits (troponin I and
troponin T) are derived from genes speciﬁcally expressed
in the myocardium. Cardiac troponin measurements
provide highly sensitive results speciﬁc for detecting
cardiomyocyte necrosis (34,173). Highly sensitive assays
can identify cardiac troponin not only in the blood of
patients with acute cardiac injury, but also in the blood of
most healthy people (64,68,70,166,176,177). As assay
sensitivity increases, a greater proportion of patients will
have detectable long-term elevations in troponin, thus
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of MI. Clinicians should be aware of the sensitivity of the
tests used for troponin evaluation in their hospitals and
cutpoint concentrations for clinical decisions. Markedly
elevated values are usually related to MI, myocarditis,
rare analytical factors, or chronic elevations in patients
with renal failure and in some patients with HF.
CPGs endorse the 99th percentile of the upper refer-
ence level as the appropriate cutpoint for considering
myocardial necrosis (21,22). For the diagnosis of acute
myocardial necrosis, it is important to determine not only
the peak troponin value, but also serial changes:
1. A troponin value above the 99th percentile of the upper
reference level is required. Additionally, evidence for a
serial increase or decrease $20% is required if the
initial value is elevated (21,178).
2. For any troponin values below or close to the 99th
percentile, evidence for acute myocardial necrosis is
indicated by a change of $3 standard deviations of the
variation around the initial value as determined by the
individual laboratory (21,179).
3. Clinical laboratory reports should indicate whether
signiﬁcant changes in cardiac troponin values for the
particular assay have occurred.
Absolute changes in nanograms per liter of high-sensitivity
cardiac troponin T levels appear to have a signiﬁcantly
higher diagnostic accuracy for AMI than relative changes and
may distinguish AMI from other causes of high-sensitivity
cardiac troponin T elevations (71). This has also been sug-
gested for some contemporary assays (71). Troponins are
elevated in MI as early as 2 to 4 hours after symptom onset
(64,70), and many medical centers obtain troponins at 3
hours. Depending on the assay, values may not become
abnormal for up to 12 hours. In the vast majority of patients
with symptoms suggestive of ACS, MI can be excluded or
conﬁrmed within 6 hours, because very few patients present
immediately after symptom onset. In high-risk patients,
measurements after 6 hours may be required to identify ACS.
Solitary elevations of troponin cannot be assumed
to be due to MI, because troponin elevations can be
due to tachyarrhythmia, hypotension or hypertension,
cardiac trauma, acute HF, myocarditis and pericarditis,
acute pulmonary thromboembolic disease, and severe
noncardiac conditions such as sepsis, burns, respiratory
failure, acute neurological diseases, and drug toxicity
(including cancer chemotherapy). Chronic elevations can
result from structural cardiac abnormalities such as LV
hypertrophy or ventricular dilatation and are also com-
mon in patients with renal insufﬁciency (34). Patients
with end-stage renal disease and no clinical evidence of
ACS frequently have elevations of cardiac troponin
(180–182). With conventional assays, this is more common
with cardiac troponin T than with cardiac troponin I (180).In the diagnosis of NSTEMI, cardiac troponin values must
manifest an acute pattern consistent with the clinical
events, including ischemic symptoms and electrocardio-
graphic changes. Troponin elevations may persist for up
to 14 days or occasionally longer. There is a paucity of
guidelines for establishment of reinfarction during the
acute infarct period on the basis of troponin measure-
ments. References suggest that an increase of >20% of
previous troponin levels or an absolute increase of high-
sensitivity cardiac troponin T values (e.g., >7 ng/L over
2 hours) may indicate reinfarction (183–185).
During pregnancy, troponin values are within the
normal range in the absence of cardiovascular morbid-
ities. There is controversy as to whether troponin levels
are elevated in pre-eclampsia, eclampsia, or gestational
hypertension (186–189). When present, cardiac troponin
elevations reﬂect myocardial necrosis.
Point-of-care troponin values may provide initial
diagnostic information, although their sensitivity is sub-
stantially below that of central laboratory methods
(154,155,190–192). In addition, the rigorous quantitative
assay standardization needed for routine diagnosis favors
central laboratory testing.
3.4.3.1. Prognosis
Troponin elevations convey prognostic assessment
beyond that of clinical information, the initial ECG, and
the predischarge stress test (71). In addition, troponin
elevations may provide information to direct therapy.
Patients with cardiac troponin elevations are at high risk
and beneﬁt from intensive management and early revas-
cularization (193–195). High risk is optimally deﬁned by
the changing pattern as described in Section 3.4.3. Cardiac
troponin elevations correlate with estimation of infarct
size and risk of death; persistent elevation 72 to 96 hours
after symptom onset may afford relevant information in
this regard (164). Elevations of cardiac troponin can occur
for multiple reasons other than MI. In these cases, there is
often substantial risk of adverse outcomes, as troponin
elevation indicates cardiomyocyte necrosis (181).
3.4.4. CK-MB and Myoglobin Compared With Troponin
Previously, CK-MB was used for early evidence of myo-
cardial injury. Because myoglobin is a relatively small
molecule, it is rapidly released from infarcted myocar-
dium. CK-MB is much less sensitive for detection of
myocardial injury than troponin, and substantially more
tissue injury is required for its detection. With the
availability of cardiac troponin, CK-MB, myoglobin, and
other diagnostic biomarkers are no longer necessary
(158,160–163,196–198). CK-MB may be used to estimate MI
size. Detection of MI after percutaneous coronary inter-
vention (PCI) remains an area of controversy. Because of
the increased sensitivity of cardiac troponin, the
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elevation remains unclear.
See Online Data Supplements 5, 6, and 7 for additional
information on cardiac injury markers.
3.5. Immediate Management
3.5.1. Discharge From the ED or Chest Pain Unit:
Recommendations
CLASS IIa
1. It is reasonable to observe patients with symptoms con-
sistent with ACS without objective evidence of myocardial
ischemia (nonischemic initial ECG and normal cardiac
troponin) in a chest pain unit or telemetry unit with serial
ECGs and cardiac troponin at 3- to 6-hour intervals
(196,197,199–201). (Level of Evidence: B)
2. It is reasonable for patients with possible ACS who have
normal serial ECGs and cardiac troponins to have a
treadmill ECG (200–202) (Level of Evidence: A), stress
myocardial perfusion imaging (200), or stress echocardiog-
raphy (203,204) before discharge or within 72 hours after
discharge. (Level of Evidence: B)
3. In patients with possible ACS and a normal ECG, normal
cardiac troponins, and no history of CAD, it is reasonable to
initially perform (without serial ECGs and troponins) coro-
nary CT angiography to assess coronary artery anatomy
(205–207) (Level of Evidence: A) or rest myocardial perfu-
sion imaging with a technetium-99m radiopharmaceutical
to exclude myocardial ischemia (208,209). (Level of
Evidence: B)
4. It is reasonable to give low-risk patients who are referred for
outpatient testing daily aspirin, short-acting nitroglycerin,
and other medication if appropriate (e.g., beta blockers),
with instructions about activity level and clinician follow-up.
(Level of Evidence: C)
The majority of patients presenting to the ED with chest
pain do not have ACS (Figure 1), and most are at low risk for
major morbidity and mortality (35). Low-risk patients are
usually identiﬁed by an absence of history of cardiovascular
disease, normal or near-normal initial ECG, normal initial
troponin, and clinical stability (35,202). The utility of an
accelerated diagnostic protocol for detecting patients with
benign conditions versus those who require admission for
serious disease has been established (35). At minimum,
these protocols involve serial ECGs and troponin measure-
ments, both of which can be performed in the ED, a sepa-
rate chest pain unit, or a telemetry unit. A 30-day negative
predictive value >99% for ACS has been reported for pa-
tients presenting to the ED with chest pain who undergo a
2-hour accelerated diagnostic protocol composed of a TIMI
risk score of 0, normal ECG, and normal high-sensitivity
troponin at 0 hours and 2 hours (assuming appropriate
follow-up care) (65,210). Some protocols also call for
a functional or anatomic test (e.g., treadmill test, restscintigraphy, coronary CT angiography, stress imaging).
Coronary CT angiography is associated with rapid assess-
ment, high negative predictive value, decreased length of
stay, and reduced costs (205–207); however, in the latter
studies, it increased the rate of invasive coronary angiog-
raphy and revascularization with uncertain long-term
beneﬁts in low-risk patients without ECG or troponin al-
terations (211). Accelerated diagnostic protocols are also
potentially applicable in intermediate-risk patients, whose
presentation includes a history of cardiovascular disease,
diabetes mellitus, chronic kidney disease (CKD), and/or
advanced age (202).
See Online Data Supplement 8 for additional informa-
tion on discharge from the ED or chest pain unit.
4. EARLY HOSPITAL CARE
The standard of care for patients who present with
NSTE-ACS, including those with recurrent symptoms,
ischemic electrocardiographic changes, or positive car-
diac troponins, is admission for inpatient management.
The goals of treatment are the immediate relief of
ischemia and the prevention of MI and death. Initially,
stabilized patients with NSTE-ACS are admitted to an
intermediate (or step-down) care unit. Patients undergo
continuous electrocardiographic rhythm monitoring and
observation for recurrent ischemia. Bed or chair rest is
recommended for patients admitted with NSTE-ACS.
Patients with NSTE-ACS should be treated with anti-
anginal (Section 4.1.2.5), antiplatelet, and anticoagulant
therapy (Section 4.3). Patients are managed with either
an early invasive strategy or an ischemia-guided strategy
(Section 4.4).
Patients with continuing angina, hemodynamic insta-
bility, uncontrolled arrhythmias, or a large MI should be
admitted to a coronary care unit. The nurse-to-patient
ratio should be sufﬁcient to provide 1) continuous elec-
trocardiographic rhythm monitoring, 2) frequent assess-
ment of vital signs and mental status, and 3) ability to
perform rapid cardioversion and deﬁbrillation. These
patients are usually observed in the coronary care unit for
at least 24 hours. Those without recurrent ischemia, sig-
niﬁcant arrhythmias, pulmonary edema, or hemodynamic
instability can be considered for admission or transfer to
an intermediate care or telemetry unit.
An assessment of LV function is recommended because
depressed LV function will likely inﬂuence pharmaco-
logical therapies (e.g., angiotensin-converting enzyme
[ACE] inhibitors for depressed left ventricular ejection
fraction [LVEF]), may suggest the presence of more
extensive CAD, and may inﬂuence the choice of revascu-
larization (PCI versus coronary artery bypass graft surgery
[CABG]). Because signiﬁcant valvular disease may also
inﬂuence the type of revascularization, echocardiography
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assessment of LV function.
4.1. Standard Medical Therapies.
See Table 6 for a summary of recommendations from this
section.
4.1.1. Oxygen: Recommendation
CLASS I
1. Supplemental oxygen should be administered to patients
with NSTE-ACS with arterial oxygen saturation less than
90%, respiratory distress, or other high-risk features of
hypoxemia. (Level of Evidence: C)TABLE 6 Summary of Recommendations for Early Hospital Care
Recommendations
Oxygen
Administer supplemental oxygen only with oxygen saturation <90%, respiratory dist
features for hypoxemia
Nitrates
Administer sublingual NTG every 5 min  3 for continuing ischemic pain and then ass
Administer IV NTG for persistent ischemia, HF, or hypertension
Nitrates are contraindicated with recent use of a phosphodiesterase inhibitor
Analgesic therapy
IV morphine sulfate may be reasonable for continued ischemic chest pain despite ma
medications
NSAIDs (except aspirin) should not be initiated and should be discontinued during ho
because of the increased risk of MACE associated with their use
Beta-adrenergic blockers
Initiate oral beta blockers within the ﬁrst 24 h in the absence of HF, low-output stat
other contraindications to beta blockade
Use of sustained-release metoprolol succinate, carvedilol, or bisoprolol is recommend
concomitant NSTE-ACS, stabilized HF, and reduced systolic function
Re-evaluate to determine subsequent eligibility in patients with initial contraindicatio
It is reasonable to continue beta-blocker therapy in patients with normal LV function
IV beta blockers are potentially harmful when risk factors for shock are present
CCBs
Administer initial therapy with nondihydropyridine CCBs with recurrent ischemia and
in the absence of LV dysfunction, increased risk for cardiogenic shock, PR interva
third-degree atrioventricular block without a cardiac pacemaker
Administer oral nondihydropyridine calcium antagonists with recurrent ischemia after
the absence of contraindications
CCBs are recommended for ischemic symptoms when beta blockers are not successfu
unacceptable side effects*
Long-acting CCBs and nitrates are recommended for patients with coronary artery sp
Immediate-release nifedipine is contraindicated in the absence of a beta blocker
Cholesterol management
Initiate or continue high-intensity statin therapy in patients with no contraindications
Obtain a fasting lipid proﬁle, preferably within 24 h
*Short-acting dihydropyridine calcium channel antagonists should be avoided.
CCB indicates calcium channel blocker; COR, Class of Recommendation; HF, heart failure; IV
event; N/A, not available; NSAIDs, nonsteroidal anti-inﬂammatory drugs; NSTE-ACS, non–STPatients with cyanosis, arterial oxygen saturation <90%,
respiratory distress, or other high-risk features of hypoxemia
are treated with supplemental oxygen. The 2007 UA/
NSTEMI CPG recommended the routine administration of
supplemental oxygen to all patients with NSTE-ACS during
the ﬁrst 6 hours after presentation on the premise that it is
safe and may alleviate hypoxemia (212). The beneﬁt of
routine supplemental oxygen administration in normoxic
patients with NSTE-ACS has never been demonstrated. At
the time of GWC deliberations, data emerged that routine
use of supplemental oxygen in cardiac patients may have
untoward effects, including increased coronary vascular
resistance, reduced coronary blood ﬂow, and increased risk
of mortality (213–215).COR LOE References
ress, or other high-risk I C N/A
ess need for IV NTG I C (216–218)
I B (219–224)
III: Harm B (225–227)
ximally tolerated anti-ischemic IIb B (232,233)
spitalization for NSTE-ACS III: Harm B (234,35)
e, risk for cardiogenic shock, or I A (240–242)
ed for beta-blocker therapy with I C N/A
ns to beta blockers I C N/A
with NSTE-ACS IIa C (241,243)
III: Harm B (244)
contraindications to beta blockers
l >0.24 s, or second- or
I B (248–250)
use of beta blocker and nitrates in I C N/A
l, are contraindicated, or cause I C N/A
asm I C N/A
III: Harm B (251,252)
I A (269–273)
IIa C N/A
, intravenous; LOE, Level of Evidence; LV, left ventricular; MACE, major adverse cardiac
-elevation acute coronary syndromes; and NTG, nitroglycerin.
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4.1.2.1. Nitrates: Recommendations
CLASS I
1. Patients with NSTE-ACS with continuing ischemic pain
should receive sublingual nitroglycerin (0.3 mg to 0.4 mg)
every 5 minutes for up to 3 doses, after which an assessment
should be made about the need for intravenous nitroglycerin
if not contraindicated (216–218). (Level of Evidence: C)
2. Intravenous nitroglycerin is indicated for patients with
NSTE-ACS for the treatment of persistent ischemia, HF, or
hypertension (219–224). (Level of Evidence: B)
CLASS III: HARM
1. Nitrates should not be administered to patients with NSTE-
ACS who recently received a phosphodiesterase inhibitor,
especially within 24 hours of sildenaﬁl or vardenaﬁl, or
within 48 hours of tadalaﬁl (225–227). (Level of Evidence: B)
Nitrates are endothelium-independent vasodilators with
peripheral and coronary vascular effects. By dilating the
capacitance vessels, nitrates decrease cardiac preload and
reduce ventricular wall tension. More modest effects on the
arterial circulation result in afterload reduction and further
decrease in MVO2. This may be partially offset by reﬂex
increases in heart rate and contractility, which counteract the
reduction in MVO2 unless a beta blocker is concurrently
administered. Nitrates also dilate normal and atherosclerotic
coronary arteries and increase coronary collateral ﬂow.
Nitrates may also inhibit platelet aggregation (228).
RCTs have not shown a reduction inMACEwith nitrates.
The rationale for nitrate use in NSTE-ACS is extra-
polated from pathophysiological principles and extensive
(although uncontrolled) clinical observations, experi-
mental studies, and clinical experience. The decision to
administer nitrates should not preclude therapywith other
proven mortality-reducing interventions such as beta
blockers.
Intravenous nitroglycerin is beneﬁcial in patients
with HF, hypertension, or symptoms that are not
relieved with sublingual nitroglycerin and administra-
tion of a beta blocker (219,221–224). Patients who require
intravenous nitroglycerin for >24 hours may require
periodic increases in the infusion rate and use of
nontolerance-producing regimens (e.g., intermittent
dosing) to maintain efﬁcacy. In current practice, most
patients who require continued intravenous nitroglyc-
erin for the relief of angina undergo prompt coronary
angiography and revascularization. Topical or oral ni-
trates are acceptable alternatives to intravenous nitro-
glycerin for patients who do not have refractory or
recurrent ischemia (229,230). Side effects of nitrates
include headache and hypotension. Nitrates should
not be administered to patients with hypotension or tothose who received a phosphodiesterase inhibitor and
are administered with caution to patients with right
ventricular infarction (231).
See Online Data Supplement 9 for additional infor-
mation on nitrates.4.1.2.2. Analgesic Therapy: Recommendations
CLASS IIb
1. In the absence of contraindications, it may be reasonable to
administer morphine sulfate intravenously to patients with
NSTE-ACS if there is continued ischemic chest pain despite
treatment with maximally tolerated anti-ischemic medica-
tions (232,233). (Level of Evidence: B)
CLASS III: HARM
1. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) (except
aspirin) should not be initiated and should be discontinued
during hospitalization for NSTE-ACS because of the
increased risk of MACE associated with their use (234,235).
(Level of Evidence: B)
The role of morphine sulfate was re-evaluated for this CPG
revision, including studies that suggest the potential for
adverse events with its use (232). Morphine sulfate has
potent analgesic and anxiolytic effects, as well as hemody-
namic actions, that are potentially beneﬁcial in NSTE-ACS. It
causes venodilation and produces modest reductions in
heart rate (through increased vagal tone) and systolic BP. In
patients with symptoms despite antianginal treatment,
morphine (1 mg to 5 mg IV) may be administered during
intravenous nitroglycerin therapy with BP monitoring. The
morphine dose may be repeated every 5 to 30 minutes to
relieve symptoms and maintain the patient’s comfort. Its use
should not preclude the use of other anti-ischemic therapies
with proven beneﬁts in patients with NSTE-ACS. To our
knowledge, no RCTs have assessed the use of morphine in
patients with NSTE-ACS or deﬁned its optimal adminis-
tration schedule. Observational studies have demonstrated
increased adverse events associated with the use of
morphine sulfate in patients with ACS and acute decom-
pensated HF (232,233,236). Although these reports were
observational, uncontrolled studies limited by selection bias,
they raised important safety concerns.
Although constipation, nausea, and/or vomiting
occur in >20% of patients, hypotension and respiratory
depression are the most serious complications of exces-
sive use of morphine. Naloxone (0.4 mg to 2.0 mg IV) may
be administered for morphine overdose with respiratory
or circulatory depression.
Traditional NSAIDs and selective cyclooxygenase
(COX)-2 inhibitors markedly block endothelial prostacy-
clin production, which leads to unopposed platelet
aggregation by platelet-derived thromboxane A2. Both
yShort-acting dihydropyridine calcium channel antagonists should be avoided.
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and interfere with the inhibition of COX-1, thromboxane
A2 production, and platelet aggregation. Because of
their inhibitory activity on the ubiquitous COXs, NSAIDs
have an extensive adverse side effect proﬁle, particularly
renal and gastrointestinal. The increased cardio-
vascular hazards associated with NSAIDs have been
observed in several studies of patients without ACS
(234,235,237,238). The PRECISION (Prospective Random-
ized Evaluation of Celecoxib Integrated Safety Versus
Ibuprofen Or Naproxen) trial, in progress at the time of
publication, is the ﬁrst study of patients with high car-
diovascular risk who are receiving long-term treatment
with a selective COX-2 inhibitor or traditional NSAIDs.
PRECISION will examine the relative cardiovascular
safety proﬁles of celecoxib, ibuprofen, and naproxen in
patients without ACS (239).
See Online Data Supplement 10 for additional infor-
mation on analgesic therapy.
4.1.2.3. Beta-Adrenergic Blockers: Recommendations
CLASS I
1. Oral beta-blocker therapy should be initiated within the ﬁrst
24 hours in patients who do not have any of the following:
1) signs of HF, 2) evidence of low-output state, 3) increased
risk for cardiogenic shock, or 4) other contraindications to
beta blockade (e.g., PR interval >0.24 second, second- or
third-degree heart block without a cardiac pacemaker, active
asthma, or reactive airway disease) (240–242). (Level of
Evidence: A)
2. In patients with concomitant NSTE-ACS, stabilized HF,
and reduced systolic function, it is recommended to continue
beta-blocker therapy with 1 of the 3 drugs proven to
reduce mortality in patients with HF: sustained-release
metoprolol succinate, carvedilol, or bisoprolol. (Level of
Evidence: C)
3. Patients with documented contraindications to beta blockers
in the ﬁrst 24 hours of NSTE-ACS should be re-evaluated to
determine their subsequent eligibility. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to continue beta-blocker therapy in patients
with normal LV function with NSTE-ACS (241,243). (Level of
Evidence: C)
CLASS III: HARM
1. Administration of intravenous beta blockers is potentially
harmful in patients with NSTE-ACS who have risk factors for
shock (244). (Level of Evidence: B)
Beta blockers decrease heart rate, contractility, and BP,
resulting in decreased MVO2. Beta blockers without
increased sympathomimetic activity should be administered
orally in the absence of contraindications. Although earlyadministration does not reduce short-term mortality
(241,244), beta blockers decrease myocardial ischemia,
reinfarction, and the frequency of complex ventricular dys-
rhythmias (240,245), and they increase long-term survival.
Early beta blockade, particularly if given intravenously, can
increase the likelihood of shock in patients with risk factors.
Risk factors for shock include patients >70 years of age, heart
rate >110 beats per minute, systolic BP <120 mm Hg, and late
presentation (244). In patients with LV dysfunction
(LVEF <0.40) with or without pulmonary congestion, beta
blockers are strongly recommended before discharge. Beta
blockers should be used prudently with ACE inhibitors or
angiotensin-receptor blockers (ARBs) in patients with HF.
Renin-angiotensin-aldosterone system blocking agents
should be cautiously added in patients with decompensated
HF (246). Beta blockers without intrinsic sympathomimetic
activity should be used, especially beta-1 blockers such as
sustained-release metoprolol succinate, bisoprolol, or car-
vedilol, a beta-1 and alpha-1 blocker. This is because of their
mortality beneﬁt in patients with HF and systolic dysfunc-
tion (246,247). In patients with chronic obstructive lung
disease or a history of asthma, beta blockers are not contra-
indicated in the absence of active bronchospasm. Beta-1
selective beta blockers are preferred and should be initiated
at a low dosage.
See Online Data Supplement 11 for additional informa-
tion on beta blockers, including risk factors for shock.4.1.2.4. Calcium Channel Blockers: Recommendations
CLASS I
1. In patients with NSTE-ACS, continuing or frequently recurring
ischemia, and a contraindication to beta blockers, a non-
dihydropyridine calcium channel blocker (CCB) (e.g., verap-
amil or diltiazem) should be given as initial therapy in the
absence of clinically signiﬁcant LV dysfunction, increased risk
for cardiogenic shock, PR interval greater than 0.24 second,
or second- or third-degree atrioventricular block without a
cardiac pacemaker (248–250). (Level of Evidence: B)
2. Oral nondihydropyridine calcium antagonists are recom-
mended in patients with NSTE-ACS who have re-
current ischemia in the absence of contraindications, after
appropriate use of beta blockers and nitrates. (Level of
Evidence: C)
3. CCBsy are recommended for ischemic symptoms when beta
blockers are not successful, are contraindicated, or cause
unacceptable side effects. (Level of Evidence: C)
4. Long-acting CCBs and nitrates are recommended in patients
with coronary artery spasm. (Level of Evidence: C)
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1. Immediate-release nifedipine should not be administered to
patients with NSTE-ACS in the absence of beta-blocker
therapy (251,252). (Level of Evidence: B)
CCBs include dihydropyridines and nondihydropyridines.
The dihydropyridines (nifedipine and amlodipine) produce
the most marked peripheral vasodilation and have little
direct effect on contractility, atrioventricular conduction,
and heart rate. The nondihydropyridines (diltiazem and
verapamil) have signiﬁcant negative inotropic actions and
negative chronotropic and dromotropic effects. All CCBs
cause similar coronary vasodilation and are preferred in
vasospastic angina (253). They also alleviate ischemia due
to obstructive CAD by decreasing heart rate and BP.
Verapamil and diltiazem decreased reinfarction in patients
without LV dysfunction in some (248,249,254) but not all
studies (255,256). Verapamil may be beneﬁcial in reducing
long-term events after AMI in hypertensive patients
without LV dysfunction (250) and in patients with MI and
HF receiving an ACE inhibitor (257). Immediate-release
nifedipine causes a dose-related increase in mortality in
patients with CAD and harm in ACS and is not recom-
mended for routine use in patients with ACS (251,258).
Long-acting preparations may be useful in older patients
with systolic hypertension (259). There are no signiﬁcant
trial data on efﬁcacy of amlodipine or felodipine in pa-
tients with NSTE-ACS.
See Online Data Supplement 12 for additional infor-
mation on CCBs.
4.1.2.5. Other Anti-Ischemic Interventions
Ranolazine
Ranolazine is an antianginal medication with minimal
effects on heart rate and BP (260,261). It inhibits the
late inward sodium current and reduces the deleterious
effects of intracellular sodium and calcium overload
that accompany myocardial ischemia (262). Ranolazine
is currently indicated for treatment of chronic angina.
The MERLIN-TIMI (Metabolic Efﬁciency With Ranola-
zine for Less Ischemia in Non–ST-Elevation Acute Cor-
onary Syndromes-Thrombosis In Myocardial Infarction)
36 trial examined the efﬁcacy and safety of ranolazine
in 6,560 patients with NSTE-ACS who presented within
48 hours of ischemic symptoms (263). In a post hoc
analysis in women, ranolazine was associated with a
reduced incidence of the primary endpoint (cardiovas-
cular death, MI, or recurrent ischemia), principally
owing to a 29% reduction in recurrent ischemia (116). In
the subgroup with prior chronic angina (n¼3,565),
ranolazine was associated with a lower primary com-
posite endpoint, a signiﬁcant reduction of worsening
angina, and increased exercise duration (264). Because
the primary endpoint of the original MERLIN-TIMI36 trial was not met, all additional analyses should be
interpreted with caution. The recommended initial dose
is 500 mg orally twice daily, which can be uptitrated to
a maximum of 1,000 mg orally twice daily. Ranolazine
is usually well tolerated; its major adverse effects are
constipation, nausea, dizziness, and headache. Ranola-
zine prolongs the QTc interval in a dose-related
manner, but QTc prolongation requiring dose reduc-
tion was comparable with ranolazine and placebo in the
MERLIN-TIMI 36 trial (263).
See Online Data Supplement 13 for additional infor-
mation on ranolazine.
Intra-Aortic Balloon Pump (IABP) Counterpulsation
IABP counterpulsation may be used in patients with
NSTE-ACS to treat severe persistent or recurrent
ischemia, especially in patients awaiting invasive angi-
ography and revascularization, despite intensive medical
therapy. In experimental studies, IABP counterpulsation
increases diastolic BP and coronary blood ﬂow and
potentially augments cardiac output while diminishing
LV end-diastolic pressure. The use of IABP for refractory
ischemia dates back several decades, and its current
application is predominantly driven by clinical experi-
ence and nonrandomized observational studies (265).
When studied in rigorous RCTs, IABP counterpulsation
failed to reduce MACE in high-risk elective PCI (266),
decrease infarct size after primary PCI for acute STEMI
(267), or diminish early mortality in patients with
cardiogenic shock complicating AMI (268).
4.1.2.6. Cholesterol Management
CLASS I
1. High-intensity statin therapy should be initiated or
continued in all patients with NSTE-ACS and no contraindi-
cations to its use (269–273). (Level of Evidence: A)
CLASS IIa
1. It is reasonable to obtain a fasting lipid proﬁle in patients
with NSTE-ACS, preferably within 24 hours of presentation.
(Level of Evidence: C)
Therapy with statins in patients with NSTE-ACS reduces the
rate of recurrentMI, coronaryheart diseasemortality, need for
myocardial revascularization, and stroke. High-risk patients,
such as thosewith NSTE-ACS, derivemore beneﬁt in reducing
these events from high-intensity statins, such as atorvastatin
which lower low-density lipoprotein cholesterol levels
by $50% as in the PROVE IT-TIMI 22 (Pravastatin or Ator-
vastatin Evaluation and Infection Therapy-Thrombolysis In
Myocardial Infarction) and MIRACL (Myocardial Ischemia
Reduction With Acute Cholesterol Lowering) trials (273,274),
than from moderate- or low-intensity statins (18,272). These
ﬁndings provide the basis for high-intensity statin therapy
zSee Section 5.1.2.1 for recommendations at the time of PCI.
xSee Section 4.3.1.2 for prasugrel indications in either an early invasive or
ischemia-guided strategy.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (290).
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early introduction of this approach can promote improved
compliance with this regimen.
4.2. Inhibitors of the Renin-Angiotensin-Aldosterone System:
Recommendations
CLASS I
1. ACE inhibitors should be started and continued
indeﬁnitely in all patients with LVEF less than 0.40 and in
those with hypertension, diabetes mellitus, or stable CKD
(Section 7.6), unless contraindicated (275,276). (Level of
Evidence: A)
2. ARBs are recommended in patients with HF or MI with LVEF
less than 0.40 who are ACE inhibitor intolerant (277,278).
(Level of Evidence: A)
3. Aldosterone blockade is recommended in patients post–MI
without signiﬁcant renal dysfunction (creatinine >2.5 mg/dL
in men or >2.0 mg/dL in women) or hyperkalemia (Kþ >5.0
mEq/L) who are receiving therapeutic doses of ACE inhibitor
and beta blocker and have a LVEF 0.40 or less, diabetes
mellitus, or HF (279). (Level of Evidence: A)
CLASS IIa
1. ARBs are reasonable in other patients with cardiac or other
vascular disease who are ACE inhibitor intolerant (280).
(Level of Evidence: B)
CLASS IIb
1. ACE inhibitors may be reasonable in all other patients with
cardiac or other vascular disease (281,282). (Level of
Evidence: B)
ACE inhibitors reduce mortality in patients with recent MI,
primarily those with LV dysfunction (LVEF <0.40) with or
without pulmonary congestion (283–285). In patients with
normal LV function (including patients with diabetes mel-
litus), total mortality and MACE (including HF) are reduced.
It has been found that approximately 15% of patients with
NSTEMI develop HF during hospitalization, with the rate
increasing to 24% of patients 1 year later (286). A meta-
analysis demonstrated a small but signiﬁcant (0.48%) ab-
solute beneﬁt of early initiation of an ACE inhibitor on
survival at 30 days, with beneﬁt seen as early as 24 hours
after admission for AMI (283). An ACE inhibitor should be
used cautiously in the ﬁrst 24 hours of AMI, because it may
result in hypotension or renal dysfunction (283). It may be
prudent to initially use a short-acting ACE inhibitor, such as
captopril or enalapril, in patients at increased risk of these
adverse events. In patients with signiﬁcant renal dysfunc-
tion, it is sensible to stabilize renal function before initi-
ating an ACE inhibitor or an ARB, with re-evaluation of
creatinine levels after drug initiation. An ARB may be
substituted for an ACE inhibitor with similar beneﬁts on
survival (277,278). Combining an ACE inhibitor and an ARBmay result in an increase in adverse events (277,278). In a
study in which patients with AMI with LV dysfunction
(LVEF <0.40) with or without HF were randomized 3 to 14
days after AMI to receive eplerenone (a selective aldoste-
rone blocker), eplerenone was efﬁcacious as an adjunct to
ACE inhibitors and beta blockers in decreasing long-term
mortality (279,287). In a study of patients with HF,
>50% of whom had an ischemic etiology, spironolactone
(a nonselective aldosterone inhibitor) was beneﬁcial (279);
however, RCT data on MI are not available.
See Online Data Supplement 14 for additional informa-
tion on inhibitors of the renin-angiotensin-aldosterone
system.
4.3. Initial Antiplatelet/Anticoagulant Therapy in Patients With
Deﬁnite or Likely NSTE-ACS
4.3.1. Initial Oral and Intravenous Antiplatelet Therapy in
Patients With Deﬁnite or Likely NSTE-ACS Treated With an
Initial Invasive or Ischemia-Guided Strategy:
Recommendations
See Table 7 for a summary of recommendations from this
section and Online Data Supplement 15 for additional infor-
mation on initial oral and intravenous antiplatelet therapy
in patients with deﬁnite or likely NSTE-ACS treated with
an early invasive or an ischemia-guided strategy.
CLASS Iz
1. Non–enteric-coated, chewable aspirin (162 mg to 325 mg)
should be given to all patients with NSTE-ACS without
contraindications as soon as possible after presentation,
and a maintenance dose of aspirin (81 mg/d to 325 mg/d)
should be continued indeﬁnitely (288–290,293,391). (Level
of Evidence: A)
2. In patients with NSTE-ACS who are unable to take aspirin
because of hypersensitivity or major gastrointestinal intol-
erance, a loading dose of clopidogrel followed by a daily
maintenance dose should be administered (291). (Level of
Evidence: B)
3. A P2Y12 inhibitor (either clopidogrel or ticagrelor) in addition
to aspirin should be administered for up to 12 months to all
patients with NSTE-ACS without contraindications who are
treated with either an early invasivex or ischemia-guided
strategy. Options include:
 Clopidogrel: 300-mg or 600-mg loading dose, then 75
mg daily (289,292) (Level of Evidence: B)
 Ticagrelork: 180-mg loading dose, then 90 mg twice daily
(293,294) (Level of Evidence: B)
TABLE 7
Summary of Recommendations for Initial Antiplatelet/Anticoagulant Therapy in Patients With Deﬁnite or Likely
NSTE-ACS and PCI
Recommendations Dosing and Special Considerations COR LOE References
Aspirin
 Non–enteric-coated aspirin to all patients promptly after
presentation
162 mg–325 mg I A (288–290)
 Aspirin maintenance dose continued indeﬁnitely 81 mg/d–325 mg/d* I A (288–290,
293,391)
P2Y12 inhibitors
 Clopidogrel loading dose followed by daily maintenance
dose in patients unable to take aspirin
75 mg I B (291)
 P2Y12 inhibitor, in addition to aspirin, for up to 12 mo for
patients treated initially with either an early invasive or
initial ischemia-guided strategy:
 Clopidogrel
 Ticagrelor*
I B
300-mg or 600-mg loading dose,
then 75 mg/d
(289,292)
180-mg loading dose, then 90 mg BID (293,294)
 P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor)
continued for at least 12 mo in post–PCI patients treated with
coronary stents
N/A I B (293,296,302,
330,331)
 Ticagrelor in preference to clopidogrel for patients treated
with an early invasive or ischemia-guided strategy
N/A IIa B (293,294)
GP IIb/IIIa inhibitors
 GP IIb/IIIa inhibitor in patients treated with an early invasive
strategy and DAPT with intermediate/high-risk features
(e.g., positive troponin)
Preferred options are eptiﬁbatide or
tiroﬁban
IIb B (43,94,295)
Parenteral anticoagulant and ﬁbrinolytic therapy
 SC enoxaparin for duration of hospitalization or until PCI
is performed
 1 mg/kg SC every 12 h (reduce dose to
1 mg/kg/d SC in patients with CrCl
<30 mL/min)
 Initial 30 mg IV loading dose
in selected patients
I A (133,136,309)
 Bivalirudin until diagnostic angiography or PCI is performed
in patients with early invasive strategy only
 Loading dose 0.10 mg/kg loading dose
followed by 0.25 mg/kg/h
 Only provisional use of GP IIb/IIIa inhibitor
in patients also treated with DAPT
I B (292,293,
310,311)
 SC fondaparinux for the duration of hospitalization or until
PCI is performed
2.5 mg SC daily I B (312–314)
 Administer additional anticoagulant with anti-IIa activity if
PCI is performed while patient is on fondaparinux
N/A I B (313–315)
 IV UFH for 48 h or until PCI is performed  Initial loading dose 60 IU/kg (max
4,000 IU) with initial infusion 12 IU/kg/h
(max 1,000 IU/ h)
 Adjusted to therapeutic aPTT range
I B (316–322)
 IV ﬁbrinolytic treatment not recommended in patients with
NSTE-ACS
N/A III: Harm A (93,329)
See Section 5.1.2.1 for recommendations on antiplatelet/anticoagulant therapy at the time of PCI and Sections 6.2.1 and 6.3 for recommendations on posthospital therapy.
*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (290).
aPTT indicates activated partial thromboplastin time; BID, twice daily; COR, Class of Recommendation; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; GP, glycoprotein;
IV, intravenous; LOE, Level of Evidence; max, maximum; N/A, not available; NSTE-ACS, non–ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention; SC,
subcutaneous; and UFH, unfractionated heparin.
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1. It is reasonable to use ticagrelor in preference to clopidogrel
for P2Y12 treatment in patients with NSTE-ACS who undergo
an early invasive or ischemia-guided strategy (293,294).
(Level of Evidence: B)
CLASS IIb
1. In patients with NSTE-ACS treated with an early in-
vasive strategy and dual antiplatelet therapy (DAPT)
with intermediate/high-risk features (e.g., positive troponin),a GP IIb/IIIa inhibitor may be considered as part of initial an-
tiplatelet therapy. Preferred options are eptiﬁbatide or tir-
oﬁban (43,94,295). (Level of Evidence: B)
Despite the large number of new antiplatelet and antith-
rombotic agents, aspirin, which targets COX and subsequent
thromboxane A2 inhibition, is the mainstay of antiplatelet
therapy. Multiple other pathways of platelet activation can be
targeted by agents that inhibit the platelet P2Y12 receptor,
including thienopyridine prodrug agents, such as clopidogrel
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bind irreversibly to the P2Y12 receptor. Additional pyrimidine
derivatives, including ticagrelor, do not require biotransfor-
mation and bind reversibly to the P2Y12 receptor, antagonizing
adenosine diphosphate platelet activation. In addition to these
oral agents, intravenous GP IIb/IIIa receptor inhibitors,
including abciximab, eptiﬁbatide, and tiroﬁban, target the ﬁnal
common pathway of platelet aggregation. In the EARLY ACS
(Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-
Segment Elevation Acute Coronary Syndrome) trial, patients
were randomly assigned to either early, pre–PCI double-bolus
eptiﬁbatide or delayed, provisional eptiﬁbatide. Seventy-ﬁve
percent of the patients received upstream, preprocedure clo-
pidogrel. The risk of TIMI major bleeding in the early eptiﬁ-
batide group was 2.6% compared with 1.8% (p¼0.02) in the
delayed provisional group (295). In the GUSTO IV-ACS (Global
Use of Strategies To Open Occluded Coronary Arteries IV-
Acute Coronary Syndromes) trial, there was no clinical
beneﬁt of abciximab in this population; in troponin-negative
patients, mortality was 8.5% compared with 5.8% in controls
(p¼0.002) (288,289,296,297).
4.3.1.1. Aspirin
Aspirin is the established ﬁrst-line therapy in patients
with NSTE-ACS and reduces the incidence of recurrent MI
and death (288,289). A loading dose of non–enteric-
coated aspirin 162 mg to 325 mg is the initial antiplatelet
therapy. The subsequent maintenance dose is 81 mg per
day to 162 mg per day; in special circumstances, a higher
maintenance dose up to 325 mg daily has been used (391).
The lower dose is favored and all patients treated with
ticagrelor should receive only 81 mg per day (290). In
other countries, available low-dose aspirin formations
may include 75 mg and 100 mg. High-dose ($160 mg)
versus low-dose (<160 mg) aspirin is associated with
increased bleeding risk in the absence of improved
outcomes (298). Most NSAIDs reversibly bind to COX-1,
preventing inhibition by aspirin and by COX-2 and
may cause prothrombotic effects. Enteric-coated aspirin
should be avoided initially because of its delayed and
reduced absorption (299).
4.3.1.2. P2Y12 Receptor Inhibitors
Three P2Y12 receptor inhibitors are approved in the United
States for treatment of ischemic myocardial disorders,
including NSTE-ACS. For discontinuation before surgery,
see Section 5.
Clopidogrel
Administration of clopidogrel with aspirin was superior
to administration of aspirin alone in reducing the inci-
dence of cardiovascular death and nonfatal MI or
stroke both acutely and over the following 11 months
(289,296). There was a slight increase in major bleedingevents with clopidogrel, including a nonsigniﬁcant in-
crease in life-threatening bleeding and fatal bleeding
(289). An initial loading dose of 300 mg to 600 mg is
recommended (289,296,300). A 600-mg loading dose re-
sults in a greater, more rapid, and more reliable platelet
inhibition compared with a 300-mg loading dose (301).
Use of clopidogrel for patients with NSTE-ACS who are
aspirin intolerant is based on a study in patients with
stable ischemic heart disease (291). When possible, dis-
continue clopidogrel at least 5 days before surgery (301).
Prasugrel
The metabolic conversion pathways of prasugrel produce
more rapid and consistent platelet inhibition than
clopidogrel (300). In patients with NSTE-ACS and deﬁned
coronary anatomy undergoing planned PCI, a 60-mg
loading dose of prasugrel followed by 10 mg daily was
compared with a 300-mg loading dose and 75 mg daily of
clopidogrel. The composite primary endpoint (cardiovas-
cular death, nonfatal MI, and stroke) was reduced in
patients treated with prasugrel (hazard ratio [HR]: 0.81;
p¼0.001). This was driven by a risk reduction for MI and
stent thrombosis with no difference in mortality (302).
Counterbalancing the salutary effects of prasugrel was a
signiﬁcant increase in spontaneous bleeding, life-
threatening bleeding, and fatal bleeding in the patients
treated with prasugrel compared with patients treated
with clopidogrel. There was net harm in patients with a
history of cerebrovascular events and no clinical beneﬁt
in patients >75 years of age or those with low body weight
(<60 kg) (302). In patients with NSTE-ACS treated with an
ischemia-guided strategy, 1 RCT comparing aspirin and
either clopidogrel or prasugrel evaluated the primary
endpoint of death from cardiovascular causes,MI, or stroke
for up to 30 months; there were similar bleeding rates and
no beneﬁt of treatment with prasugrel when compared
with treatment with clopidogrel (303). The ACCOAST (A
Comparison of Prasugrel at the Time of Percutaneous Cor-
onary Intervention or as Pretreatment at the Time of
Diagnosis in Patients With Non–ST-Elevation Myocardial
Infarction) RCT of high-risk patients with NSTE-ACS
scheduled to undergo early coronary angiography found
that a strategy of administration of prasugrel at the time of
randomization before angiography did not lead to a
reduction in the composite primary endpoint when
compared with a strategy of administration of prasugrel
only at the time of PCI; however, it did lead to an increase in
bleeding complications (304). On the basis of TRITON (Trial
to Assess Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel) study design
and the results of TRILOGY ACS (Targeted Platelet Inhibi-
tion to Clarify the Optimal Strategy to Medically Manage
Acute Coronary Syndromes) and ACCOAST, prasugrel is
not recommended for “upfront” therapy in patients with
zSee Section 5.1.2.1 for recommendations at the time of PCI.
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PCI is addressed in Section 5.
Ticagrelor
Ticagrelor is an oral, reversibly binding P2Y12 inhibitor
with a relatively short plasma half-life (12 hours).
Compared with clopidogrel, ticagrelor has a more rapid
and consistent onset of action and, because it is revers-
ible, it has a faster recovery of platelet function. The
loading dose of ticagrelor for patients treated either
invasively or with an ischemia-guided strategy is 180 mg
followed by a maintenance dose of 90 mg twice daily
(293,294). In patients with NSTE-ACS treated with tica-
grelor compared with clopidogrel, there was a reduction in
the composite outcome of death from vascular causes, MI,
or stroke (reduction: 11.7% to 9.8%; HR: 0.84; p<0.001)
(293). The mortality rate was also lower in those patients
treated with ticagrelor. Although overall major bleeding
was not increased with ticagrelor, a modest increase in
major bleeding and non–procedure-related bleeding
occurred in the subgroup of patients who did not undergo
CABG (major bleeding: 4.5% versus 3.8%; p¼0.02; non-
procedure major bleeding: 3.1% versus 2.3%; p¼0.05);
however, there was no difference in blood transfusion or
fatal bleeding (305). Side effects unique to ticagrelor
include dyspnea (which occurs in up to 15% of patients
within the ﬁrst week of treatment but is rarely severe
enough to cause discontinuation of treatment) (293) and
bradycardia. The beneﬁt of ticagrelor over clopidogrel was
limited to patients taking 75 mg to 100 mg of aspirin (290).
The short half-life requires twice-daily administration,
which could potentially result in adverse events in non-
compliant patients, particularly after stent implantation.
When possible, ticagrelor should be discontinued at least
5 days before surgery (306). Although ticagrelor has not
been studied in the absence of aspirin, its use in aspirin-
intolerant patients is a reasonable alternative.
Intravenous GP IIb/IIIa Receptor Inhibitors
The small molecule GP IIb/IIIa receptor antagonists,
tiroﬁban and eptiﬁbatide, bind reversibly to the GP
IIb/IIIa receptor. Because the drug-to-receptor ratio is
high, platelet infusion is not effective in cases of severe
bleeding after use of eptiﬁbatide or tiroﬁban, and they
must be cleared from the circulation to reduce bleeding.
In contrast, with abciximab, the drug-to-receptor ratio is
low, and platelet infusion may be effective.
Several large RCTs evaluated the impact of GP IIb/IIIa
receptor inhibitors in patients with NSTE-ACS who were
committed to an invasive strategy (295,296,306). The
ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) trial evaluated unfractionated heparin
(UFH) versus bivalirudin with or without GP IIb/IIIa in-
hibitors (295,307). The rates of composite ischemia(death, MI, unplanned revascularization) in patients who
received bivalirudin alone compared with those who
received UFH plus GP IIb/IIIa inhibitors were similar (9%
versus 8%; p¼0.45) (307). Fewer patients experienced
major bleeding with bivalirudin alone than did with
heparin plus GP IIb/IIIa inhibitors (4% versus 7%; relative
risk [RR]: 0.52; 95% conﬁdence interval [CI]: 0.40 to 0.66;
p<0.0001) (307). The ACUITY Timing trial evaluated the
beneﬁt of upstream GP IIb/IIIa receptor antagonist
compared with its deferred use, testing the hypothesis
that earlier administration of GP IIb/IIIa inhibitors in pa-
tients destined for PCI would be superior (308). Com-
posite ischemia at 30 days occurred in 7.9% of patients
assigned to deferred use compared with 7.1% assigned to
upstream administration (RR: 1.12; 95% CI: 0.97 to 1.29;
p¼0.044 for noninferiority; p¼0.13 for superiority). De-
ferred GP IIb/IIIa inhibitors reduced the 30-day rates of
major bleeding compared with upstream use (4.9% versus
6.1%; p<0.001) (308). Similar results were reported by the
EARLY ACS investigators, who evaluated eptiﬁbatide
given upstream versus delayed, provisional admini-
stration in >9,000 patients with NSTE-ACS (295).
The composite endpoint of death, MI, recurrent
ischemia requiring urgent revascularization, or throm-
botic complications occurred in 9.3% of patients in the
early-eptiﬁbatide group compared with 10% in the
delayed-eptiﬁbatide group (odds ratio [OR]: 0.92; 95% CI:
0.80 to 1.06; p¼0.23) (308). As in the ACUITY Timing trial,
the early-eptiﬁbatide group had signiﬁcantly higher rates
of bleeding and red cell transfusions (295,308).
4.3.2. Initial Parenteral Anticoagulant Therapy in Patients With
Deﬁnite NSTE-ACS: Recommendations
See Table 7 for a summary of recommendations regarding
antiplatelet/anticoagulant therapy in patients with deﬁ-
nite or likely NSTE-ACS and Online Data Supplement 16
for additional information on combined oral anticoagu-
lant therapy and antiplatelet therapy in patients with
deﬁnite NSTE-ACS.
CLASS Iz
1. In patients with NSTE-ACS, anticoagulation, in addition to
antiplatelet therapy, is recommended for all patients irre-
spective of initial treatment strategy. Treatment options
include:
 Enoxaparin: 1 mg/kg subcutaneous (SC) every 12 hours
(reduce dose to 1 mg/kg SC once daily in patients with
creatinine clearance [CrCl]<30 mL/min), continued for the
duration of hospitalization or until PCI is performed. An
initial intravenous loading dose of 30 mg has been used
in selected patients (133,136,309). (Level of Evidence: A)
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mg/kg per hour (only in patients managed with an early
invasive strategy), continued until diagnostic angiography
or PCI, with only provisional use of GP IIb/IIIa inhibitor,
provided the patient is also treated with DAPT
(292,293,310,311). (Level of Evidence: B)
 Fondaparinux: 2.5 mg SC daily, continued for the duration
of hospitalization or until PCI is performed (312–314).
(Level of Evidence: B)
 If PCI is performed while the patient is on fondaparinux, an
additional anticoagulant with anti-IIa activity (either UFH
or bivalirudin) should be administered because of the risk
of catheter thrombosis (313–315). (Level of Evidence: B)
 UFH IV: initial loading dose of 60 IU/kg (maximum
4,000 IU) with initial infusion of 12 IU/kg per hour
(maximum 1,000 IU/h) adjusted per activated partial
thromboplastin time to maintain therapeutic anti-
coagulation according to the speciﬁc hospital protocol,
continued for 48 hours or until PCI is performed
(316–322). (Level of Evidence: B)4.3.2.1. Low-Molecular-Weight Heparin
LMWHs have a molecular weight approximately one
third that of UFH and have balanced anti-Xa and anti-IIa
activity. LMWHs are readily absorbed after subcutane-
ous administration and have less platelet activation
(323). The anticoagulant activity of LMWH does not
require routine monitoring. The dose of enoxaparin is
1 mg/kg SC every 12 hours for NSTE-ACS; an initial
intravenous loading dose of 30 mg has been used in
selected patients. In the presence of impaired renal
function (CrCl <30 mL per minute), which is a common
ﬁnding in older patients, the dose should be reduced to
1 mg/kg SC once daily, and strong consideration should
be given to UFH as an alternative. Calculation of CrCl is
prudent in patients considered for enoxaparin therapy.
In the ESSENCE trial, in patients with UA or non–
Q-wave MI, the rates of recurrent ischemic events and
invasive diagnostic and therapeutic procedures were
signiﬁcantly reduced by enoxaparin therapy in the short
term, and beneﬁt was sustained at 1 year (324).
In the SYNERGY (Superior Yield of the New Strategy of
Enoxaparin, Revascularization and Glycoprotein IIb/IIIa
Inhibitors) trial of high-risk patients with NSTE-ACS
treated with an early invasive strategy, there was no sig-
niﬁcant difference in death or MI at 30 days between
those randomized to enoxaparin versus UFH. There was
more TIMI major bleeding in those treated with enox-
aparin without statistically signiﬁcant increase in GUSTO
severe bleeding or transfusion. Some of the increased
bleeding may have been related to patients randomized to
enoxaparin who received additional UFH at the time of
PCI (325,326).4.3.2.2. Bivalirudin
The direct thrombin inhibitor bivalirudin is administered
intravenously. Bivalirudin was evaluated in the ACUITY
trial, a randomized open-label trial, in 13,819 moderate- to
high-risk patients with NSTE-ACS with a planned invasive
strategy. Three treatment arms were tested, including
UFH or LMWH with a GP IIb/IIIa receptor inhibitor, biva-
lirudin with a GP IIb/IIIa receptor inhibitor, or bivalirudin
alone. The majority of patients received clopidogrel (300
mg) before intervention, in addition to aspirin, anticoag-
ulants, and GP IIb/IIIa inhibitors. Bivalirudin alone was
noninferior to the standard UFH/LMWH combined with
GP IIb/IIIa inhibitor (composite ischemia endpoint 7.8%
versus 7.3%; HR: 1.08; p¼0.32), but there was a signiﬁ-
cantly lower rate of major bleeding with bivalirudin (3.0%
versus 5.7%; HR: 0.53; p<0.001) (310). The anticoagulant
effect of bivalirudin can be monitored in the catheteri-
zation laboratory by the activated clotting time.
4.3.2.3. Fondaparinux
Fondaparinux is a synthetic polysaccharide molecule and
the only selective inhibitor of activated factor X available
for clinical use. Fondaparinux is well absorbed when
given subcutaneously and has a half-life of 17 hours,
enabling once-daily administration. Because it is excreted
by the kidneys, it is contraindicated if CrCl is <30 mL per
minute. Monitoring of anti-Xa activity is not required,
and fondaparinux does not affect usual anticoagulant
parameters such as activated partial thromboplastin time
or activated clotting time. In NSTE-ACS, the dose of fon-
daparinux is 2.5 mg SC administered daily and continued
for the duration of hospitalization or until PCI is per-
formed (312–314). In the OASIS (Organization to Assess
Strategies in Ischemic Syndromes)-5 study, patients with
NSTE-ACS were randomized to receive 2.5 mg SC fonda-
parinux daily or enoxaparin 1 mg/kg SC twice daily for 8
days. The incidence of the primary composite ischemic
endpoint at 9 days was similar between fondaparinux and
enoxaparin, but major bleeding was signiﬁcantly less
frequent with fondaparinux. To avert catheter thrombosis
when fondaparinux is used alone in patients undergoing
PCI, an anticoagulant with anti-IIa activity is also
administered (313–315). One regimen is 85 IU/kg of UFH
loading dose at the time of PCI (reduced to 60 IU/kg if a GP
IIb/IIIa inhibitor is used concomitantly) (314).
4.3.2.4. Unfractionated Heparin
Studies supporting the addition of a parenteral anti-
coagulant to aspirin in patients with NSTE-ACS were
performed primarily on patients with a diagnosis of
“unstable angina” in the era before DAPT and early
catheterization and revascularization. In general, those
studies found a strong trend for reduction in composite
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aspirin therapy (316–322).
Clinical trials indicate that a weight-adjusted dosing
regimen of UFH can provide more predictable anti-
coagulation (327) than a ﬁxed initial dose (e.g., 5,000 IU
loading dose, 1,000 IU/h initial infusion). The recom-
mended weight-adjusted regimen is an initial loading
dose of 60 IU/kg (maximum 4,000 IU) and an initial
infusion of 12 IU/kg/h (maximum 1,000 IU/h), adjusted
using a standardized nomogram.
4.3.2.5. Argatroban
Argatroban, a direct thrombin inhibitor, is indicated for
prophylaxis or treatment of thrombosis in patients with
heparin-induced thrombocytopenia, including those un-
dergoing PCI (328). Steady state plasma concentrations
are achieved in 1 to 3 hours after intravenous adminis-
tration. Because of its hepatic metabolism, argatroban can
be used in patients with renal insufﬁciency. The usual
dose is 2 mcg/kg per minute by continuous intravenous
infusion, adjusted to maintain the activated partial
thromboplastin time at 1.5 to 3 times baseline (but not
>100 s).
4.3.3. Fibrinolytic Therapy in Patients With Deﬁnite NSTE-ACS:
Recommendation
CLASS III: HARM
1. In patients with NSTE-ACS (i.e., without ST-elevation, true
posterior MI, or left bundle-branch block not known to be
old), intravenous ﬁbrinolytic therapy should not be used
(93,329). (Level of Evidence: A)
There is no role for ﬁbrinolytic therapy in patients with
NSTE-ACS. Fibrinolysis with or without subsequent PCI in
patients with NSTE-ACS was evaluated by the Fibrinolytic
Trialists and TIMI investigators (93,329). There was no
beneﬁt for mortality or MI. Intracranial hemorrhage and fatal
and nonfatal MI occurred more frequently in patients treated
with ﬁbrinolytic therapy.
See Online Data Supplement 17 for additional in-
formation on parenteral anticoagulant and ﬁbrinolytic
therapy in patients with deﬁnite NSTE-ACS.
4.4. Ischemia-Guided Strategy Versus Early Invasive Strategies
See Figure 3 for the management algorithm for ischemia-
guided versus early invasive strategy.
4.4.1. General Principles
Two treatment pathways have emerged for all patients
with NSTE-ACS. The invasive strategy triages patients to
an invasive diagnostic evaluation (i.e., coronary angiog-
raphy). In contrast, the initial ischemia-guided strategy
calls for an invasive evaluation for those patients who
1) fail medical therapy (refractory angina or angina at restor with minimal activity despite vigorous medical
therapy), 2) have objective evidence of ischemia (dyna-
mic electrocardiographic changes, myocardial perfusion
defect) as identiﬁed on a noninvasive stress test, or
3) have clinical indicators of very high prognostic risk (e.g.,
high TIMI or GRACE scores). In both strategies, patients
should receive optimal anti-ischemic and antithrombotic
medical therapy as outlined in Section 4.1. A subgroup of
patients with refractory ischemic symptoms or hemody-
namic or rhythm instability are candidates for urgent
coronary angiography and revascularization.
4.4.2. Rationale and Timing for Early Invasive Strategy
This strategy seeks to rapidly risk stratify patients by
assessing their coronary anatomy. The major advantages
of invasive therapy when appropriate are 1) the rapid and
deﬁnitive nature of the evaluation, 2) the potential for
earlier revascularization in appropriate patients that
might prevent occurrence of further complications of ACS
that could ensue during medical therapy, and 3) facilita-
tion of earlier discharge from a facility.
4.4.2.1. Routine Invasive Strategy Timing
The optimal timing of angiography has not been con-
clusively deﬁned. In general, 2 options have emerged:
early invasive (i.e., within 24 hours) or delayed invasive
(i.e., within 25 to 72 hours). In most studies using the
invasive strategy, angiography was deferred for 12 to
72 hours while antithrombotic and anti-ischemic thera-
pies were intensiﬁed (138,332–337). The concept of de-
ferred angiography espouses that revascularization may
be safer once plaque is stabilized with optimal antith-
rombotic and/or anti-ischemic therapies. Conversely,
early angiography facilitates earlier risk stratiﬁca-
tion and consequently speeds revascularization and
discharge but can place greater logistic demands on a
healthcare system.
4.4.3. Rationale for Ischemia-Guided Strategy
The ischemia-guided strategy seeks to avoid the routine
early use of invasive procedures unless patients experi-
ence refractory or recurrent ischemic symptoms or
develop hemodynamic instability. When the ischemia-
guided strategy is chosen, a plan for noninvasive evalu-
ation is required to detect severe ischemia that occurs at a
low threshold of stress and to promptly refer these pa-
tients for coronary angiography and revascularization as
indicated. The major advantage offered by the ischemia-
guided strategy is that some patients’ conditions stabi-
lize during medical therapy and will not require coronary
angiography and revascularization. Consequently, the
ischemia-guided strategy may potentially avoid costly
and possibly unnecessary invasive procedures.
FIGURE 3 Algorithm for Management of Patients With Deﬁnite or Likely NSTE-ACS*
*See corresponding full-sentence recommendations and their explanatory footnotes.
†In patients who have been treated with fondaparinux (as upfront therapy) who are undergoing PCI, an additional anticoagulant with anti-IIa activity should be
administered at the time of PCI because of the risk of catheter thrombosis.
ASA indicates aspirin; CABG, coronary artery bypass graft; cath, catheter; COR, Class of Recommendation; DAPT, dual antiplatelet therapy; GPI, glycoprotein IIb/IIIa
inhibitor; LOE, Level of Evidence; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; pts, patients; and UFH,
unfractionated heparin.
J A C C V O L . 6 4 , N O . 2 4 , 2 0 1 4 Amsterdam et al.
D E C E M B E R 2 3 , 2 0 1 4 : e 1 3 9 – 2 2 8 2014 AHA/ACC NSTE-ACS Guideline
e167
TABLE 8
Factors Associated With Appropriate Selection
of Early Invasive Strategy or Ischemia-Guided
Strategy in Patients With NSTE-ACS
Immediate invasive
(within 2 h)
Refractory angina
Signs or symptoms of HF or new or worsening mitral
regurgitation
Hemodynamic instability
Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Sustained VT or VF
Ischemia-guided
strategy
Low-risk score (e.g., TIMI [0 or 1], GRACE [<109])
Low-risk Tn-negative female patients
Patient or clinician preference in the absence of
high-risk features
Early invasive
(within 24 h)
None of the above, but GRACE risk score >140
Temporal change in Tn (Section 3.4)
New or presumably new ST depression
Delayed invasive
(within 2572 h)
None of the above but diabetes mellitus
Renal insufﬁciency (GFR <60 mL/min/1.73 m2)
Reduced LV systolic function (EF <0.40)
Early postinfarction angina
PCI within 6 mo
Prior CABG
GRACE risk score 109–140; TIMI score $2
CABG indicates coronary artery bypass graft; EF, ejection fraction; GFR, glomerular
ﬁltration rate; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; LV,
left ventricular; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percuta-
neous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; Tn, troponin;
VF, ventricular ﬁbrillation; and VT, ventricular tachycardia.
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Recommendations
CLASS I
1. An urgent/immediate invasive strategy (diagnostic angiog-
raphy with intent to perform revascularization if appropriate
based on coronary anatomy) is indicated in patients (men
and women{) with NSTE-ACS who have refractory angina or
hemodynamic or electrical instability (without serious
comorbidities or contraindications to such procedures)
(42,44,138,338). (Level of Evidence: A)
2. An early invasive strategy (diagnostic angiography with
intent to perform revascularization if appropriate based on
coronary anatomy) is indicated in initially stabilized patients
with NSTE-ACS (without serious comorbidities or contrain-
dications to such procedures) who have an elevated risk for
clinical events (Table 8) (42,44,138,333,334,338,339).
(Level of Evidence: B)
CLASS IIa
1. It is reasonable to choose an early invasive strategy (within
24 hours of admission) over a delayed invasive strategy
(within 25 to 72 hours) for initially stabilized high-risk pa-
tients with NSTE-ACS. For those not at high/intermediate
risk, a delayed invasive approach is reasonable (139). (Level
of Evidence: B)
CLASS IIb
1. In initially stabilized patients, an ischemia-guided strategy
may be considered for patients with NSTE-ACS (without
serious comorbidities or contraindications to this approach)
who have an elevated risk for clinical events (333,334,338).
(Level of Evidence: B)
2. The decision to implement an ischemia-guided strategy in
initially stabilized patients (without serious comorbidities or
contraindications to this approach) may be reasonable after
considering clinician and patient preference. (Level of
Evidence: C)
CLASS III: NO BENEFIT
1. An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is not recommended in
patients with:
a. Extensive comorbidities (e.g., hepatic, renal, pulmonary
failure; cancer), in whom the risks of revascularization and
comorbid conditions are likely to outweigh the beneﬁts of
revascularization. (Level of Evidence: C)
b. Acute chest pain and a low likelihood of ACS who
are troponin-negative (Level of Evidence: C), especially
women (141). (Level of Evidence: B){See Section 7.7 for additional information on women.Several studies (93,138,334–337) and meta-analyses (141,340)
have concluded that a strategy of routine invasive therapy is
generally superior to an ischemia-guided strategy or selec-
tively invasive approach. One study reported that the routine
invasive strategy resulted in an 18% relative reduction in
death or MI, including a signiﬁcant reduction in MI alone
(341). The routine invasive arm was associated with higher
in-hospital mortality (1.8% versus 1.1%), but this disadvan-
tage was more than compensated for by a signiﬁcant
reduction in mortality between discharge and the end of
follow-up (3.8% versus 4.9%). The invasive strategy was also
associated with less angina and fewer rehospitalizations.
Patients undergoing routine invasive treatment also had
improved quality of life. In an analysis of individual patient
data (340) that reported 5-year outcomes from the FRISC
(Framingham and Fast Revascularization During Instability
in Coronary Artery Disease)-II trial (339), ICTUS (Invasive
Versus Conservative Treatment in Unstable Coronary Syn-
dromes) trial (338), and RITA (Randomized Trial of a Con-
servative Treatment Strategy Versus an Interventional
Treatment Strategy in Patients with Unstable Angina)-3 trial
(334), 14.7% of patients (389 of 2,721) randomized to a routine
invasive strategy experienced cardiovascular death or
nonfatal MI versus 17.9% of patients (475 of 2,746) in the
selective invasive strategy (HR: 0.81; 95% CI: 0.71 to 0.93;
p¼0.002). The most marked treatment effect was on MI
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invasive strategy), and there were consistent trends for fewer
cardiovascular deaths (HR: 0.83; 95% CI: 0.68 to 1.01;
p¼0.068) and all-cause mortality (HR: 0.90; 95% CI: 0.77 to
1.05). There were absolute reductions of 2.0% to 3.8% in
cardiovascular death or MI in the low- and intermediate-risk
groups and an 11.1% absolute risk reduction in the highest-
risk patients. The invasive strategy demonstrated its great-
est advantage in the highest-risk stratum of patients with no
signiﬁcant beneﬁt on mortality over the noninvasive
approach in moderate- and low-risk patients (342). An
ischemia-guided strategy has been used with favorable
results in initially stabilized patients with NSTE-ACS at
elevated risk for clinical events, including those with positive
troponin levels (338). One limitation of these studies is the
absence of adherence to optimal medical therapy in non-
invasively treated patients during long-termmanagement. In
addition, in FRISC-II, invasive management was delayed and
patients with markedly positive stress tests (up to 2.9-mm
exercise-induced ST depression) were randomized to
noninvasive or invasive therapy (338).
See Online Data Supplement 18 for additional infor-
mation on comparison of early invasive strategy and
ischemia-guided strategy.
4.4.4.1. Comparison of Early Versus Delayed Angiography
In some studies, early angiography and coronary inter-
vention have been more effective in reducing ischemic
complications than delayed interventions, particularly in
patients at high risk (deﬁned by a GRACE score >140)
(139,336). A more delayed strategy is also reasonable in
low- to intermediate-risk patients. The advantage of
early intervention was achieved in the context of
intensive background antithrombotic and anti-ischemic
therapy. However, this question was also assessed by a
meta-analysis of 11 trials (7 RCTs and 4 observational
studies) (343). Meta-analysis of the RCTs was inconclu-
sive for a survival beneﬁt of the early invasive strategy
(OR: 0.83 [95% CI: 0.64 to 1.09]; p¼0.180), and there
were no signiﬁcant differences in MI or major bleeding;
a similar result was found with the observational
studies. These data are limited by the small sample size
of the individual trials, low event rates, inconsistency in
timing of intervention, and heterogeneous patient
proﬁles.
See Online Data Supplement 19 for additional infor-
mation on comparison of early versus delayed angiography.
4.4.5. Subgroups: Early Invasive Strategy Versus
Ischemia-Guided Strategy
The TACTICS-TIMI (Treat Angina With Tiroﬁban and
Determine Cost of Therapy With an Invasive or Conser-
vative Strategy-Thrombolysis In Myocardial Infarction)
18 trial demonstrated a reduction in the 6-monthendpoint of death or MI in older adults with ACS (138).
Controversy exists over revascularization treatment dif-
ferences between men and women with ACS. The FRISC-
II trial showed a beneﬁt of revascularization in men for
death or MI that was not observed for women (344). In
contrast, death, MI, or rehospitalization rates were
reduced for both men and women in TACTICS-TIMI 18
(138). RITA-3 showed that the routine strategy of inva-
sive evaluation resulted in a beneﬁcial effect in high-risk
men that was not seen in women (342). A meta-analysis
suggests that in NSTE-ACS, an invasive strategy has a
comparable beneﬁt in men and high-risk women for
reducing the composite endpoint of death, MI, or reho-
spitalization (141,345,346). In contrast, an ischemia-
guided strategy is preferred in low-risk women (141).
Another collaborative meta-analysis of randomized trials
reported that an early invasive strategy yielded similar
RR reductions in overall cardiovascular events in pa-
tients with and without diabetes mellitus (347). How-
ever, an invasive strategy appeared to reduce recurrent
nonfatal MI to a greater extent in patients with diabetes
mellitus.
4.4.6. Care Objectives
Coronary angiography is designed to provide detailed
information about the size and distribution of coronary
vessels, the location and extent of atherosclerotic
obstruction, and the suitability for revascularization.
The LV angiogram, usually performed with coronary
angiography, provides an assessment of the extent of
focal and global LV dysfunction and of the presence and
severity of coexisting disorders (e.g., valvular or other
associated lesions). Patients with NSTE-ACS can be
divided into risk groups on the basis of their initial
clinical presentation. The TIMI, PURSUIT, and GRACE
scores are useful tools for assigning risk to patients with
NSTE-ACS.
Risk stratiﬁcation identiﬁes patients who are most
likely to beneﬁt from subsequent revascularization.
Patients with left main disease or multivessel CAD with
reduced LV function are at high risk for adverse outcomes
and are likely to beneﬁt from CABG. Clinical evaluation
and noninvasive testing aid in the identiﬁcation of most
patients at high risk because they often have $1 of the
following high-risk features: advanced age (>70 years
of age), prior MI, revascularization, ST deviation, HF,
depressed resting LV function (i.e., LVEF #0.40) on
noninvasive study, or noninvasive stress test ﬁndings,
including magnetic resonance imaging (348). Any of these
risk factors or diabetes mellitus may aid in the identiﬁ-
cation of high-risk patients who could beneﬁt from an
invasive strategy.
Some patients with NSTE-ACS are not in the very high-
risk group and do not have ﬁndings that portend a high
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the same degree of beneﬁt from routine revascularization
afforded to high-risk patients, and an invasive study is
optional for those at lower risk and can be safely deferred
pending further clinical evidence. Decisions about coro-
nary angiography in patients who are not at high risk
according to ﬁndings on clinical examination and nonin-
vasive testing can be individualized on the basis of
patient preferences and/or symptoms.
4.5. Risk Stratiﬁcation Before Discharge for Patients With an
Ischemia-Guided Strategy of NSTE-ACS: Recommendations
CLASS I
1. Noninvasive stress testing is recommended in low- and
intermediate-risk patients who have been free of ischemia at
rest or with low-level activity for a minimum of 12 to 24
hours (349–353). (Level of Evidence: B)
2. Treadmill exercise testing is useful in patients able to ex-
ercise in whom the ECG is free of resting ST changes that
may interfere with interpretation (349–352). (Level of
Evidence: C)
3. Stress testing with an imaging modality should be used in
patients who are able to exercise but have ST changes on
resting ECG that may interfere with interpretation. In pa-
tients undergoing a low-level exercise test, an imaging
modality can add prognostic information (349–352). (Level
of Evidence: B)
4. Pharmacological stress testing with imaging is recom-
mended when physical limitations preclude adequate exer-
cise stress. (Level of Evidence: C)
5. A noninvasive imaging test is recommended to evaluate LV
function in patients with deﬁnite ACS (349–352). (Level of
Evidence: C)
The management of patients with NSTE-ACS requires
continuous risk stratiﬁcation. Important prognostic infor-
mation is derived from initial assessment, the patient’s
course during the early days of management, and the
response to anti-ischemic and antithrombotic therapy. The
choice of stress test is based on the patient’s resting ECG and
ability to exercise, local expertise, and available technolo-
gies. The exercise intensity of the treadmill test (low level or
symptom-limited) is used at the discretion of the attending
clinician based on individual patient assessment. For inva-
sively managed patients with residual nonculprit lesions,
additional evaluation may be indicated to ascertain the
signiﬁcance of such lesions. Refer to the PCI CPG for addi-
tional details (26).
4.5.1. Noninvasive Test Selection
The goals of noninvasive testing in patients with a low or
intermediate likelihood of CAD and high-risk patients
who did not have an early invasive strategy are to detectischemia and estimate prognosis. This information guides
further diagnostic steps and therapeutic measures.
Because of its simplicity, lower cost, and widespread
familiarity with its performance and interpretation, the
standard low-level exercise electrocardiographic stress
test remains the most reasonable test in patients who are
able to exercise and who have a resting ECG that is
interpretable for ST shifts. There is evidence that imaging
studies are superior to exercise electrocardiographic
evaluation in women for diagnosis of CAD (350). How-
ever, for prognostic assessment in women, treadmill ex-
ercise testing has provided comparable results to stress
imaging (354). Patients with an electrocardiographic
pattern that would interfere with interpretation of the ST
segment (baseline ST abnormalities, bundle-branch block,
LV hypertrophy with ST-T changes, intraventricular con-
duction defect, paced rhythm, pre-excitation, and
digoxin) should have an exercise test with imaging.
Patients who are unable to exercise should have a
pharmacological stress test with imaging. Low- and
intermediate-risk patients with NSTE-ACS may undergo
symptom-limited stress testing, provided they have been
asymptomatic and clinically stable at 12 to 24 hours for
those with UA and 2 to 5 days for patients at similar risk
with NSTEMI (349). The optimal testing strategy in
women is less well deﬁned than in men.
4.5.2. Selection for Coronary Angiography
In contrast to noninvasive tests, coronary angiography
provides detailed structural information for assessment
of prognosis and appropriate management. When com-
bined with LV angiography, it also provides an assess-
ment of global and regional LV function. Coronary
angiography is usually indicated in patients with NSTE-
ACS who have recurrent symptoms or ischemia despite
adequate medical therapy or who are at high risk as
categorized by clinical ﬁndings (HF, serious ventricular
arrhythmias), noninvasive test ﬁndings (signiﬁcant LV
dysfunction with EF <0.40, large anterior or multiple
perfusion defects or wall motion abnormalities on
echocardiography, high-risk Duke treadmill score #11),
high-risk TIMI or GRACE scores, or markedly elevated
troponin levels. Patients with NSTE-ACS who have had
previous PCI or CABG should also be considered for early
coronary angiography, unless prior coronary angiography
data indicate that no further revascularization is
feasible.
The general indications for coronary angiography and
revascularization should be tempered by individual
patient characteristics and preferences (a patient-
centered approach). Patient and clinician judgments
about risks and beneﬁts are important for patients who
might not be candidates for coronary revascularization,
such as very frail older adults and those with serious
#Patients should receive a loading dose of prasugrel, provided that they were
not pretreated with another P2Y12 receptor inhibitor.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (290).
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or renal failure; active or inoperable cancer).
See Online Data Supplement 20 for additional infor-
mation on risk stratiﬁcation.
5. MYOCARDIAL REVASCULARIZATION
Recommendations about coronary artery revasculariza-
tion indications, beneﬁts, and choice of revascularization
procedure (PCI or CABG) for all anatomic subsets have
been published in the 2011 PCI CPG (26), the 2011 CABG
CPG (23), and the 2012 stable ischemic heart disease CPG
and its 2014 focused update (10,11). The main difference
between management of patients with stable ischemic
heart disease and NSTE-ACS is a stronger impetus for
revascularization in those with NSTE-ACS. Myocardial
ischemia in ACS may progress to MI and is potentially life
threatening. In addition, in patients with ACS, angina
(including recurrent angina) is more likely to be reduced
by revascularization than by medical therapy (26).
A “heart team” approach to revascularization de-
cisions, involving an interventional cardiologist and
cardiothoracic surgeon, is used in patients with unpro-
tected left main or complex CAD. Calculation of SYNTAX
(Synergy Between Percutaneous Coronary Intervention
With TAXUS and Cardiac Surgery) and STS scores is
reasonable in these patients to guide the choice of
revascularization (23,26,355).
Factors that inﬂuence the choice of revascularization
procedure include the extent and complexity of CAD;
short-term risk and long-term durability of PCI; operative
mortality (which can be estimated by the STS score);
diabetes mellitus; CKD; completeness of revasculariza-
tion; LV systolic dysfunction; previous CABG; and the
ability of the patient to tolerate and comply with DAPT. In
general, the greater the extent and complexity of the
multivessel disease, the more compelling the choice of
CABG over multivessel PCI (23,26,356–358). In patients
with NSTE-ACS, PCI of a culprit unprotected left main
coronary artery lesion is an option if the patient is not a
candidate for CABG (23,26).
See Online Data Supplements 21 and 22 for additional
information on myocardial revascularization.
5.1. Percutaneous Coronary Intervention
5.1.1. PCI—General Considerations: Recommendation
CLASS IIb
1. A strategy of multivessel PCI, in contrast to culprit
lesiononly PCI, may be reasonable in patients undergoing
coronary revascularization as part of treatment for NSTE-
ACS (330,359–364). (Level of Evidence: B)
Approximately half of all PCI procedures are performed in
patients with UA or NSTEMI, and approximately 32% to40% of patients with NSTE-ACS will undergo PCI (365). As
discussed previously, in patients with NSTE-ACS, a strategy
of early angiography and revascularization (primarily with
PCI) results in lower rates of recurrent UA, recurrent reho-
spitalization, MI, and death (366,367). Although PCI of a
nonculprit lesion is not advocated in patients with STEMI
(26), there is less agreement on whether nonculprit lesions
should undergo intervention at the time of culprit-lesion
PCI for NSTE-ACS. Most reports (359–364), but not all
(330), comparing culprit lesiononly PCI with multivessel
PCI (e.g., PCI of multiple vessels performed at the same
time) in patients with NSTE-ACS did not ﬁnd an increased
risk of MACE with multivessel PCI and found a reduction in
the need for repeat revascularization. However, the data
consist predominantly of post hoc analysis of non-
randomized data with variable duration of follow-up. This
question has not been resolved and is an area of current
investigation.
5.1.2. PCI—Antiplatelet and Anticoagulant Therapy
5.1.2.1. Oral and Intravenous Antiplatelet Agents:
Recommendations
CLASS I
1. Patients already taking daily aspirin before PCI should take
81 mg to 325 mg non–enteric-coated aspirin before PCI
(26,368–370). (Level of Evidence: B)
2. Patients not on aspirin therapy should be given non–enteric-
coated aspirin 325 mg as soon as possible before PCI
(26,368–370). (Level of Evidence: B)
3. After PCI, aspirin should be continued indeﬁnitely at a dose
of 81 mg to 325 mg daily (27,288,371). (Level of Evidence: B)
4. A loading dose of a P2Y12 receptor inhibitor should be given
before the procedure in patients undergoing PCI with
stenting (26,293,302,331,372–375). (Level of Evidence: A)
Options include:
a. Clopidogrel: 600 mg (331,372–374,376–378) (Level of
Evidence: B) or
b. Prasugrel#: 60 mg (302) (Level of Evidence: B) or
c. Ticagrelork: 180 mg (293) (Level of Evidence: B)
5. In patients with NSTE-ACS and high-risk features (e.g.,
elevated troponin) not adequately pretreated with clopi-
dogrel or ticagrelor, it is useful to administer a GP IIb/IIIa
inhibitor (abciximab, double-bolus eptiﬁbatide, or high-dose
bolus tiroﬁban) at the time of PCI (379–382). (Level of
Evidence: A)
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eluting stent [DES]) during PCI for NSTE-ACS, P2Y12 inhibi-
tor therapy should be given for at least 12 months (330).
Options include:
a. Clopidogrel: 75 mg daily (296,331) (Level of Evidence: B) or
b. Prasugrel#: 10 mg daily (302) (Level of Evidence: B) or
c. Ticagrelork: 90 mg twice daily (293) (Level of Evidence: B)
CLASS IIa
1. It is reasonable to choose ticagrelor over clopidogrel for
P2Y12 inhibition treatment in patients with NSTE-ACS
treated with an early invasive strategy and/or coronary
stenting (293,294). (Level of Evidence: B)
2. It is reasonable to choose prasugrel over clopidogrel for
P2Y12 treatment in patients with NSTE-ACS who undergo PCI
who are not at high risk of bleeding complications
(302,303). (Level of Evidence: B)
3. In patients with NSTE-ACS and high-risk features (e.g.,
elevated troponin) treated with UFH and adequately pre-
treated with clopidogrel, it is reasonable to administer a GP
IIb/IIIa inhibitor (abciximab, double-bolus eptiﬁbatide, or
high-bolus dose tiroﬁban) at the time of PCI (195,383,384).
(Level of Evidence: B)
4. After PCI, it is reasonable to use 81 mg per day of aspirin in
preference to higher maintenance doses (331,368,385–388).
(Level of Evidence: B)
5. If the risk of morbidity from bleeding outweighs the antici-
pated beneﬁt of a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation
(e.g., <12 months) of P2Y12 inhibitor therapy is reasonable
(330). (Level of Evidence: C)
CLASS IIb
1. Continuation of DAPT beyond 12 months may be con-
sidered in patients undergoing stent implantation. (Level of
Evidence: C)
CLASS III: HARM
1. Prasugrel should not be administered to patients with a prior
history of stroke or transient ischemic attack (302). (Level of
Evidence: B)
Comprehensive recommendations on the use of antiplatelet
and anticoagulant therapy in patients with NSTE-ACS under-
going PCI are given in the 2011 PCI CPG (26). Aspirin reduces
the frequency of ischemic complications after PCI and is
ideally administered at least 2 hours, and preferably 24 hours,#Patients should receive a loading dose of prasugrel, provided that they were
not pretreated with another P2Y12 receptor inhibitor.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (290).before PCI (26,368,369). DAPT, consisting of aspirin and a
P2Y12 inhibitor, in patients treated with coronary stents re-
duces the risk of stent thrombosis and composite ischemic
events (296,331,372–375,389,390). Compared with a loading
dose of 300 mg of clopidogrel, a loading dose of 600 mg of
clopidogrel in patients undergoing PCI achieves greater
platelet inhibition with fewer low responders and decreases
the incidence of MACE (376–378). In patients with ACS who
have undergone coronary stenting, treatment with prasugrel
or ticagrelor, compared with treatment with clopidogrel, re-
sults in a greater reduction in composite ischemic events and
the incidence of stent thrombosis, although at a risk of
increased non–CABG bleeding (293,302). The optimal duration
of DAPT therapy in patients treated with DES is not well
established (26). However, aspirin is continued indeﬁnitely in
all patients managed with a bare-metal stent or DES, and
DAPT is an option for >12 months in patients who have
received a DES. This determination should balance the risks of
stent thrombosis and ischemic complications versus bleeding
and should be jointly made by the clinician and the patient.
Loading and short-term maintenance doses of clopi-
dogrel were studied in CURRENT–OASIS (Clopidogrel
Optimal Loading Dose Usage to Reduce Recurrent Events–
Organization to Assess Strategies in Ischemic Syndromes)
7, which demonstrated a potential beneﬁt of higher-dose
clopidogrel (600-mg loading dose, 150 mg daily for
6 days, 75 mg daily thereafter) in patients with NSTE-ACS
undergoing an invasive management strategy (292,391).
Although the overall trial (292) failed to demonstrate a
signiﬁcant difference in the primary endpoint between the
clopidogrel and aspirin groups (4.2% versus 4.4%), the PCI
subset (n¼17,263) showed signiﬁcant differences in the
clopidogrel arm (391). Notably, the higher-dose clopidogrel
therapy increased major bleeding in the entire group (2.5%
versus 2.0%; p¼0.012) and the PCI subgroup (1.1% versus
0.7%; p¼0.008). In addition, during the period of several
hours required for conversion of clopidogrel to its active
metabolite, there is reduced effectiveness. However,
efﬁcacy is restored following conversion.
Patients undergoing PCI who have previously received
a loading dose of 300 mg of clopidogrel and are on a 75-mg
daily maintenance dose should receive another 300-mg
loading dose (315). There are no data appropriate for
prasugrel because this drug is administered before PCI.
For ticagrelor, there are no data on additional loading.
5.1.2.2. GP IIb/IIIa Inhibitors: Recommendations
CLASS I
1. In patients with NSTE-ACS and high-risk features (e.g.,
elevated troponin) who are not adequately pretreated with
clopidogrel or ticagrelor, it is useful to administer a GP IIb/
IIIa inhibitor (abciximab, double-bolus eptiﬁbatide, or high-
dose bolus tiroﬁban) at the time of PCI (379–382). (Level of
Evidence: A)
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1. In patients with NSTE-ACS and high-risk features (e.g.,
elevated troponin) treated with UFH and adequately pre-
treated with clopidogrel, it is reasonable to administer a GP
IIb/IIIa inhibitor (abciximab, double-bolus eptiﬁbatide, or
high-dose bolus tiroﬁban) at the time of PCI (195,383).
(Level of Evidence: B)
GP IIb/IIIa receptor antagonist therapy in patients with
NSTE-ACS undergoing PCI reduced the incidence of com-
posite ischemic events, primarily through a decrease in
documented MI, although in some trials this is counter-
balanced by an increased rate of bleeding (193,195,310,379–
382,392). Most, but not all, randomized trials of the use of
GP IIb/IIIa inhibitor were conducted in the era before clopi-
dogrel therapy (193,195,310,379–383,392). Abciximab, double-
bolus eptiﬁbatide, and high-bolus dose tiroﬁban result in a
high degree of platelet inhibition, reduce ischemic compli-
cations in patients undergoing PCI, and appear to afford
comparable angiographic and clinical outcomes (26). As trials
of the GP IIb/IIIa inhibitors generally excluded patients at
high risk of bleeding, recommendations for the use of GP IIb/
IIIa inhibitors are best understood as applying to patients not
at high risk of bleeding complications. Although GP IIb/IIIa
inhibitors were used in 27% and 55% of patients, respec-
tively, in the PLATO (Platelet Inhibition and Patient Out-
comes) and TRITON studies of ticagrelor and prasugrel, there
are insufﬁcient data (293,302,393) (and no RCT data) from
which to make speciﬁc recommendations about GP IIb/IIIa
inhibitor use in patients treated with either of these P2Y12
inhibitors.
See Online Data Supplement 21 for additional informa-
tion on GP IIb/IIIa inhibitors.
5.1.2.3. Anticoagulant Therapy in Patients Undergoing PCI:
Recommendations
CLASS I
1. An anticoagulant should be administered to patients with
NSTE-ACS undergoing PCI to reduce the risk of intracoronary
and catheter thrombus formation. (Level of Evidence: C)
2. Intravenous UFH is useful in patients with NSTE-ACS
undergoing PCI. (Level of Evidence: C)
3. Bivalirudin is useful as an anticoagulant with or without prior
treatment with UFH in patients with NSTE-ACS undergoing
PCI (310,394–398). (Level of Evidence: B)
4. An additional dose of 0.3 mg/kg IV enoxaparin should be
administered at the time of PCI to patients with NSTE-ACS
who have received fewer than 2 therapeutic subcutaneous
doses (e.g., 1 mg/kg SC) or received the last subcutaneous
enoxaparin dose 8 to 12 hours before PCI (309,399–403).
(Level of Evidence: B)
5. If PCI is performed while the patient is on fondaparinux, an
additional 85 IU/kg of UFH should be given intravenously
immediately before PCI because of the risk of catheterthrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with
UFH dosing based on the target-activated clotting time)
(26,313–315,404). (Level of Evidence: B)
6. In patients with NSTE-ACS, anticoagulant therapy should be
discontinued after PCI unless there is a compelling reason to
continue such therapy. (Level of Evidence: C)
CLASS IIa
1. In patients with NSTE-ACS undergoing PCI who are at
high risk of bleeding, it is reasonable to use bivalirudin
monotherapy in preference to the combination of UFH
and a GP IIb/IIIa receptor antagonist (310,396). (Level of
Evidence: B)
CLASS IIb
1. Performance of PCI with enoxaparin may be reasonable in
patients treated with upstream subcutaneous enoxaparin for
NSTE-ACS (26,309,399–402,405,406). (Level of Evidence: B)
CLASS III: HARM
1. Fondaparinux should not be used as the sole anticoagulant
to support PCI in patients with NSTE-ACS due to an
increased risk of catheter thrombosis (26,313–315). (Level of
Evidence: B)
Anticoagulant therapy prevents thrombus formation at the
site of arterial injury, on the coronary guide wire, and in
the catheters used for PCI (26,407). With rare exceptions,
all PCI studies have used some form of anticoagulant at
the time of PCI (26). Intravenous UFH and bivalirudin both
have Class I recommendations in patients undergoing
PCI in the 2011 PCI CPG (26). Patients who have received
multiple doses of subcutaneously-administered enoxaparin
who undergo PCI within 8 hours of the last subcutaneous
dose generally have received adequate anticoagulation to
undergo PCI, but the degree of anticoagulation may
diminish 8 to 12 hours after the last subcutaneous dose. In
such patients, as well as in patients who have received
fewer than 2 subcutaneous doses of enoxaparin, the
addition of enoxaparin (0.3 mg/kg IV) at the time of
PCI provides additional anticoagulation and has become
standard practice (26,309,399–403). Patients who undergo
PCI >12 hours after the last subcutaneous dose of enox-
aparin are usually treated with full-dose de novo anti-
coagulation with an established regimen (e.g., full-dose
UFH or bivalirudin). Fondaparinux as the sole anticoagu-
lant during PCI has been associated with catheter throm-
bosis, and use of an anticoagulant with anti-IIa activity is
recommended when patients treated with fondaparinux
undergo PCI (313–315). One suggested regimen is UFH 85
IU/kg IV if no GP IIb/IIIa inhibitor is used and 60 IU/kg IV
if a GP IIb/IIIa inhibitor is used with UFH dosing based on
the target-activated clotting time (314,404) (Table 9)
(26,313–315).
TABLE 9 Dosing of Parenteral Anticoagulants During PCI
Drug*
In Patients Who Have Received
Prior Anticoagulant Therapy
In Patients Who Have Not Received
Prior Anticoagulant Therapy
Enoxaparin  For prior treatment with enoxaparin, if last SC dose was
administered 812 h earlier or if <2 therapeutic SC doses
of enoxaparin have been administered, an IV dose of enoxaparin
0.3 mg/kg should be given
 If the last SC dose was administered within prior 8 h,
no additional enoxaparin should be given
 0.5 mg/kg–0.75 mg/kg IV loading dose
Bivalirudin  For patients who have received UFH, wait 30 min, then
give 0.75 mg/kg IV loading dose, then 1.75 mg/kg/h IV infusion
 For patients already receiving bivalirudin infusion, give
additional
loading dose 0.5 mg/kg and increase infusion to 1.75 mg/kg/h
during PCI
 0.75 mg/kg loading dose, 1.75 mg/kg/h IV infusion
Fondaparinux  For prior treatment with fondaparinux, administer additional IV
treatment with anticoagulant possessing anti-IIa activity, considering
whether GPI receptor antagonists have been administered
N/A
UFH  IV GPI planned: additional UFH as needed (e.g., 2,000–5,000 U) to
achieve ACT of 200–250 s
 No IV GPI planned: additional UFH as needed (e.g., 2,000–5,000 U)
to achieve ACT of 250–300 s for HemoTec, 300–350 s for Hemochron
 IV GPI planned: 50–70 U/kg loading dose to achieve
ACT of 200–250 s
 No IV GPI planned: 70–100 U/kg loading dose to achieve
target ACT of 250–300 s for HemoTec, 300–350 s
for Hemochron
*Drugs presented in order of the COR and then the LOE as noted in the Preamble. When more than 1 drug exists within the same LOE, and there are no comparative data, then the drugs
are listed alphabetically.
ACT indicates activated clotting time; COR, Class of Recommendation; GPI, glycoprotein IIb/IIIa inhibitor; IV, intravenous; LOE, Level of Evidence; N/A, not applicable; PCI,
percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin.
Modiﬁed from Levine et al. (26).
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Relation to Use of Antiplatelet Agents: Recommendations
CLASS I
1. Non–enteric-coated aspirin (81 mg to 325 mg daily) should
be administered preoperatively to patients undergoing
CABG (408–410). (Level of Evidence: B)
2. In patients referred for elective CABG, clopidogrel and
ticagrelor should be discontinued for at least 5 days before
surgery (23,411–413) (Level of Evidence: B) and prasugrel for
at least 7 days before surgery (8,414). (Level of Evidence: C)
3. In patients referred for urgent CABG, clopidogrel and tica-
grelor should be discontinued for at least 24 hours to reduce
major bleeding (8,412,415–417). (Level of Evidence: B)
4. In patients referred for CABG, short-acting intravenous GP
IIb/IIIa inhibitors (eptiﬁbatide or tiroﬁban) should be dis-
continued for at least 2 to 4 hours before surgery (418,419)
and abciximab for at least 12 hours before to limit blood loss
and transfusion (389). (Level of Evidence: B)
CLASS IIb
1. In patients referred for urgent CABG, it may be rea-
sonable to perform surgery less than 5 days after clopi-
dogrel or ticagrelor has been discontinued and less than 7 days
after prasugrel has been discontinued. (Level of Evidence: C)
In-hospital CABG is performed in 7% to 13% of patients hospi-
talized with NSTE-ACS (420–422). Approximately one third of
patients with NSTEMI undergo CABG within 48 hours of hos-
pital admission (421). In these patients, CABG was performed
at a median time of 73 hours after admission (interquartilerange: 42 to 122 hours) (421). In-hospital mortality in patients
with NSTEMI undergoing CABG is approximately 3.7% (421).
Recommendations for management of patients treated
with oral and intravenous antiplatelet agents who undergo
CABG are given in the 2011 CABG CPG (23). Preoperative
aspirin reduces operative morbidity and mortality, and
CABG can be performed safely in patients on aspirin ther-
apy with only a modest increase in bleeding risk (23,408–
410). The use of P2Y12 inhibitors in patients with NSTE-
ACS is associated with an increase in post–CABG bleeding
and the need for transfusion (293,302,411,413,423–425).
Although it is recommended that clopidogrel and ticagrelor
be discontinued at least 5 days before surgery and prasu-
grel at least 7 days before surgery in patients referred for
elective CABG (23,411–413), the timing of CABG in patients
with NSTE-ACS treated with a P2Y12 inhibitor (330) should
reﬂect a balance of the potential increase in bleeding
against the potential beneﬁts of not delaying surgery 5 to 7
days. The risk of major bleeding complications is
increased when CABG is performed <24 hours after
discontinuation of clopidogrel (23,416,417). In patients
who undergo CABG 1 to 4 days after discontinuation of
clopidogrel, it appears that the incidence of life-
threatening bleeding is not signiﬁcantly increased, but
an increase in blood transfusions is likely
(23,415,416,425,426). In the TRITON-TIMI 38 trial (302),
the incidence of CABG-related major bleeding was higher
in patients treated with prasugrel than in patients treated
with clopidogrel (23,386). In the PLATO trial, the rates of
major bleeding and transfusion requirements were similar
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (290).
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treated with clopidogrel (294). The more rapid recovery of
platelet function in pharmacokinetic studies of ticagrelor
did not translate to a lower risk of bleeding or lessen the
need for transfusion compared with clopidogrel when
CABG was performed early (i.e., <5 days) after drug
discontinuation (23,293,412).
See Online Data Supplements 21 and 22 for more
information on myocardial revascularization.
6. LATE HOSPITAL CARE, HOSPITAL DISCHARGE,
AND POSTHOSPITAL DISCHARGE CARE
6.1. General Principles (Cardioprotective Therapy and
Symptom Management)
The goals of therapy after NSTE-ACS are to restore the patient
to normal activities to the extent possible and to use the
acute event to re-evaluate the plan of care, particularly life-
style and risk factor modiﬁcation. Aggressive risk factor
modiﬁcations that can prolong survival should be the main
goal of long-term management of patients with stable CAD.
Patients presenting with NSTE-ACS represent a high-risk
cohort in whom secondary cardiovascular disease preven-
tion is likely to be particularly effective (Table 10). Clinicians
have an opportunity to provide evidence-based care to this
high-risk cohort and to aggressively treat the underlying
atherosclerotic process through lifestyle modiﬁcation and
effective pharmacological therapies (427). In most cases, the
inpatient anti-ischemic medical regimen should be
continued after discharge, and the antiplatelet/anticoagulant
medications should be changed to an outpatient regimen.
The goals for continued medical therapy after discharge
relate to potential prognostic beneﬁts (primarily shown for
antiplatelet agents, beta blockers, statins, and inhibitors of
the renin-angiotensin aldosterone system, especially for
LVEF <0.40). Added beneﬁts are control of ischemic symp-
toms (nitrates, beta blockers, CCBs, and ranolazine) and
treatment of major risk factors such as smoking, hyperten-
sion, dyslipidemia, physical inactivity, obesity, and diabetes
mellitus (427). Selection of a medical regimen should be
individualized to each patient on the basis of in-hospital
ﬁndings, risk factors for CAD, drug tolerability, and recent
procedural interventions. The mnemonic “ABCDE” (Aspirin,
Antianginals, and ACE Inhibitors; Beta Blockers and BP;
Cholesterol and Cigarettes; Diet and Diabetes Mellitus;
Education and Exercise) is useful in guiding treatment (428).
6.2. Medical Regimen and Use of Medications at Discharge:
Recommendations
CLASS I
1. Medications required in the hospital to control ischemia
should be continued after hospital discharge in patients with
NSTE-ACS who do not undergo coronary revascularization,
patients with incomplete or unsuccessful revascularization,and patients with recurrent symptoms after revasculariza-
tion. Titration of the doses may be required (427,428).
(Level of Evidence: C)
2. All patients who are post–NSTE-ACS should be given sub-
lingual or spray nitroglycerin with verbal and written
instructions for its use (429). (Level of Evidence: C)
3. Before hospital discharge, patients with NSTE-ACS should
be informed about symptoms of worsening myocardial
ischemia and MI and should be given verbal and written
instructions about how and when to seek emergency care for
such symptoms (429). (Level of Evidence: C)
4. Before hospital discharge, patients who are post–NSTE-ACS
and/or designated responsible caregivers should be pro-
vided with easily understood and culturally sensitive verbal
and written instructions about medication type, purpose,
dose, frequency, side effects, and duration of use (429).
(Level of Evidence: C)
5. For patients who are post–NSTE-ACS and have initial
angina lasting more than 1 minute, nitroglycerin (1 dose
sublingual or spray) is recommended if angina does not
subside within 3 to 5 minutes; call 9-1-1 immediately
to access emergency medical services (429). (Level of
Evidence: C)
6. If the pattern or severity of angina changes, suggesting
worsening myocardial ischemia (e.g., pain is more frequent
or severe or is precipitated by less effort or occurs at rest),
patients should contact their clinician without delay to
assess the need for additional treatment or testing (429).
(Level of Evidence: C)
7. Before discharge, patients should be educated about
modiﬁcation of cardiovascular risk factors (428). (Level of
Evidence: C)6.2.1. Late Hospital and Posthospital Oral Antiplatelet Therapy:
Recommendations
CLASS I
1. Aspirin should be continued indeﬁnitely. The maintenance
dose should be 81 mg daily in patients treated with tica-
grelor and 81 mg to 325 mg daily in all other patients
(288–290). (Level of Evidence: A)
2. In addition to aspirin, a P2Y12 inhibitor (either clopidogrel or
ticagrelor) should be continued for up to 12 months in all
patients with NSTE-ACS without contraindications who are
treated with an ischemia-guided strategy. Options include:
 Clopidogrel: 75mg daily (289,296) (Level of Evidence: B) or
 Ticagrelork: 90 mg twice daily (293,294) (Level of
Evidence: B)
TABLE 10 Plan of Care for Patients With NSTE-ACS
Plan of Care Resources/References
Medications
Antithrombotic therapies  Sections 6.2.1 and 6.2.2
Beta blockers  Section 4.1.2.3
ACE inhibitors/ARBs/aldosterone antagonists  Section 4.2
CCBs  Section 4.1.2.4
Statins  2013 Blood cholesterol CPG (18)
Discontinuation of antithrombotic therapies for elective surgical and
medical procedures with increased risk of bleeding
 2014 SIHD focused update (10)
 2012 SIHD CPG (11)
 2012 Management of AMI in patients with persistent STEMI CPG (19)
 2011 Secondary prevention CPG (27)
 2007 Science Advisory on the prevention of premature discontinuation of DAPT in
patients with coronary artery stents (504)
Inappropriate use of analgesics (NSAIDs)  2010 Expert consensus document on PPIs and thienopyridines (430)
Use of PPIs  2011 PCI CPG (26)
Risk factor modiﬁcation/lifestyle interventions and physical activity/cardiac rehabilitation
Smoking cessation  Tobacco cessation toolkit (505)
Diet nutrition  2013 Lifestyle CPG (15)
Physical activity  2013 Lifestyle CPG (15)
 2011 Secondary prevention CPG (27)
Cardiorespiratory ﬁtness (MET capacity)  2011 Secondary prevention CPG (27)
 2010 Performance measures on cardiac rehabilitation (454)
 2012 Scientiﬁc statement on sexual activity and cardiovascular disease (231)
Management of comorbidities
Overweight/obesity  2013 Obesity CPG (16)
 2011 Secondary prevention CPG (27)
Statins  2013 Lifestyle CPG (15)
 2013 Blood cholesterol CPG (18)
Hypertension  2014 Report on high BP (501)
 2013 Science advisory on high BP control (506)
Diabetes mellitus  2013 Position statement on standards of medical care in diabetes (507)
HF  2013 HF CPG (14)
Arrhythmia/Arrhythmia risk  2012 Focused update incorporated into the 2008 DBT CPG (20)
 2014 AF CPG (12)
Psychosocial factors
Sexual activity  2012 Scientiﬁc statement on sexual activity and cardiovascular disease (231)
 2013 Consensus document on sexual counseling for individuals with cardiovascular
disease and their partners (508)
Gender-Speciﬁc issues  2007 Cardiovascular disease prevention in women CPG (475)
Depression, stress, and anxiety  2008 Science advisory on depression and coronary heart disease (509)
Alcohol use  2011 Secondary prevention CPG (27)
Culturally sensitive issues  2009 Consensus report on a comprehensive framework and preferred practices for
measuring and reporting cultural competency (510)
Return to work schedule
Clinician follow-up
Cardiologist  2011 Secondary prevention CPG (27)
 2013 Hospital to Home Quality Initiative (511)
Primary care clinician
Advanced practice nurse/physician assistant
Pharmacists  2013 Discharge counseling for patients with HF or MI (512)
Other relevant medical specialists
Electronic personal health records
Inﬂuenza vaccination  2005 Recommendations for prevention and control of inﬂuenza (37)
Continued on the next page
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TABLE 10 Continued
Plan of Care Resources/References
Patient/family education
Plan of care for AMI  2010 CPG for cardiopulmonary resuscitation and emergency cardiovascular
care—part 9: postcardiac arrest care (31)
 2013 STEMI CPG (17)
Recognizing symptoms of MI
Activating EMS, signs and symptoms for urgent vs.
emergency evaluations
CPR training for family members
Risk assessment and prognosis
Advanced directives
Social networks/social isolation
Socioeconomic factors
Access to health insurance coverage
Access to clinicians  Effective communication and care coordination (513)
Disability  Cardiovascular disability: updating Social Security listings (514)
Social services
Community services
ACE indicates angiotensin-converting enzyme; AF, atrial ﬁbrillation; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel
blocker; CPG, clinical practice guideline; CPR, cardiopulmonary resuscitation; DAPT, dual antiplatelet therapy; DBT, device-based therapy; ECC, emergency cardiovascular care; EMS,
emergency medical services; HF, heart failure; MET, metabolic equivalent; MI, myocardial infarction; NSAID, nonsteroidal anti-inﬂammatory drug; NSTE-ACS, non–ST-elevation acute
coronary syndromes; PCI, percutaneous coronary intervention; PPI, protein pump inhibitor; SIHD, stable ischemic heart disease; and STEMI, ST-elevation myocardial infarction.
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PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given
for at least 12 months (330). Options include:
 Clopidogrel: 75 mg daily (296,331) (Level of Evidence: B) or
 Prasugrel#: 10 mg daily (302) (Level of Evidence: B) or
 Ticagrelork: 90 mg twice daily (293) (Level of Evidence: B)
CLASS IIa
1. It is reasonable to use an aspirin maintenance dose of 81 mg per
day in preference to higher maintenance doses in patients with
NSTE-ACS treated either invasively or with coronary stent
implantation (26,331,368,385–388). (Level of Evidence: B)
2. It is reasonable to use ticagrelor in preference to clopidogrel
for maintenance P2Y12 treatment in patients with NSTE-ACS
who undergo an early invasive or ischemia-guided strategy
(293,294). (Level of Evidence: B)
3. It is reasonable to choose prasugrel over clopidogrel for
maintenance P2Y12 treatment in patients with NSTE-ACS
who undergo PCI who are not at high risk for bleeding
complications (302,303). (Level of Evidence: B)
4. If the risk of morbidity from bleeding outweighs the antici-
pated beneﬁt of a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation
(e.g., <12 months) of P2Y12 inhibitor therapy is reasonable
(330). (Level of Evidence: C)#Patients should receive a loading dose of prasugrel, provided they were not
pretreated with another PY12 receptor inhibitor.
kThe recommendedmaintenance dose of aspirin to be used with ticagrelor is 81
mg daily (290).CLASS IIb
1. Continuation of DAPT beyond 12 months may be considered in
patients undergoing stent implantation. (Level of Evidence: C)6.2.2. Combined Oral Anticoagulant Therapy and Antiplatelet
Therapy in Patients With NSTE-ACS
CLASS I
1. The duration of triple antithrombotic therapy with a
vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor
in patients with NSTE-ACS should be minimized to the
extent possible to limit the risk of bleeding. (Level of
Evidence: C)
2. Proton pump inhibitors should be prescribed in patients
with NSTE-ACS with a history of gastrointestinal bleeding
who require triple antithrombotic therapy with a vitamin
K antagonist, aspirin, and a P2Y12 receptor inhibitor
(26,430,431). (Level of Evidence: C)
CLASS IIa
1. Proton pump inhibitor use is reasonable in patients with
NSTE-ACS without a known history of gastrointestinal
bleeding who require triple antithrombotic therapy with a
vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor
(26,430,431). (Level of Evidence: C)
CLASS IIb
1. Targeting oral anticoagulant therapy to a lower international
normalized ratio (INR) (e.g., 2.0 to 2.5) may be reasonable in
patients with NSTE-ACS managed with aspirin and a P2Y12
inhibitor. (Level of Evidence: C)
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anticoagulant therapy signiﬁcantly increases the risk of
bleeding. This risk varies widely, but on average, the
addition of a single antiplatelet agent increased the risk
of bleeding from a range of 2% to 3% to a range of 4%
to 6%, whereas the addition of DAPT to oral antico-
agulant therapy (“triple therapy”) increased the risk of
bleeding from a range of 4% to 6% to a range of 10% to
14% (432–435). This risk was also related to the duration of
triple therapy.
In patients with NSTE-ACS in whom there are in-
dications for triple therapy, the beneﬁt of such therapy
in terms of prevention of stent thrombosis, thrombo-
embolic events, and recurrent MI must be weighed
against the risk of bleeding complications. Similarly,
DAPT, in addition to anticoagulant therapy, requires
consideration of the increased risk of bleeding. It is
essential that therapeutic decision making in this crit-
ical area include discussion with the patient about
the options, advantages, and limitations of available
approaches.
Recommendations about the management of pa-
tients treated with triple therapy have been pub-
lished in ACC/AHA CPGs and by other organizations
(17,26,430,433,436). Although some organizations have
recommended a target INR of 2.0 to 2.5 in patients with
atrial ﬁbrillation (AF) who require triple therapy (437),
others continue to recommend a target INR of 2.0 to
3.0 (12,436). The HAS-BLED (Hypertension, Abnormal
Renal/Liver Function, Stroke, Bleeding History or
Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly) score has relevance in these delibera-
tions (439). No prospective study to date has demon-
strated that a target INR of 2.0 to 2.5 reduces bleeding
complications.
Whenever possible, shorter durations of triple ther-
apy are favored in preference to longer durations of
triple therapy. In patients with NSTE-ACS who require
oral anticoagulation for AF, mechanical heart valve,
deep venous thrombosis, or other conditions, a bare-
metal stent may offer the advantages of lower
bleeding risk over a DES because of the potentially
shorter duration of triple antithrombotic therapy. The
WOEST (What is the Optimal Antiplatelet and Antico-
agulant Therapy in Patients With Oral Anticoagulation
and Coronary Stenting) trial is the ﬁrst published
study to address the question of optimal antiplatelet
therapy in patients taking oral anticoagulant medication
(440). WOEST was a randomized, open-label trial of
563 patients (approximately 25% of whom had NSTE-
ACS) receiving oral anticoagulant therapy and under-
going coronary stenting. Patients randomized to single
antiplatelet treatment with clopidogrel had signiﬁcantly
fewer bleeding complications and no increase inthrombotic events compared with those randomized
to DAPT with aspirin and clopidogrel. Larger clinical
trials are needed to compare double versus triple ther-
apy in the setting of coronary stenting and NSTE-ACS.
One such study that has been initiated is PIONEER
AF-PCI (an Open-Label, Randomized, Controlled,
Multicenter Study Exploring two Treatment Strategies
of Rivaroxaban and a Dose-Adjusted Oral Vitamin K
Antagonist Treatment Strategy in Subjects With
Atrial Fibrillation who Undergo Percutaneous Coronary
Intervention).
Although there are some data on therapy with aspirin,
clopidogrel, and warfarin, there is sparse information on
the use of newer P2Y12 inhibitors (prasugrel, ticagrelor),
direct thrombin inhibitor (dabigatran), or factor-Xa in-
hibitors (rivaroxaban, apixaban) in patients receiving
triple therapy. Prasugrel (302) and ticagrelor (412) pro-
duce a greater degree of platelet inhibition than clopi-
dogrel and are associated with greater rates of bleeding
(300,302,412,441). These are important potential disad-
vantages in patients requiring triple therapy, a group in
which the inherent risks of bleeding are signiﬁcantly
increased. (Overall bleeding risk was not increased with
ticagrelor, although there was increased bleeding in
certain subgroups on this drug (412)). Because there are
no well-established therapies to reverse the anticoagu-
lant effects of the newer oral antiplatelet agents,
caution is required when considering the use of these
agents in patients who require triple therapy and are
at signiﬁcantly increased risk of bleeding. This admo-
nition is especially important in elderly patients, a
group in which bleeding risk is inherently increased
(Section 7.1).
Proton pump inhibitors decrease the risk of gastroin-
testinal bleeding in patients treated with DAPT (431) and
are used in patients treated with DAPT who have a history
of gastrointestinal bleeding and those at increased risk of
bleeding, which is associated with oral anticoagulation
therapy even if there is no history of gastrointestinal
bleeding (430). On the basis of these results, proton pump
inhibitors are also used in patients receiving triple
antithrombotic therapy who have a history of gastroin-
testinal bleeding. Although the clinical evidence that
omeprazole and esomeprazole diminish the antiplatelet
efﬁcacy of clopidogrel is weak (430), the U.S. Food and
Drug Administration has issued a warning to avoid
concomitant use of these 2 proton pump inhibitors with
clopidogrel (442).6.2.3. Platelet Function and Genetic Phenotype Testing
Although higher platelet reactivity has been associated
with a greater incidence of adverse events in patients
undergoing stent implantation, a strategy of adjusting
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testing has not been beneﬁcial in reducing ischemic
complications (26,443–445). Similarly, a strategy of
routine genetic phenotype testing has also not been
beneﬁcial and thus is not recommended (26,446–448). A
more detailed discussion of these issues and current
recommendations about platelet function testing and
genetic testing are in the 2011 PCI CPG (26).
6.3. Risk Reduction Strategies for Secondary Prevention
Secondary prevention is a critical aspect of the manage-
ment of care for the survivor of NSTE-ACS. It has been
clearly established that in this high-risk cohort, subse-
quent cardiovascular morbidity and mortality can be
reduced by a comprehensive approach to favorably
modifying patients’ risk proﬁles (27).
Secondary prevention comprises lifestyle changes, risk
factor education, medical therapy, and, where appro-
priate, revascularization. These elements are discussed in
Section 6.4. Despite the proven utility of secondary pre-
vention, its implementation remains suboptimal, and
enhanced application is a major goal in this patient
population.
See Online Data Supplement 23 for additional infor-
mation on risk reduction strategies.
6.3.1. Cardiac Rehabilitation and Physical Activity:
Recommendation
CLASS I
1. All eligible patients with NSTE-ACS should be referred to a
comprehensive cardiovascular rehabilitation program either
before hospital discharge or during the ﬁrst outpatient visit
(449–452). (Level of Evidence: B)
The U.S. Public Health Service emphasizes comprehensive
cardiac rehabilitation programs (449), and the 2011 sec-
ondary prevention CPG underscores referral to cardiac
rehabilitation for survivors of ACS (27). Since 2007, referral
to these programs has been designated a quality perfor-
mance measure (453–455). Barriers to referral can be obvi-
ated by discussion with the patient and referral by the
patient’s primary care clinician and/or cardiovascular care-
giver. These comprehensive programs provide patient ed-
ucation, enhance regular exercise, monitor risk factors, and
address lifestyle modiﬁcation (456). Aerobic exercise
training can generally begin 1 to 2 weeks after discharge in
patients treated with PCI or CABG (457). Mild-to-moderate
resistance training can be considered and started 2 to
4 weeks after aerobic training (458). Unsupervised exercise
may target a heart rate range of 60% to 75% of maximum
age-predicted heart rate based on the patient’s exercise
stress test. Supervised training may target a higher heart
rate (70% to 85% of age-predicted maximum) (457). Addi-
tional restrictions apply when residual ischemia is present.Daily walking can be encouraged soon after discharge for
most patients. Resource publications on exercise prescrip-
tion in cardiovascular patients are available (456,457). Reg-
ular physical activity reduces symptoms in patients with
cardiovascular disease, enhances functional capacity, im-
proves other risk factors such as insulin resistance and
glucose control, and is important in weight control (456).
Questionnaires and nomograms for cardiac patients have
been developed to guide exercise prescription if an exercise
test is unavailable (459–462). See Section 6.4 and Table 10 for
more information.6.3.2. Patient Education: Recommendations
CLASS I
1. Patients should be educated about appropriate cholesterol
management, BP, smoking cessation, and lifestyle manage-
ment (15,16,18). (Level of Evidence: C)
2. Patients who have undergone PCI or CABG derive beneﬁt
from risk factor modiﬁcation and should receive counseling
that revascularization does not obviate the need for lifestyle
changes (463). (Level of Evidence: C)
Results of testing should be discussed with the patient, the
patient’s family, and/or the patient’s advocate in an under-
standable manner. Test results should be used to help
determine the advisability of coronary angiography, the need
for adjustments in the medical regimen, and the speciﬁcs for
secondary prevention measures. See Section 6.4 and Table 10
for more information on plan of care.
6.3.3. Pneumococcal Pneumonia: Recommendation
CLASS I
1. The pneumococcal vaccine is recommended for patients 65
years of age and older and in high-risk patients with car-
diovascular disease (464–466). (Level of Evidence: B)
Vaccination with the 23-valent pneumococcal polysaccharide
vaccine is recommended for all adults $65 years of age.
Adults of any age who are at increased risk, including
smokers and those with asthma, should also be given the
vaccine. Immunocompromised adults should receive the
13-valent conjugate vaccine in addition to the 23-valent
vaccine (464–466). The inﬂuenza vaccine is discussed in
Section 6.4.
6.3.4. NSAIDs: Recommendations
CLASS I
1. Before hospital discharge, the patient’s need for treatment
of chronic musculoskeletal discomfort should be assessed,
and a stepped-care approach should be used for selection of
treatments. Pain treatment before consideration of NSAIDs
should begin with acetaminophen, nonacetylated salicylates,
tramadol, or small doses of narcotics if these medications are
not adequate (17,237). (Level of Evidence: C)
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1. It is reasonable to use nonselective NSAIDs, such as nap-
roxen, if initial therapy with acetaminophen, nonacetylated
salicylates, tramadol, or small doses of narcotics is insufﬁ-
cient (237). (Level of Evidence: C)
CLASS IIb
1. NSAIDs with increasing degrees of relative COX-2 selectivity
may be considered for pain relief only for situations in which
intolerable discomfort persists despite attempts at stepped-
care therapy with acetaminophen, nonacetylated salicylates,
tramadol, small doses of narcotics, or nonselective NSAIDs.
In all cases, use of the lowest effective doses for the shortest
possible time is encouraged (234,235,237,467). (Level of
Evidence: C)
CLASS III: HARM
1. NSAIDs with increasing degrees of relative COX-2 selectivity
should not be administered to patients with NSTE-ACS and
chronic musculoskeletal discomfort when therapy with
acetaminophen, nonacetylated salicylates, tramadol, small
doses of narcotics, or nonselective NSAIDs provide accept-
able pain relief (234,235,237,467). (Level of Evidence: B)
Selective COX-2 inhibitors and other nonselective NSAIDs
have been associated with increased cardiovascular risk, and
the risk appears to be ampliﬁed in patients with established
cardiovascular disease (17,234,235,467,469). In a large Danish
observational study of patients with ﬁrst MI (n¼58,432), the
HR and 95% CI for death were 2.80 (2.41 to 3.25) for rofe-
coxib, 2.57 (2.15 to 3.08) for celecoxib, 1.50 (1.36 to 1.67) for
ibuprofen, 2.40 (2.09 to 2.80) for diclofenac, and 1.29 (1.16 toFIGURE 4 Stepped-Care Approach to Pharmacological Therapy for Musculos
Factors for Ischemic Heart Disease
ASA indicates aspirin; COX-2, cyclooxygenase-2; GI, gastrointestinal; NSAIDs, no
Modiﬁed from Jneid et al. (8).1.43) for other NSAIDs (234). There were dose-related in-
creases in risk of death and non–dose-dependent trends for
rehospitalization for MI for all drugs (234,467). An AHA sci-
entiﬁc statement on the use of NSAIDs concluded that the
risk of cardiovascular events is proportional to COX-2 selec-
tivity and the underlying risk in the patient (237). Non-
pharmacological approaches were recommended as the ﬁrst
line of treatment, followed by the stepped-care approach to
pharmacological therapy, as shown in Figure 4.
6.3.5. Hormone Therapy: Recommendation
CLASS III: HARM
1. Hormone therapy with estrogen plus progestin, or estrogen
alone, should not be given as new drugs for secondary pre-
vention of coronary events to postmenopausal women after
NSTE-ACS and should not be continued in previous users un-
less the beneﬁts outweigh the estimated risks (17,470–472).
(Level of Evidence: A)
Although prior observational data suggested a protective
effect of hormone therapy for coronary events, a randomized
trial of hormone therapy for secondary prevention of death
and MI (the HERS [Heart and Estrogen/Progestin Replace-
ment] study) failed to demonstrate a beneﬁcial effect (473).
There was an excess risk for death and MI early after initia-
tion of hormone therapy. The Women’s Health Initiative
included randomized primary prevention trials of estrogen
plus progestin and estrogen alone (472). Both trials were
stopped early owing to an increased risk related to hormone
therapy that was believed to outweigh the potential beneﬁts
of further study (470–472). It is recommended that post-
menopausal women receiving hormone therapy at the timekeletal Symptoms in Patients With Known Cardiovascular Disease or Risk
nsteroidal anti-inﬂammatory drugs; and PPI, proton-pump inhibitor.
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mone therapy should not be initiated for the primary or
secondary prevention of coronary events. However, there
may be other permissible indications for hormone therapy in
postmenopausal women (e.g., treatment of perimenopausal
symptoms such as ﬂushing or prevention of osteoporosis) if
the beneﬁts are believed to outweigh the increased cardio-
vascular risk. Postmenopausal women who are >1 to 2 years
past the initiation of hormone therapy who wish to continue
such therapy for another compelling indication should weigh
the risks and beneﬁts, recognizing the greater risk of car-
diovascular events and breast cancer (combination therapy)
or stroke (estrogen) (473).
6.3.6. Antioxidant Vitamins and Folic Acid: Recommendations
CLASS III: NO BENEFIT
1. Antioxidant vitamin supplements (e.g., vitamins E, C, or beta
carotene) should not be used for secondary prevention in
patients with NSTE-ACS (474,475). (Level of Evidence: A)
2. Folic acid, with or without vitamins B6 and B12, should not be
used for secondary prevention in patients with NSTE-ACS
(476,477). (Level of Evidence: A)
Although there is an association of elevated homocysteine
blood levels and CAD, a reduction in homocysteine levels
with routine folate supplementation did not reduce the risk
of CAD events in 2 trials (the NORVIT [Norwegian Vitamin
Trial] and the HOPE [Heart Outcomes Prevention Evaluation]
study) that included post–MI or high-risk stable patients
(476–478) and produced poorer outcomes in another study
(479). Additionally, in the NORVIT trial, there was a trend
toward increased cardiovascular events (95% CI: 1.00 to 1.50;
p¼0.05) in the cohort receiving the combination of folic acid,
vitamin B6, and vitamin B12; the authors cautioned against
using the treatment for secondary prevention (476). Simi-
larly, experience in large clinical trials with antioxidant
vitamins has failed to demonstrate beneﬁt for primary or
secondary prevention (474,475,480).
See Online Data Supplement 23 for additional infor-
mation on antioxidant vitamins and folic acid.
6.4. Plan of Care for Patients With NSTE-ACS:
Recommendations
CLASS I
1. Posthospital systems of care designed to prevent hospital
readmissions should be used to facilitate the transition to
effective, coordinated outpatient care for all patients with
NSTE-ACS (481–485). (Level of Evidence: B)
2. An evidence-based plan of care (e.g., GDMT) that promotes
medication adherence, timely follow-up with the healthcare
team, appropriate dietary and physical activities, and
compliance with interventions for secondary prevention
should be provided to patients with NSTE-ACS. (Level of
Evidence: C)3. In addition to detailed instructions for daily exercise, pa-
tients should be given speciﬁc instruction on activities (e.g.,
lifting, climbing stairs, yard work, and household activities)
that are permissible and those to avoid. Speciﬁc mention
should be made of resumption of driving, return to work, and
sexual activity (452,486,487). (Level of Evidence: B)
4. An annual inﬂuenza vaccination is recommended for patients
with cardiovascular disease (27,488). (Level of Evidence: C)
Education of patients with NSTEMI and their families is
critical and often challenging, especially during transitions of
care. Failure to understand and comply with a plan of care
may account for the high rate of AMI rehospitalization rates
in the United States (489,490). An important intervention to
promote coordination is to provide patients and caregivers
with a comprehensive plan of care and educational materials
during the hospital stay that support compliance with
evidence-based therapies (491–493). The posthospitalization
plan of care for patients with NSTE-ACS (Table 10) should
address in detail several complex issues, including medica-
tion adherence and titration, timely follow-up, dietary
interventions, physical and sexual activities, cardiac reha-
bilitation, compliance with interventions for secondary pre-
vention, and reassessment of arrhythmic and HF risks. In
addition, clinicians should pay close attention to psychoso-
cial and socioeconomic issues, including access to care, risk
of depression, social isolation, and healthcare disparities
(494–496).
6.4.1. Systems to Promote Care Coordination
There has been improved understanding of the system
changes necessary to achieve safer care (497). This in-
cludes adoption by all U.S. hospitals of a standardized set
of “Safe Practices” endorsed by the National Quality
Forum (498), which overlap with the National Patient
Safety Goals espoused by The Joint Commission (499).
Examples of patient safety standards for all patients after
AMI include improved communication among clinicians,
nurses, and pharmacists; medication reconciliation;
careful transitions between care settings; and consistent
documentation. The National Quality Forum has also
endorsed a set of patient-centered “Preferred Practices for
Care Coordination” (500), which detail comprehensive
speciﬁcations that are necessary to achieve successful
care coordination for patients and their families. Systems
of care designed to support patients with NSTE-ACS,
STEMI, and other cardiac diseases can result in signiﬁ-
cant improvement in patient outcomes. Table 10 provides
reference documents for multiple risk-reduction strate-
gies for secondary prevention in the posthospital phase of
NSTE-ACS. These include the 2013 ACC/AHA CPGs on
management of blood cholesterol (18), obesity (16), and
lifestyle (15) and the 2014 recommendations for manage-
ment of hypertension (501), which were published during
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terventions and services listed in Table 10, appropriate
resources must be used so that patients with MI have full
access to evidence-based therapies and follow-up care.
There is a growing emphasis on penalizing hospitals for
avoidable hospital readmissions. It is imperative for
health systems to work with clinicians, nurses, pharma-
cists, communities, payers, and public agencies to sup-
port the interventions that achieve comprehensive care.
Several patient characteristics have been predictors of
readmission after AMI (502,503).
7. SPECIAL PATIENT GROUPS
See Table 11 for summary of recommendations for this
section.
7.1. NSTE-ACS in Older Patients: Recommendations
CLASS I
1. Older patients** with NSTE-ACS should be treated with
GDMT, an early invasive strategy, and revascularization as
appropriate (515–519). (Level of Evidence: A)
2. Pharmacotherapy in older patients** with NSTE-ACS should
be individualized and dose adjusted by weight and/or CrCl to
reduce adverse events caused by age-related changes in
pharmacokinetics/dynamics, volume of distribution, comor-
bidities, drug interactions, and increased drug sensitivity
(515,520–522). (Level of Evidence: A)
3. Management decisions for older patients** with NSTE-ACS
should be patient centered, and consider patient prefer-
ences/goals, comorbidities, functional and cognitive status,
and life expectancy (515,523–525). (Level of Evidence: B)
CLASS IIa
1. Bivalirudin, rather than a GP IIb/IIIa inhibitor plus UFH, is
reasonable in older patients** with NSTE-ACS, both initially
and at PCI, given similar efﬁcacy but less bleeding risk
(396,526–528). (Level of Evidence: B)
2. It is reasonable to choose CABG over PCI in older patients**
with NSTE-ACS who are appropriate candidates, particularly
those with diabetes mellitus or complex 3-vessel CAD
(e.g., SYNTAX score >22), with or without involvement of
the proximal LAD artery, to reduce cardiovascular disease
events and readmission and to improve survival (529–534).
(Level of Evidence: B)
In this CPG, “older adults” refers to patients $75 years of age
(515). Older adults have the highest incidence, prevalence,
and adverse outcomes of NSTE-ACS (9,515–517,535,536).
Older age is accompanied by comorbidities, polypharmacy,
and age- and disease-related physiological changes that**Those $75 years of age (see text).adversely impact NSTE-ACS presentation, management,
and outcome. As older patients are under-represented
in clinical trials, the recommendations in this CPG are
largely supported by registry data and meta-analyses
(516,537).
Older patients with NSTE-ACS primarily present with
chest pain but frequently have atypical symptoms. ECGs
may be less diagnostic than in younger patients (517,538).
Older patients with NSTE-ACS derive the same or greater
beneﬁt from pharmacological therapies, interventional
therapies, and cardiac rehabilitation as younger patients,
but older patients receive signiﬁcantly less GDMT than
younger patients, even when adjusted for comorbidities
(515–517,535,538,539). In the ACSIS (Acute Coronary Syn-
drome Israeli Survey) registry, patients >80 years of age
referred for early coronary angiography, compared with
no angiography, had lower 30-day and 1-year mortality
rates (540).
Age-related pharmacokinetics and pharmacodynamic
changes can alter drug dosing, efﬁcacy, and safety of
many NSTE-ACS therapies, as can drug–drug interactions
(Appendix 4, Table B) (515,520,521,541,542). CrCl or
glomerular ﬁltration rate (GFR) should be estimated
initially and throughout care for all older patients with
NSTE-ACS, and pharmaceutical agents should be renally
and weight dose-adjusted to limit drug toxicity (espe-
cially bleeding risk), given the unreliability of serum
creatinine to assess age-related renal dysfunction
(515,522,526,543–545) (Appendix 4, Table C). Bleeding in
older patients with NSTE-ACS is multifactorial, resulting
in narrower therapeutic windows (541,542,544,546,547).
In the CRUSADE (Can Rapid Risk Stratiﬁcation of
Unstable Angina Patients Suppress Adverse Outcomes
With Early Implementation of the American College of
Cardiology/American Heart Association Guidelines) study,
excessive doses of UFH, LMWH, and GP IIb/IIIa inhibitors
accounted for 15% of major bleeding, longer lengths of
stay, and increased mortality (522,548). Aspirin should be
maintained at 81 mg per day (after initial stent implanta-
tion). Owing to excess bleeding without clinical beneﬁt,
the U.S. Food and Drug Administration lists a Black Box
warning that does not recommend administration of pra-
sugrel to patients with NSTE-ACS who are $75 years of age
or weigh <60 kg except in those at very high risk. A meta-
analysis of 6 RCTs about the use of GP IIb/IIIa inhibitors in
patients with NSTE-ACS reported no signiﬁcant age-
treatment interaction, although older women had signiﬁ-
cantly more adverse events (549). Bivalirudin appears
safer for older patients with NSTE-ACS  PCI than GP
IIb/IIIa inhibitors plus UFH, with less bleeding and similar
efﬁcacy (526,550). AF is more common in older patients
with NSTE-ACS, and triple therapy (DAPT and warfarin)
entails a marked bleeding risk (551). In the WOEST (What is
the Optimal Antiplatelet and Anticoagulant Therapy in
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study, it was found that in patients taking oral coagulants
who required PCI, use of clopidogrel without aspirin was
associated with a signiﬁcant reduction in bleeding com-
plications and no increase in thrombotic events (440).
Nonetheless, practice should not be changed on the basis
of this limited study alone.
Older patients with NSTE-ACS beneﬁt as much or
more than younger patients from an early invasive
strategy compared with an ischemia-guided strategy
(340,341,515,518,519). In a 5-year follow-up meta-analysis
of FRISC-II and RITA-3, an early invasive strategy versus
an ischemia-guided strategy was associated with a sig-
niﬁcant reduction in death/MI and MI in patients $75
years of age but not in patients <65 years of age (518).
Although the highest risk reduction in death/MI with an
early invasive strategy occurred in those $75 years of age,
this strategy was associated with a 3-fold bleeding risk
(552). However, despite the overall favorable evidence for
an early invasive strategy in older patients, age is the
strongest risk factor for this group not undergoing an
early invasive strategy (553).
PCI has increased in older patients, including the very
elderly ($90 years of age), with success rates similar to
younger patients and declining complication rates,
including major bleeding (515,517,526–528,554). Several
large registries report a greater RR reduction in mortality
of older patients treated with revascularization versus
medical therapy compared with those #65 years of age,
despite increased comorbidities (517,540,554–556).
Operative mortality rates for CABG in patients $80
years of age with NSTE-ACS range from 5% to 8% (11% for
urgent cases) and increase to approximately 13% at $90
years of age. Complications occur more frequently in
older patients with CABG (557,558). Length of stay aver-
ages 6 days longer in older patients than in patients <50
years of age, and discharge (to home [52%]) is less
frequent than in younger patients (557). In a meta-
analysis, off-pump CABG appeared to offer a potentially
safer and more effective revascularization technique
compared with on-pump CABG in older patients with
NSTE-ACS (559). Older patients with NSTE-ACS with dia-
betes mellitus had a greater survival advantage with
CABG (529). Evaluation tools can help identify older
patients with NSTE-ACS whose risk and comorbidity
proﬁle predict mortality within 6 to 12 months and
possibly guide a palliative approach (524).
See Online Data Supplement 24 for additional informa-
tion on older patients.
7.2. HF: Recommendations
CLASS I
1. Patients with a history of HF and NSTE-ACS should be treated
according to the same risk stratiﬁcation guidelines andrecommendations for patients without HF (14,42–44,75–81).
(Level of Evidence: B)
2. Selection of a speciﬁc revascularization strategy should be
based on the degree, severity, and extent of CAD; associated
cardiac lesions; the extent of LV dysfunction; and the history
of prior revascularization procedures (14,138,141,333,334,
337,341,560,561). (Level of Evidence: B)
In patients with HF and NSTE-ACS, the plan of care should be
implemented as in patients without HF using medical ther-
apy and an early invasive approach, because patients with
abnormal LV function are at increased risk of mortality and
morbidity (562). HF itself may be associated with elevated
serum troponin in the presence or absence of obstructive
CAD. After angiography, risk stratiﬁcation can be used to
select revascularization strategies. The effect of surgical
revascularization on improving survival has been most
clearly demonstrated in patients with both extensive CAD
and LV dysfunction (356,357,563–567). Such patients should
undergo testing to identify the severity and extent of
ischemia and should in general be referred for coronary
angiography. In selected patients with appropriate anatomy,
PCI has been used (23,568). In patients who have already
undergone CABG or in whom the anatomy is not favorable
for CABG, PCI has been performed using CPG-based PCI
performance strategies if speciﬁc targeted areas that are
amenable to PCI can be identiﬁed (26). If there is a large
amount of ischemic territory and very poor LV function,
percutaneous ventricular assist devices or, in less severe
cases, an IABP can be used for support during the procedure
(266,569–573).
See Online Data Supplement 25 for additional informa-
tion on HF.
7.2.1. Arrhythmias
Ventricular arrhythmias are common early after onset of
NSTE-ACS, and not all require intervention. The mech-
anisms for these arrhythmias include continuing
ischemia, hemodynamic and electrolyte abnormalities,
reentry, and enhanced automaticity. Approximately 5%
to 10% of hospitalized patients may develop ventricular
tachycardia (VT)/ventricular ﬁbrillation (VF), usually
within 48 hours of presentation (574). The incidence of
VF in otherwise uncomplicated AMI appears to have
decreased within the past few years from >4% to <2%,
of which 59% of patients had non–Q-wave MI (574). A
study of 277 consecutive patients with NSTE-ACS who
underwent cardiac catheterization within 48 hours
found VT/VF occurring in 7.6% of patients, 60% of which
developed within 48 hours after admission (575). Risk
factors for VT/VF include HF, hypotension, tachycardia,
shock, and low TIMI ﬂow grade. Treatment consists of
immediate deﬁbrillation or cardioversion for VF or
pulseless sustained VT. Early administration of beta
TABLE 11 Summary of Recommendations for Special Patient Groups
Recommendations COR LOE References
NSTE-ACS in older patients
Treat older patients ($75 y of age) with GDMT, early invasive strategy, and revascularization as appropriate I A (515–519)
Individualize pharmacotherapy in older patients, with dose adjusted by weight and/or CrCl to reduce
adverse events caused by age-related changes in pharmacokinetics/dynamics, volume of distribution,
comorbidity, drug interactions, and increased drug sensitivity
I A (515,520–522)
Undertake patient-centered management for older patients, considering patient preferences/goals,
comorbidities, functional and cognitive status, and life expectancy
I B (515,523–525)
Bivalirudin rather than GP IIb/IIIa inhibitor plus UFH is reasonable for older patients ($75 y of age), given
similar efﬁcacy but less bleeding risk
IIa B (396,526–528)
It is reasonable to choose CABG over PCI in older patients, particularly those with DM or multivessel disease,
because of the potential for improved survival and reduced CVD events
IIa B (529–534)
HF
Treat patients with a history of HF according to the same risk stratiﬁcation guidelines and recommendations
for patients without HF
I B (14,42–44,75–81)
Select a revascularization strategy based on the extent of CAD, associated cardiac lesions, LV dysfunction,
and prior revascularization
I B (14,138,141,333,334,
337,341,560,561)
Cardiogenic shock
Recommend early revascularization for cardiogenic shock due to cardiac pump failure I B (560,588,589)
DM
Recommend medical treatment and decisions for testing and revascularization similar to those for patients
without DM
I A (138,339,601)
PostCABG
Recommend GDMT antiplatelet and anticoagulant therapy and early invasive strategy because of increased
risk with prior CABG
I B (67,68,141,340–342)
Perioperative NSTE-ACS
Administer GDMT to perioperative patients with limitations imposed by noncardiac surgery I C (626,627)
Direct management at underlying cause of perioperative NSTE-ACS I C (21,626–634)
CKD
Estimate CrCl and adjust doses of renally cleared medications according to pharmacokinetic data I B (649,650)
Administer adequate hydration to patients undergoing coronary and LV angiography I C N/A
Invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD IIa B (649–652)
Women
Manage women with the same pharmacological therapy as that for men for acute care and secondary
prevention, with attention to weight and/or renally calculated doses of antiplatelet and anticoagulant
agents to reduce bleeding risk
I B (669–673)
Early invasive strategy is recommended in women with NSTE-ACS and high-risk features (troponin positive) I A (141,345,346,561)
Myocardial revascularization is reasonable for pregnant women if ischemia-guided strategy is ineffective for
management of life-threatening complications
IIa C (674)
Women with low-risk features (Section 3.3.1) should not undergo early invasive treatment because of lack of
beneﬁt and the possibility of harm
III: No Beneﬁt B (141,345,346)
Anemia, bleeding, and transfusion
Evaluate all patients for risk of bleeding I C N/A
Recommend that anticoagulant and antiplatelet therapy be weight-based where appropriate and adjusted for
CKD to decrease the risk of bleeding
I B (522,697,698)
There is no beneﬁt of routine blood transfusion in hemodynamically stable patients with hemoglobin levels >8 g/dL III: No Beneﬁt B (699–703)
Cocaine and methamphetamine users
Manage patients with recent cocaine or methamphetamine use similarly to those without cocaine- or
methamphetamine-related NSTE-ACS. The exception is in patients with signs of acute intoxication
(e.g., euphoria, tachycardia, and hypertension) and beta-blocker use unless patients are receiving
coronary vasodilator therapy
I C N/A
It is reasonable to use benzodiazepines alone or in combination with NTG to manage hypertension and
tachycardia and signs of acute cocaine or methamphetamine intoxication
IIa C (741–744)
Do not administer beta blockers to patients with recent cocaine or methamphetamine use who have signs
of acute intoxication due to risk of potentiating coronary spasm
III: Harm C N/A
Continued on the next page
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TABLE 11 Continued
Recommendations COR LOE References
Vasospastic (Prinzmetal) angina
Recommend CCBs alone or in combination with nitrates I B (753–758)
Recommend HMG-CoA reductase inhibitor, cessation of tobacco use, and atherosclerosis risk factor modiﬁcation I B (759–763)
Recommend coronary angiography (invasive or noninvasive) for episodic chest pain with transient
ST-elevation to detect severe CAD
I C N/A
Provocative testing during invasive coronary angiography* may be considered for suspected vasospastic
angina when clinical criteria and noninvasive assessment fail to determine diagnosis
IIb B (764–767)
ACS with angiographically normal coronary arteries
Invasive physiological assessment (coronary ﬂow reserve measurement) may be considered with normal
coronary arteries if endothelial dysfunction is suspected
IIb B (629,773–776)
Stress (Takotsubo) cardiomyopathy
Consider stress-induced cardiomyopathy in patients with apparent ACS and nonobstructive CAD I C N/A
Perform ventriculography, echocardiography, or MRI to conﬁrm or exclude diagnosis I B (795–798)
Treat with conventional agents (ACE inhibitors, beta blockers, aspirin, and diuretics) if hemodynamically stable I C N/A
Administer anticoagulant therapy for LV thrombi I C N/A
It is reasonable to administer catecholamines for symptomatic hypotension in the absence of LV outﬂow
tract obstruction
IIa C N/A
It is reasonable to use IABP for refractory shock IIa C N/A
It is reasonable to use beta blockers and alpha-adrenergic agents for LV outﬂow tract obstruction IIa C N/A
Prophylactic anticoagulation may be considered to prevent LV thrombi IIb C N/A
*Provocative testing during invasive coronary angiography (e.g., using ergonovine, acetylcholine, methylergonovine) is relatively safe, especially when performed in a controlled
manner by experienced operators. However, sustained spasm, serious arrhythmias, and even death can also occur but very infrequently. Therefore, provocative tests should be avoided
in patients with signiﬁcant left main disease, advanced 3-vessel disease, presence of high-grade obstructive lesions, signiﬁcant valvular stenosis, signiﬁcant LV systolic dysfunction, and
advanced HF.
ACE indicates angiotensin-converting enzyme; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CKD,
chronic kidney disease; COR, Class of Recommendation; CrCl, creatinine clearance; CVD, cardiovascular disease; DM, diabetes mellitus; GDMT, guideline-directed medical therapy; GP,
glycoprotein; HF, heart failure; IABP, intra-aortic balloon pump; LOE, Level of Evidence; LV, left ventricular; MRI, magnetic resonance imaging; N/A, not available; NSTE-ACS,
non–ST-elevation acute coronary syndrome; NTG, nitroglycerin; PCI, percutaneous coronary intervention; and UFH, unfractionated heparin.
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e185blockers has been associated with reduction in incidence
of VF (576). The prophylactic use of lidocaine is not
recommended. Although VT/VF is associated with higher
90-day mortality risk, premature ventricular contractions
not associated with hemodynamic compromise and
accelerated ventricular rhythms do not confer higher
mortality risks and do not require speciﬁc therapy other
than maintaining electrolyte balance. NSTE-ACS non-
sustained VT occurring >48 hours after admission in-
dicates an increased risk of cardiac and sudden death,
especially when associated with accompanying myocar-
dial ischemia (577). Life-threatening ventricular ar-
rhythmias that occur >48 hours after NSTE-ACS are
usually associated with LV dysfunction and signify poor
prognosis. RCTs in patients with ACS have shown
consistent beneﬁt of implantable cardioverter-
deﬁbrillator therapy for survivors of VT or VF arrest
(578–582). For other at-risk patients, especially those
with signiﬁcantly reduced LVEF, candidacy for primary
prevention of sudden cardiac death with an implantable
cardioverter-deﬁbrillator should be readdressed $40
days after discharge (583). A life vest may be considered
in the interim.AF, atrial ﬂutter, and other supraventricular arrhyth-
mias may be triggered by excessive sympathetic stimu-
lation, atrial stress due to volume overload, atrial
infarction, pericarditis, electrolyte abnormalities, hypox-
ia, or pulmonary disease. AF is the most common of these
arrhythmias and may develop in >20% of patients. AF is
associated with shock, HF, stroke, and increased 90-day
mortality (584). Management of AF requires rate control
and adequate anticoagulation according to the 2014 AF
CPG (12). For hemodynamically unstable patients and
those with continuing ischemia, treatment should be
implemented according to the 2010 advanced cardiac life
support CPGs (585).
Sinus bradycardia is especially common with inferior
NSTEMI. Symptomatic or hemodynamically signiﬁcant
sinus bradycardia should be treated with atropine and, if
not responsive, temporary pacing. The incidence of
complete heart block is 1.0% to 3.7% in NSTEMI, based on
anterior or posterior/inferior location, respectively (586).
Atrioventricular block and bundle-branch block develop
in approximately 5% of patients (587). High-degree
atrioventricular block or bundle-branch block in anterior
NSTEMI is more ominous because of a greater extent of
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system (587).
First-degree atrioventricular block does not require
treatment. High-grade atrioventricular block after inferior
NSTEMI usually is transient, with a narrow QRS complex
and a junctional escape rhythm that can be managed with
an ischemia-guided strategy. Prophylactic placement of a
temporary pacemaker is recommended for high-grade
atrioventricular block, new bundle-branch block, or
bifascicular block with anterior infarction. Indications for
permanent pacing are reviewed in the 2012 device-based
therapy CPG (20).
7.2.2. Cardiogenic Shock: Recommendation
CLASS I
1. Early revascularization is recommended in suitable patients
with cardiogenic shock due to cardiac pump failure after
NSTE-ACS (560,588,589). (Level of Evidence: B)
AMI is the leading cause of cardiogenic shock. Early revas-
cularization is a mainstay in the treatment of cardiogenic
shock (560,589). Compared with medical therapy, early
revascularization is associated with improved 6-month
mortality (560) and 13% absolute mortality reduction at 6
years (588). Urgent revascularization with CABG may be
indicated for failed PCI, coronary anatomy not amenable to
PCI, and at the time of surgical repair of a mechanical defect
(e.g., septal, papillary muscle, free-wall rupture). Age alone is
not a contraindication to urgent revascularization for
cardiogenic shock (589,590). Mortality after cardiogenic
shock has steadily improved (591), including in older adults
(589,590), with 30-day mortality ranging from approximately
40% with milder forms of shock (268) to >45% with re-
fractory shock (592). Approximately 30% of patients in the
IABP-SHOCK (Intra-Aortic Balloon Pump in Cardiogenic
Shock) II trial presented with NSTEMI (268), and 22% of pa-
tients in the TRIUMPH (Tilarginine Acetate Injection in a
Randomized International Study in Unstable Acute Myocar-
dial Infarction Patients With Cardiogenic Shock) trial had ST
depression on presentation (592). Of the 23% of patients with
ACS who had NSTEMI in the GRACE registry, 4.6% of pa-
tients experienced cardiogenic shock (593). Of the 2,992
patients in shock, 57% underwent cardiac catheterization,
and in-hospital revascularization was performed in 47% of
this group.
In-hospital mortality of all patients with shock was
59% (594). Patients with NSTEMI developed cardiogenic
shock later than patients with STEMI, and had higher-risk
clinical characteristics, more extensive CAD, and more
recurrent ischemia and infarction before developing
shock compared with patients with STEMI, and shock
developed later in patients with NSTEMI (151). Patients
with NSTEMI constituted >17% of those in the SHOCK trial
registry (595). They were also older and had morecomorbidities but had comparable mortality to patients
with STEMI. The left circumﬂex coronary artery was the
culprit vessel in 30% of patients with NSTEMI, suggesting
the presence of true posterior MI (595). Dopamine in pa-
tients with cardiogenic shock may be associated with
increased mortality compared with norepinephrine (596).
The use of percutaneous ventricular assist devices has
been hampered by the need for interventional expertise,
cost, and lack of supportive evidence (597). IABP has been
used for decades (265,598), and it may facilitate inter-
vention in patients who are hemodynamically unstable,
but it did not reduce mortality or secondary endpoints
in 1 RCT of 598 patients with cardiogenic shock
complicating AMI (268). Newer devices with higher levels
of support have provided better hemodynamic support
but without improved clinical outcomes compared with
IABP (599,600).
See Online Data Supplement 26 for additional information
on cardiogenic shock.
7.3. Diabetes Mellitus: Recommendation
CLASS I
1. Medical treatment in the acute phase of NSTE-ACS and decisions
to perform stress testing, angiography, and revascularization
should be similar in patients with and without diabetes mellitus
(138,339,601). (Level of Evidence: A)
CAD accounts for 75% of deaths in patients with diabetes
mellitus; >30% of patients with NSTE-ACS have diabetes
mellitus; and patients with NSTE-ACS and diabetes mellitus
have more adverse outcomes (e.g., death, MI, readmission
with ACS, or HF) during follow up (593,602,603). The latter
may be related to increased plaque instability and comor-
bidities, including hypertension, LV hypertrophy, cardio-
myopathy, HF, and autonomic dysfunction (603–605).
Patients with diabetes mellitus and ACS have longer delays
from symptom onset to presentation (593,606,607), which
may be attributable to their atypical symptoms.
There is a U-shaped relationship between glucose levels
and mortality in patients with diabetes mellitus and ACS
(543). Both hyperglycemia and hypoglycemia have similar
adverse effects on in-hospital and 6-month mortality. The
urgency to aggressively control blood glucose has been
moderated by the results of the NICE-SUGAR (Normoglyce-
mia in Intensive Care Evaluation and Survival Using Glucose
Algorithm Regimen) trial (608). In this study of patients
admitted to medical and surgical intensive care units,
intensive glucose control (target 81 mg/dL to 108 mg/dL)
resulted in increased all-cause mortality and hypoglycemia
compared with moderate glucose control (target <180 mg/dL).
Blood glucose should be maintained at <180 mg/dL while
avoiding hypoglycemia. There is no established role for the
administration of glucose-insulin-potassium infusions in
NSTE-ACS (609–611).
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ACS are at higher risk for in-hospital and longer-term
events, they undergo less frequent revascularization
procedures. In a multinational study of 6,385 patients
with ACS, 25% of whom had diabetes mellitus, those with
diabetes mellitus had more adverse risk proﬁles, more
atypical presentations, longer treatment delays, more
HF, and renal insufﬁciency but underwent less angiog-
raphy and revascularization (607). In the GRACE Registry
(593) and other studies (606), patients with diabetes
mellitus and NSTE-ACS in the United Kingdom (603) and
Finland (612) had higher baseline risk proﬁles but
received effective medical cardiac therapies and revas-
cularization less frequently.
Although there are no RCTs of patients speciﬁcally
diagnosed with diabetes mellitus and ACS, there are
ample data on patients with diabetes mellitus treated
with PCI or CABG (564,565,613–615). The largest RCT,
the FREEDOM (Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Management
of Multivessel Disease) trial (616), evaluated 1,900
patients (approximately 30% with “recent” [interval
unspeciﬁed] ACS) with 2- or 3-vessel CAD randomized
to a DES or CABG. At 5 years, there was a signiﬁcant
decrease in all-cause mortality (p¼0.049; MI: p<0.001)
associated with CABG. There was no speciﬁc analysis
of outcomes in patients with “recent” (interval un-
speciﬁed) ACS. CABG was also superior to PCI in
reducing MACE in other trials (564,613–615) (Appendix
4, Table D).
The importance of the severity and complexity of CAD
was underscored in the SYNTAX trial, in which those with
less severe and complex CAD had similar outcomes with
PCI and CABG compared with those with more severe and
complex disease, in which CABG improved outcomes,
including survival (355,565).
7.3.1. Adjunctive Therapy
A meta-analysis (6 trials: 23,072 patients without dia-
betes mellitus, 6,458 patients with diabetes mellitus) of
the effect of GP IIb/IIIa platelet receptor inhibitors
(abciximab, eptiﬁbatide, and tiroﬁban) on mortality in
NSTEMI revealed that for the entire patient group, a GP
IIb/IIIa inhibitor was associated with reduced 30-day
mortality (6.2% to 4.6%; p¼0.007) (392). This beneﬁt
was particularly large in the 1,279 patients with diabetes
mellitus who underwent PCI (4.0% to 1.2%; p¼0.002).
The ACUITY trial in ACS (13,819 patients, 3,852 with
diabetes mellitus) reported that 30-day adverse clinical
outcomes (death, MI, or unplanned revascularization) or
major bleeding were increased in patients with diabetes
mellitus (12.9% versus 10.6%; p<0.001) (617). Bivalirudin
plus a GP IIb/IIIa inhibitor resulted in increased similar
rates of the composite ischemia compared with heparinplus a GP IIb/IIIa inhibitor. Bivalirudin alone was asso-
ciated with a similar increased rate of composite
ischemia but less major bleeding (3.7% versus 7.1%;
p<0.001).
Several studies evaluated the beneﬁt of oral antiplate-
let therapy during ACS in patients with diabetes mellitus.
In TRITON-TIMI 38, patients with diabetes mellitus had a
greater reduction in ischemic events without an observed
increase in TIMI major bleeding with prasugrel compared
with clopidogrel (618). In PLATO, ticagrelor compared
with clopidogrel reduced ischemic events irrespective of
diabetic status and glycemic control, without an increase
in major bleeding (619).
See Online Data Supplement 27 for additional infor-
mation on diabetes mellitus.7.4. Post–CABG: Recommendation
CLASS I
1. Patients with prior CABG and NSTE-ACS should receive
antiplatelet and anticoagulant therapy according to GDMT
and should be strongly considered for early invasive strategy
because of their increased risk (67,68,141,340–342). (Level
of Evidence: B)
Although CABG reduces morbidity and mortality in selected
patients with complex CAD, they remain at risk for devel-
opment of disease progression of ungrafted native vessels or
signiﬁcant atherothrombotic disease in saphenous vein
grafts and subsequent ACS. These patients constitute a
higher-risk group because they have already undergone
CABG, typically for more extensive CAD, and they have more
comorbidities (620–624).
In the PURSUIT trial, 12% (1,134) of the patients had
prior CABG and more adverse follow-up outcomes,
including increased mortality, but had a beneﬁt with
eptiﬁbatide similar to those without prior CABG (622).
Patients with prior CABG are less likely to undergo early
catheterization after NSTEMI. In the Get With The
Guidelines study of patients with NSTEMI, 18.5% had
prior CABG and a lower likelihood of early invasive eval-
uation but had higher rates of guideline-recommended
clopidogrel and bivalirudin therapy and lower rates of
GP IIb/IIIa and anticoagulant therapy (625). In patients
with prior CABG who develop NSTE-ACS that is related to
an ungrafted native coronary vessel, treatment should
follow GDMT (26).
Because patients with prior CABG presenting with
ACS are a high-risk group with increased comorbid char-
acteristics and high-risk anatomy, a strategy of early
angiography should be implemented (unless clinically
contraindicated), and these patients should receive
optimal antiplatelet and anticoagulant therapy.
See Online Data Supplement 28 for additional informa-
tion on post-CABG.
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Recommendations
CLASS I
1. Patients who develop NSTE-ACS following noncardiac sur-
gery should receive GDMT as recommended for patients in
the general population but with the modiﬁcations imposed
by the speciﬁc noncardiac surgical procedure and the
severity of the NSTE-ACS (626,627). (Level of Evidence: C)
2. In patients who develop NSTE-ACS after noncardiac surgery,
management should be directed at the underlying cause
(21,626–634). (Level of Evidence: C)
Patients with NSTE-ACS following noncardiac surgery should
be managed according to the guidelines for patients in the
general population, with risk stratiﬁcation and guideline-
based pharmacological and invasive management directed
at the etiology (e.g., hypertension, tachycardia, HF, hypo-
tension, sepsis, and anemia) with modiﬁcations based on the
severity of NSTE-ACS and the limitations imposed by the
noncardiac surgical procedure.
The deﬁnition of ACS has a substantial effect on re-
ported incidence (178,184,635–644). Some patients may
not be able to give a history of ischemic symptoms because
of the noncardiac surgery. The criteria in the 2012 Third
Universal Deﬁnition of MI should be applied (21). In pa-
tients at risk of ACS following noncardiac surgery, routine
monitoring of troponins and ECGs may be performed. As
the sensitivity of troponin assays improves, the frequency
of identifying perioperative MI will increase. In the POISE
(Perioperative Ischemic Study Evaluation) trial (645), of
8,351 patients randomized to extended-release metoprolol
versus placebo, 5.7% of patients in the control group had a
perioperative MI typically occurring within 48 hours and
often not associated with ischemic symptoms.
ACS in the setting of noncardiac surgery is associated
with increased mortality. Several risk scores have been
developed to determine the probability of mortality
(646–648). A meta-analysis of the prognostic value of
troponin and CK-MB after noncardiac surgery that included
14 studies enrolling 3,318 patients demonstrated that
elevated troponin after surgery was an independent pre-
dictor of mortality both in the hospital and at 1-year follow-
up (639). Markedly elevated troponins are associated
with increased mortality compared with minimal troponin
elevation, even though the latter still indicates a post-
operativeMI (184,639,641,642). In patients with UA in whom
the risks of bleeding with antiplatelet therapy outweigh the
beneﬁts, GDMT with beta blockers, nitrates, and ACE in-
hibitors should be optimized to achieve symptom control. In
patients with a relative or absolute contraindication to
antiplatelet or anticoagulant therapy, coronary angiography
may be helpful to identify anatomy requiring revasculari-
zation after recovery from the noncardiac surgery.7.6. CKD: Recommendations
CLASS I
1. CrCl should be estimated in patients with NSTE-ACS, and
doses of renally cleared medications should be adjusted
according to the pharmacokinetic data for speciﬁc medica-
tions (649,650). (Level of Evidence: B)
2. Patients undergoing coronary and LV angiography should
receive adequate hydration. (Level of Evidence: C)
CLASS IIa
1. An invasive strategy is reasonable in patients with mild
(stage 2) and moderate (stage 3) CKD (649–652). (Level of
Evidence: B)
CKD is a major risk factor for poor outcomes in patients
with NSTEMI (652–657). Patients with impaired renal func-
tion have additional adverse baseline characteristics,
including older age, a history of prior HF, and peripheral
arterial disease. It is prudent to omit LV angiography
in patients with CKD and assess LV function with
echocardiography.
In an analysis from 3 ACS trial databases of 19,304 pa-
tients with NSTEMI, 42% (8,152 patients) had abnormal
renal function on the basis of serum creatinine and
calculated CrCl; total mortality and mortality/MI were
increased at 30 days and 180 days. CrCl was indepen-
dently associated with mortality (HR: 0.81) and the risk of
mortality/MI (HR: 0.93) (656). The VALIANT (Valsartan in
Acute Myocardial Infarction) trial included 14,527 high-
risk patients with AMI with LV dysfunction or HF and a
serum creatinine level $1.5 mg/dL (658,659). The Modi-
ﬁcation of Diet in Renal Disease equation was used, and
patients were analyzed based on their estimated GFR.
There was an increasing adjusted HR for both death
and the composite endpoint of cardiovascular death,
reinfarction, HF, stroke, or resuscitation after cardiac ar-
rest with decreasing estimated GFR. For death, with a
GFR <45.0 mL per minute/1.73 m2, the adjusted HR was
1.70 compared with patients with a GFR of 60.0 mL per
minute/1.73 m2 to 74.9 mL per minute/1.73 m2 in whom
the adjusted HR was 1.14. There are insufﬁcient data on
the beneﬁt-to-risk ratio of an invasive strategy in patients
with NSTE-ACS and advanced CKD (stages 4 and 5)
(652). There is also less evidence-based medical therapy
and revascularization data in patients with CKD because
of the risk for contrast-induced nephropathy, increased
need for dialysis, and increased mortality. Multiple
studies have evaluated radiographic agents, including
ionic versus nonionic media and isosmolar or low-osmolar
agents.
The strength and consistency of relationships between
speciﬁc isosmolar or low-osmolar agents and contrast-
induced nephropathy or renal failure are insufﬁcient
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tation of the risk of contrast-induced nephropathy is
based on reduced contrast volume (660) and adequate
hydration (661).
A recent meta-analysis of 5 RCTs evaluated 1,453
patients with NSTE-ACS and CKD, all with GFR <60 mL
per minute/1.73 m2 (651). Patients were analyzed ac-
cording to baseline renal function: stage 3a, 3b, and 4 to
5. An invasive strategy was associated with a nonsig-
niﬁcant reduction in all-cause mortality and the com-
posite of death or nonfatal MI. An early invasive
strategy in patients with CKD and ACS reduced reho-
spitalization and resulted in a trend toward lower
mortality and nonfatal reinfarction. The increased risk
of mortality associated with mild, moderate, and
severe CKD is evident across studies, and risks are
increased as the gradient of renal dysfunction worsens
(649–651,662).
See Online Data Supplement 29 for additional infor-
mation on CKD.
7.6.1. Antiplatelet Therapy
Patients with CKD with ACS are at increased risk for
ischemic complications, including stent thrombosis and
post–PCI ischemic events (663). They are also predisposed
to higher bleeding complications, which, in addition to
the lack of clinical trial data, result in their undertreat-
ment with antiplatelet therapy. Patients with advanced
CKD exhibit high residual platelet reactivity despite
treatment with clopidogrel independent of the presence
of diabetes mellitus (664). Hyporesponsiveness to thie-
nopyridines is associated with increased adverse cardio-
vascular outcomes, including cardiovascular mortality
(665), and higher dosing regimens of clopidogrel do not
appear to further suppress adenosine diphosphate-
induced platelet aggregation (664,666).
Although prasugrel may be more efﬁcient than
doubling the dose of clopidogrel in achieving adequate
platelet inhibition (667), no clinical studies have
demonstrated its efﬁcacy in patients with CKD with ACS.
Ticagrelor, however, was studied in a prespeciﬁed anal-
ysis from the PLATO trial (668). In patients with an
estimated GFR <60 mL per minute (nearly 21% of pa-
tients in PLATO with available central laboratory serum
creatinine levels), ticagrelor signiﬁcantly reduced the
primary cardiovascular endpoint (17.3% versus 22.0%;
HR: 0.77; 95% CI: 0.65 to 0.90) compared with clopi-
dogrel (667). Notably, this was associated with a 4% ab-
solute risk reduction in all-cause mortality favoring
ticagrelor and with no differences in major bleeding,
fatal bleeding, and non–CABG-related major bleeding
events, demonstrating its utility in patients with renal
insufﬁciency.7.7. Women: Recommendations
CLASS I
1. Women with NSTE-ACS should be managed with the same
pharmacological therapy as that for men for acute care and
for secondary prevention, with attention to weight and/or
renally calculated doses of antiplatelet and anticoagulant
agents to reduce bleeding risk (669–673). (Level of
Evidence: B)
2. Women with NSTE-ACS and high-risk features (e.g., troponin
positive) should undergo an early invasive strategy
(141,345,346,561). (Level of Evidence: A)
CLASS IIa
1. Myocardial revascularization is reasonable in pregnant
women with NSTE-ACS if an ischemia-guided strategy is
ineffective for management of life-threatening complica-
tions (674). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Women with NSTE-ACS and low-risk features (see Section
3.3.1) should not undergo early invasive treatment because
of the lack of beneﬁt (141,345,346) and the possibility of
harm (141). (Level of Evidence: B)
Women of all ages have higher rates of in-hospital and long-
term complications of NSTE-ACS than men, including
bleeding, HF, cardiogenic shock, acute renal failure, recur-
rent MI, stroke, and readmissions (670,675,676).
Women present later after symptom onset of NSTE-ACS
and have higher rates of inappropriate discharges from
the ED (671,677,678). Women more commonly report
atypical symptoms than men (675,679). Women present-
ing with chest pain are more likely than men to have
either a noncardiac cause or cardiac causes other than
obstructive epicardial coronary disease (108,677,680,681).
Women with NSTE-ACS with no apparent obstructive
epicardial disease have a 2% risk of death or MI within 30
days and require secondary prevention and symptom
management (682).
Women derive the same treatment beneﬁt as men from
aspirin, clopidogrel, anticoagulants, beta blockers, ACE
inhibitors, and statins (385,670–672,675,676,683,684).
Despite worse outcomes, women with NSTE-ACS are
underprescribed guideline-directed pharmacological
therapy, both during the acute illness and at discharge
(538,685,686). The basis for pharmacotherapy for women
with NSTE-ACS with abnormal biomarkers and/or func-
tional tests, but without signiﬁcant obstructive epicardial
disease, remains unclear (Section 7.13). In addition to risk
factor modiﬁcation, some studies support the beneﬁt of
imipramine, ranolazine, beta blockers, and/or ACE in-
hibitors to reduce adverse outcomes (687). Women with
NSTE-ACS incur a higher rate of bleeding complications
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been developed to attempt to reduce the bleeding risk in
women with NSTE-ACS (688).
The decision for an early invasive versus an
ischemia-guided strategy in women with NSTE-ACS is
based on a meta-analysis (366) and post hoc gender
analyses of clinical trials, including FRISC II, RITA-3,
and TACTICS-TIMI 18 (344,346,689). The Agency for
Healthcare Research and Quality analysis of an early
invasive versus ischemia-guided strategy (345) provides
further evidence that an early invasive strategy should
be reserved for women with positive troponins, as
shown in TACTICS-TIMI 18 (346). Such women had a
signiﬁcant reduction of death and MI at 1 year with an
early invasive versus ischemia-guided strategy. Women
with NSTE-ACS and no elevation in troponin who un-
derwent an early invasive strategy had a nonsigniﬁcant
increase in events, as did women with a low-risk TIMI
score (OR: 1.59 for early invasive versus ischemia-guided
strategy), prompting the Class III recommendation in
this CPG.
The NCDR-ACTION registry reported increased com-
plication rates of myocardial revascularization in women
(https://www.ncdr.com/webncdr/action/). Women also
have higher rates of contrast-induced nephropathy and
vascular complications (673,690,691). Despite having
fewer high-risk angiographic lesions, a higher percentage
of normal LV function, and up to 25% angiographically
normal coronary arteries, women with NSTE-ACS have a
paradoxically higher rate of persistent angina, rein-
farction, functional decline, and depression after PCI
(141,675,677,680,682). Clinical trials (692,693), and a
meta-analysis (694) of DES for NSTE-ACS reported no
gender differences in short- and long-term (up to 5
years) outcome, including target vessel revasculariza-
tion, MACE, cardiac death, or MI. However, women
were older and had more comorbidities than men at
enrollment.
Women with NSTE-ACS referred for CABG are older
with more comorbidities, which is reﬂected by higher
periprocedural mortality, HF, bleeding, MI, and renal
failure (686,695,696). Women required more periproce-
dural IABP, vasopressors, mechanical ventilation, dial-
ysis, and blood products and had longer stays in the
intensive care unit and hospital, higher rates of wound
infection, depression, and longer recovery (549,677).
An Agency for Healthcare Research and Quality meta-
analysis of 10 RCTs through December 2011 reported no
efﬁcacy or safety difference between PCI and CABG for
NSTE-ACS in men or women in 30-day or 1-year MACE
(death/MI/stroke). At 2 years, the procedural success
remained equal in women but favored CABG in men
(p¼0.002) (345,564). The Agency for Healthcare Research
and Quality reported similar outcomes in women withdiabetes mellitus with PCI and CABG for NSTE-ACS at
7 years, but men with diabetes mellitus had fewer events
with CABG. A prespeciﬁed gender analysis of the
FREEDOM trial favored CABG over PCI for women with
diabetes mellitus, although the difference was not as
signiﬁcant as it was for men (616).
Consistent with the European Society of Cardiology
recommendations, myocardial revascularization should be
reserved for pregnantwomenwithNSTE-ACSandvery serious
complications unresponsive to medical therapy (674).
See Online Data Supplement 30 for more information
on women.
7.8. Anemia, Bleeding, and Transfusion: Recommendations
CLASS I
1. All patients with NSTE-ACS should be evaluated for the risk
of bleeding. (Level of Evidence: C)
2. Anticoagulant and antiplatelet therapy should be weight-
based where appropriate and should be adjusted when
necessary for CKD to decrease the risk of bleeding in patients
with NSTE-ACS (522,697,698). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. A strategy of routine blood transfusion in hemodynamically
stable patients with NSTE-ACS and hemoglobin levels
greater than 8 g/dL is not recommended (699–703). (Level
of Evidence: B)
Anemia in patients with ACS is associated with an increased
risk for Holter monitordetected recurrent ischemia and for
MACE, with greater anemia correlating with greater risk
(704–708). In 1 large analysis of multiple studies, the risk of
adverse outcome was higher in patients with NSTE-ACS with
hemoglobin levels <11 g/dL (704). The potentially detri-
mental effects of severe anemia include decreased myocar-
dial oxygen delivery and increased MVO2 related to
maintenance of a higher cardiac output (704,709,710). Pa-
tients with anemia are less likely to be treated with aspirin,
and patients with ACS and anemia are likely to have more
bleeding complications with PCI (711). This has been corre-
lated with increased short-term risk of MACE outcomes,
including mortality; long-term risk remains controversial
(712–717). The ACUITY study suggests that the risk of mor-
tality associated with bleeding is at least as great as that
associated with procedure-related or spontaneous MI (718).
Major bleeding is a coprimary endpoint in many trials
and is a consideration when assessing the “net clinical
beneﬁt” of a new drug. A “universal deﬁnition of
bleeding” has been proposed to assist clinicians (547,719–
721). The incidence of major bleeding in patients with
ACS varies widely (0.4% to 10%) (715,722) owing to
differing deﬁnitions of major bleeding, patient pop-
ulations, anticoagulation regimens, and PCI or CABG.
Factors in patients with ACS related to an increased
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weight, history of prior bleeding and/or invasive
procedures, anemia, use of GP IIb/IIIa inhibitors or
thrombolytics, and CKD (522,711,713–715,722,723). Non–
weight-based dosing of anticoagulants and dosing of
antithrombin and antiplatelet medications that are not
adjusted for CKD are associated with an increased risk of
bleeding (522,697,698). Bleeding is related to adverse
outcomes because it may be a marker of underlying
disease, such as occult malignancy; leads to cessation of
antithrombin and antiplatelet therapy; may prompt
transfusion, which itself may have adverse effects;
can cause hypotension; and, if intracranial, can be fatal
(724). Proton pump inhibitors decrease the risk of upper
GI bleeding, including in patients treated with DAPT.
Proton pump inhibitors are used in patients with a his-
tory of prior GI bleeding who require DAPT and are an
option in patients at increased risk of GI bleeding
(26,430).
Evaluation of the risk of bleeding includes a focused
history of bleeding symptoms, identiﬁcation of pre-
disposing comorbidities, evaluation of laboratory data,
and calculation of a bleeding risk score (688,716,725).
Approximately 15% of all patients with NSTE-ACS and 3%
to 12% of those not undergoing CABG receive blood
transfusion (702). Rates vary widely and are closer to the
lower ﬁgure but increase in association with factors such
as coronary intervention, anticoagulant/antithrombotic
therapy, older age, female sex, anemia, renal insufﬁ-
ciency, and frailty. Tissue oxygenation does not change
or may actually decrease with transfusion (722). Blood
transfusion in patients with ACS is associated with an
increased risk of adverse outcome, including death
(702–704). A restrictive transfusion strategy leads to an
outcome that is at least as good, if not better, than a
liberal transfusion strategy (699,700). An analysis of a
large ACS registry found no beneﬁt from blood trans-
fusion in patients with a nadir hematocrit >24% (702). In
a meta-analysis of 10 studies of patients with AMI,
transfusion versus no transfusion was associated with an
increase in all-cause mortality (18.2% versus 10.2%;
p<0.001) and subsequent MI rate (RR: 2.0; 95% CI: 1.06 to
3.93; p¼0.03) (726). A restrictive approach to transfusion
generally consists of no routine transfusion for a hemo-
globin level >7 g/dL to 8 g/dL (699,700,727). A restrictive
approach to blood transfusion is advocated by the
American Association of Blood Banks (700) and the Eu-
ropean Society of Cardiology (727). On the basis of data
available at the time of publication, a strategy of routine
liberal blood transfusion in hemodynamically stable
patients with NSTE-ACS and mild to moderate anemia is
not recommended.
See Online Data Supplement 31 for more information
on anemia, bleeding, and transfusion.7.9. Thrombocytopenia
The incidence of thrombocytopenia in patients with ACS
varies from 1% to 13%. In 1 large prospective registry,
one third of patients treated with prolonged heparin
therapy developed some degree of thrombocytopenia
(728). Independent risk factors for the development of
thrombocytopenia include lower baseline platelet count,
older age, ACS, cardiac or vascular surgery, intravenous
UFH or both UFH and LMWH, duration of heparin therapy,
and low body mass index (728–730). The risk of throm-
bocytopenia is increased in patients treated with abcix-
imab and, to a lesser degree, with eptiﬁbatide or tiroﬁban
(731–734).
Thrombocytopenia on presentation or related to
antithrombotic therapy is associated with signiﬁcantly
increased risk of thrombotic events, MI, major bleeding,
and in-hospital mortality in patients with and without
ACS (728–731,735–739). The OR for development of these
endpoints with thrombocytopenia (compared to without
thrombocytopenia) is 2 to 8. Data from the CATCH
(Complications After Thrombocytopenia Caused by Hep-
arin) registry identiﬁed a platelet count nadir of 125 
109/L as a threshold, below which there is a linear
augmentation in probability of bleeding (740). Results
from CATCH highlighted that thrombocytopenia and
heparin-induced thrombocytopenia are often not diag-
nosed (728). Thrombocytopenia is generally a contrain-
dication for GP IIb/IIIa inhibitor therapy; direct thrombin
inhibitors are often considered in preference to UFH or
LMWH in patients with thrombocytopenia.
See Online Data Supplements 31 and 32 for additional
information on anemia, bleeding, and transfusion.7.10. Cocaine and Methamphetamine Users: Recommendations
CLASS I
1. Patients with NSTE-ACS and a recent history of cocaine or
methamphetamine use should be treated in the same manner
as patients without cocaine- or methamphetamine-related
NSTE-ACS. The only exception is in patients with signs of
acute intoxication (e.g., euphoria, tachycardia, and/or
hypertension) and beta-blocker use, unless patients are
receiving coronary vasodilator therapy. (Level of Evidence: C)
CLASS IIa
1. Benzodiazepines alone or in combination with nitroglycerin
are reasonable for management of hypertension and tachy-
cardia in patients with NSTE-ACS and signs of acute cocaine
or methamphetamine intoxication (741–744). (Level of
Evidence: C)
CLASS III: HARM
1. Beta blockers should not be administered to patients with
ACS with a recent history of cocaine or methamphetamine
yyProvocative testing during invasive coronary angiography (e.g., using ergo-
novine, acetylcholine, methylergonovine) is relatively safe, especially when
performed in a controlled manner by experienced operators. However, sus-
tained spasm, serious arrhythmias, and even death can also occur very infre-
quently. Therefore, provocative testing should be avoided in patients with
signiﬁcant left main disease, advanced 3-vessel disease, presence of high-grade
obstructive lesions, signiﬁcant valvular stenosis, signiﬁcant LV systolic
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risk of potentiating coronary spasm. (Level of Evidence: C)
Cocaine exerts multiple effects on the cardiovascular system,
which may precipitate ACS (48,744,745). Acute cocaine
exposure results in increased BP, heart rate, endothelial
dysfunction, and platelet aggregation, all of which may
precipitate ACS. Cocaine’s direct vasoconstrictor effect can
produce coronary vasospasm. Long-term use of cocaine re-
sults in progressive myocyte damage and accelerated
atherosclerosis (48,744,745).
ACS in patients with a history of cocaine use should be
treated in the same manner as patients without cocaine
use (744). The exception is in patients with ACS in the
presence of acute cocaine intoxication. Because cocaine
stimulates both alpha- and beta-adrenergic receptors,
administration of intravenous beta blockers may result in
unopposed alpha stimulation with worsening coronary
spasm (48,132,744–746). Evidence suggests it is safe to
administer intravenous beta blockers in patients with
chest pain and recent cocaine ingestion, although infor-
mation is lacking about the effects of beta-blocker
administration during the acute stages of cocaine intoxi-
cation (747,748). Intravenous beta blockers should be
avoided in patients with NSTE-ACS with signs of acute
cocaine intoxication (euphoria, tachycardia, and/or hy-
pertension). In these patients, benzodiazepines alone or
in combination with nitroglycerin have been useful for
management of hypertension and tachycardia owing to
their effects on the central and peripheral manifestations
of acute cocaine intoxication (741–744).
Methamphetamine abuse is becoming increasingly
common in the United States owing to the ease of
manufacturing and the lower cost of methamphetamines
compared with cocaine (131,749,750). Methamphetamines
may be ingested orally, inhaled, or used intravenously.
Methamphetamine affects the central nervous system by
simultaneously stimulating the release and blocking the
reuptake of dopamine and norepinephrine (751). Like
cocaine, methamphetamine exerts multiple effects on the
cardiovascular system, all of which may precipitate ACS
(131,750–752). The acute effects of methamphetamine are
euphoria, tachycardia, hypertension, and arrhythmias. MI
may result from coronary spasm or plaque rupture in the
presence of enhanced platelet aggregation. Long-term use
of methamphetamine has been associated with myocar-
ditis, necrotizing vasculitis, pulmonary hypertension, and
cardiomyopathy (750–752). Because methamphetamine
and cocaine have similar pathophysiological effects,
treatment of patients with ACS associated with metham-
phetamine and cocaine use should theoretically be
similar.
See Online Data Supplement 33 for additional infor-
mation about cocaine and methamphetamine users.7.11. Vasospastic (Prinzmetal) Angina: Recommendations
CLASS I
1. CCBs alone (753–757) or in combination with long-acting
nitrates (755,758) are useful to treat and reduce the fre-
quency of vasospastic angina. (Level of Evidence: B)
2. Treatment with HMG-CoA reductase inhibitor (759,760),
cessation of tobacco use (761,762), and additional athero-
sclerosis risk factor modiﬁcation (762,763) are useful in
patients with vasospastic angina. (Level of Evidence: B)
3. Coronary angiography (invasive or noninvasive) is recom-
mended in patients with episodic chest pain accompanied by
transient ST-elevation to rule out severe obstructive CAD.
(Level of Evidence: C)
CLASS IIb
1. Provocative testing during invasive coronary angiographyyy
may be considered in patients with suspected vasospastic
angina when clinical criteria and noninvasive testing fail to
establish the diagnosis (764–767). (Level of Evidence: B)
Vasospastic (Prinzmetal) angina chest pain typically occurs
without provocation, is associated with ST-elevation, and
usually resolves spontaneously or with rapid-acting nitro-
glycerin. Vasospastic angina may also be precipitated by
emotional stress, hyperventilation, exercise, or the cold. It
results from coronary vasomotor dysfunction leading to focal
spasm (768), which may occasionally be multifocal within a
single vessel and rarely involves >1 vessel. Vasospastic
angina occurs with normal coronary arteries, nonobstructive
CAD, and obstructive CAD, but prognosis is least favorable
with the latter. ST-elevation indicates transmural ischemia
and corresponds to the distribution of the involved artery
(769). A circadian variation is often present; most attacks
occur in the early morning (770,771). The most prominent
coronary risk factor is smoking. Most episodes resolve
without complications, but arrhythmias, syncope, MI, and
sudden death can occur (772).
Nonpharmacological provocative tests, such as cold
pressor and hyperventilation, have been used diagnosti-
cally; potent vasoconstrictors (e.g., acetylcholine) may
be useful when noninvasive assessment is uninforma-
tive (764–767). Smoking, which exacerbates coronary
vasospasm, should be proscribed, and CCBs are ﬁrst-line
therapies (642); long-acting nitrates are also effective
when combined with CCBs (755,758). Statins improvedysfunction, and advanced HF.
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vasospastic angina (759,760). Magnesium supplementa-
tion and alpha-receptor blockers may be effective and can
be added (755,758).
7.12. ACS With Angiographically Normal Coronary Arteries:
Recommendation
CLASS IIb
1. If coronary angiography reveals normal coronary arteries and
endothelial dysfunction is suspected, invasive physiological
assessment such as coronary ﬂow reserve measurement may
be considered (629,773–776). (Level of Evidence: B)
ACS associated with angiographically normal or non-
obstructive (<50% stenosis) coronary arteries (also referred
to as syndrome X) may be related to coronary endothelial
dysfunction (777); plaque rupture that may be evident only
with intracoronary ultrasound (778); coronary vasospasm
(779); and coronary artery dissection (780). Myocarditis may
present with electrocardiographic and biomarker ﬁndings
similar to ACS and can be distinguished by magnetic reso-
nance imaging (781–783). Intracoronary ultrasound and/or
optical coherence tomography to assess the extent of
atherosclerosis and exclude obstructive lesions may be
considered in patients with possible ACS and angiograph-
ically normal coronary arteries (778). If ECGs during chest
pain are not available and coronary spasm cannot be ruled
out, coronary angiography and provocative testing with
acetylcholine, adenosine, or methacholine and 24-hour
ambulatory ECG may be undertaken after a period of sta-
bilization. Endothelial dysfunction is more common in
women than in men (679,777,784–786), and chest pain is
typical or atypical (785,786). In the absence of a culprit
coronary lesion, prognosis of coronary endothelial
dysfunction and/or occult plaque rupture is favorable
(765,787).
Risk factor reduction and medical therapy with ni-
trates, beta blockers, and CCBs alone or in combination
are considered for endothelial dysfunction (788–790).
High doses of arginine have also been given (791). Imip-
ramine or aminophylline have been used in patients with
endothelial dysfunction for continued pain despite
optimal medical therapy. In postmenopausal women, es-
trogen reverses acetylcholine-induced coronary arterial
vasoconstriction, presumably by improving endothelium-
dependent coronary vasomotion, and reduces frequency
of chest pain (792). However, estrogen is not recom-
mended because of its demonstrated increase in cardio-
vascular and other risks (793).
Spontaneous coronary artery dissection affects a young,
predominantly female population. Treatment of sponta-
neous coronary artery dissection with CABG or stenting is
described to improve outcome (794), but high rates of
stenting complications are reported (780).7.13. Stress (Takotsubo) Cardiomyopathy: Recommendations
CLASS I
1. Stress (Takotsubo) cardiomyopathy should be considered in
patients who present with apparent ACS and nonobstructive
CAD at angiography. (Level of Evidence: C)
2. Imaging with ventriculography, echocardiography, or
magnetic resonance imaging should be performed to conﬁrm
or exclude the diagnosis of stress (Takotsubo) cardiomyop-
athy (795–798). (Level of Evidence: B)
3. Patients should be treated with conventional agents (ACE
inhibitors, beta blockers, aspirin, and diuretics) as otherwise
indicated if hemodynamically stable. (Level of Evidence: C)
4. Anticoagulation should be administered in patients who
develop LV thrombi. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to use catecholamines for patients with
symptomatic hypotension if outﬂow tract obstruction is not
present. (Level of Evidence: C)
2. The use of IABP is reasonable for patients with refractory
shock. (Level of Evidence: C)
3. It is reasonable to use beta blockers and alpha-adrenergic agents
in patients with outﬂow tract obstruction. (Level of Evidence: C)
CLASS IIb
1. Prophylactic anticoagulation may be considered to inhibit
the development of LV thrombi. (Level of Evidence: C)
Stress (Takotsubo) cardiomyopathy (also referred to as
transient LV apical ballooning or Takotsubo cardiomyopathy)
mimics NSTE or STEMI (799–803). There is no obstructive
CAD, and the distribution of electrocardiographic changes
and LV wall motion abnormalities usually includes >1 coro-
nary artery territory (801). Cardiac troponin elevations are
usually modest (798). The majority of cases occur in post-
menopausal women, and presentation is typically precipi-
tated by emotional or physical stress. Imaging by
echocardiography, ventriculography (696), or magnetic
resonance imaging (699) demonstrates characteristic hypo-
kinesis or dyskinesis of the LV apex with basilar increased
contractility. Variants include hypokinesis of the mid or base
of the left ventricle (795), and right ventricular involvement
is common (804). In the vast majority of patients, electro-
cardiographic and LV wall motion abnormalities normalize
within 1 to 4 weeks, and recurrences are uncommon (805).
The pathogenesis has been attributed to excess catechol-
amine release (803), coronary spasm, or small coronary
vessel hypoperfusion (806).
Care is predominantly supportive and includes beta
blockers, vasodilators, and catecholamines. The latter 2
interventions must be used cautiously, because they may
induce outﬂow tract obstruction (800). If shock is present,
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considered to prevent or treat LV thrombus (798).
7.14. Obesity
Obesity is associated with conditions such as dyslipide-
mia, diabetes mellitus, hypertension, arrhythmias, and
HF that adversely affect ACS outcomes. In the MADIT
(Multicenter Automatic Deﬁbrillator Implantation)-II
trial, there was an inverse relation between body mass
index and both all-cause mortality and sudden cardiac
death in patients with LV dysfunction after MI (807). In
the SYNERGY trial of 9,837 patients with NSTEMI, mor-
tality was lower in morbidly obese patients, consistent
with the “obesity paradox” (808). The “obesity paradox”
has not been clariﬁed and is under continuing investiga-
tion. Standard approaches to weight reduction in obese
patients are usually unsuccessful in producing large de-
creases in weight. A weight reduction study of obese and
morbidly obese patients following AMI resulted in weight
loss of only 0.5% in obese patients and 3.5% in morbidly
obese patients after 1 year (809). Two drugs, controlled-
release phentermine/topiramate (810) and lorcaserin
(811), are available for weight reduction but have not been
studied in patients following NSTE-ACS. Bariatric surgery
has been successful in reducing cardiovascular risk fac-
tors, including diabetes mellitus, hypertension, and dys-
lipidemia but has not been evaluated in post–ACS patients
(812). The 2013 obesity CPG provides comprehensive
strategies for weight reduction (16).
7.15. Patients Taking Antineoplastic/Immunosuppressive
Therapy
Antineoplastic or immunosuppressive therapy may con-
tribute to the development of NSTE-ACS. For example,
antineoplastic agents such as gemcitabine, sorafenib
sunitinib, and 5-ﬂuorouracil have been associated with
coronary artery spasm or stenosis (813,814). Trastuzumab
and possibly other anticancer drugs may alter biomarker
levels (815). Antineoplastic agents can induce changes in
the arterial wall (813), andmodulators of inﬂammationmay
promote atherogenesis (816). In patients receiving these
agents, it is prudent to communicate with the prescribing
clinician about the necessity of their continuation during
NSTE-ACS and future resumption.
8. QUALITY OF CARE AND OUTCOMES FOR
ACS—USE OF PERFORMANCE MEASURES
AND REGISTRIES
8.1. Use of Performance Measures and Registries:
Recommendation
CLASS IIa
1. Participation in a standardized quality-of-care data registry
designed to track and measure outcomes, complications, andperformance measures can be beneﬁcial in improving the
quality of NSTE-ACS care (817–825). (Level of Evidence: B)
The development of national systems for ACS is crucial
and includes the participation of key stakeholders to eval-
uate care using standardized performance and
quality-improvement measures for ACS (819,821). Standard-
ized quality-of-care data registries include the NCDR
RegistryGet With the Guidelines, the Get With the
Guidelines quality-improvement program, the Acute
Myocardial Infarction Core Measure Set, and performance
measures required by The Joint Commission and the Cen-
ters for Medicare and Medicaid Services (817,823–825). The
AHA has promoted its Mission: Lifeline initiative to
encourage cooperation among prehospital emergency
medical services personnel and cardiac care professionals
(817). The evaluation of ACS care delivery across traditional
boundaries can identify problems with systems and enable
application of modern quality-improvement methods
(818,820,822). On a local level, registries as part of the
Chronic Care Model were associated with improved out-
comes in chronic diseases, including cardiovascular disease
(826,827).
9. SUMMARY AND EVIDENCE GAPS
Despite landmark advances in the care of patients with
NSTE-ACS since the publication of the 2007 UA/NSTEMI
CPG (212), many emerging diagnostic and therapeutic
strategies have posed new challenges. There is general
acceptance of an early invasive strategy for patients with
NSTE-ACS in whom signiﬁcant coronary vascular
obstruction has been precisely quantiﬁed. Low-risk
patients with NSTE-ACS are documented to beneﬁt sub-
stantially from GDMT, but this is often suboptimally used.
Advances in noninvasive testing have the potential to
identify patients with NSTE-ACS who are at intermediate
risk and are candidates for invasive versus medical
therapy.
Newer, more potent antiplatelet agents in addition to
anticoagulant therapy are indicated irrespective of initial
treatment strategy. Evidence-based decisions will require
comparative-effectiveness studies of available and novel
agents. The paradox of newer and more potent antith-
rombotic and anticoagulant drugs that reduce major
adverse cardiac outcomes but increase bleeding risk
occurs with greater frequency in patients with AF.
Patients with AF who develop NSTE-ACS and receive a
coronary stent are the population at risk from triple
anticoagulant/antiplatelet therapy. This regimen has
been reported to be safely modiﬁed by elimination of
aspirin, a ﬁnding that requires conﬁrmation.
Among the most rapidly evolving areas in NSTE-ACS
diagnosis is the use of cardiac troponin, the preferred
biomarker of myocardial necrosis. Although a truly
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United States at the time this CPG was prepared, the
sensitivity of contemporary assays continues to increase.
This change is accompanied by higher rates of elevated
cardiac troponin unrelated to coronary plaque rupture.
The diagnostic quandary posed by these ﬁndings neces-
sitates investigation to elucidate the optimal utility of this
advanced biomarker. A promising approach to improve
the diagnostic accuracy for detecting myocardial necrosis
is measurement of absolute cardiac troponin change,
which may be more accurate than the traditional analysis
of relative alterations.
Special populations are addressed in this CPG, the most
numerous of which are older persons and women. More
than half of the mortality in NSTE-ACS occurs in older
patients, and this high-risk cohort will increase as our
population ages. An unmet need is to more clearly
distinguish which older patients are candidates for an
ischemia-guided strategy compared with an early inva-
sive management strategy. An appreciable number of
patients with NSTE-ACS have angiographically normal or
nonobstructive CAD, a group in which women predomi-
nate. Their prognosis is not benign, and the multiple
mechanisms of ACS postulated for these patients remain
largely speculative. Clinical advances are predicated on
clariﬁcation of the pathophysiology of this challenging
syndrome.
A fundamental aspect of all CPGs is that these carefully
developed, evidence-based documents cannot encompass
all clinical circumstances, nor can they replace the judg-
ment of individual physicians in management of eachpatient. The science of medicine is rooted in evidence,
and the art of medicine is based on the application of this
evidence to the individual patient. This CPG has adhered
to these principles for optimal management of patients
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e224APPENDIX 3. ABBREVIATIONSAC
AC
AF
AM
BP
CA
CA
CK
CK
CO
CP
CrC
CT
DA
DE
EC
ED
GD
GP
GF
GW
HF
IAB
IV
LM
LV
LV
MA
MI
MV
NS
NS
NS
PC
RC
SC
ST
UA
UF
VF
VTE ¼ angiotensin-converting enzyme
S ¼ acute coronary syndrome
¼ atrial ﬁbrillation
I ¼ acute myocardial infarction
¼ blood pressure
BG ¼ coronary artery bypass graft
D ¼ coronary artery disease
D ¼ chronic kidney disease
-MB ¼ creatine kinase myocardial isoenzyme
X ¼ cyclooxygenase
G ¼ clinical practice guideline
l ¼ creatinine clearance
¼ computed tomography
PT ¼ dual antiplatelet therapy
S ¼ drug-eluting stent
G ¼ electrocardiogram
¼ emergency department
MT ¼ guideline-directed medical therapy
¼ glycoprotein
R ¼ glomerular ﬁltration rate
C ¼ guideline writing committee¼ heart failure
P ¼ intra-aortic balloon pump
¼ intravenous
WH ¼ low-molecular-weight heparin
¼ left ventricular
EF ¼ left ventricular ejection fraction
CE ¼ major adverse cardiac event
¼ myocardial infarction
O2 ¼ myocardial oxygen consumption
AID ¼ nonsteroidal anti-inﬂammatory drug
TE-ACS ¼ non–ST-elevation acute coronary syndromes
TEMI ¼ non–ST-elevation myocardial infarction
I ¼ percutaneous coronary intervention
T ¼ randomized controlled trial
¼ subcutaneous
EMI ¼ ST-elevation myocardial infarction
¼ unstable angina
H ¼ unfractionated heparin
¼ ventricular ﬁbrillation
¼ ventricular tachycardia
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e225APPENDIX 4. ADDITIONAL TABLESTABLE A Universal Classiﬁcation of MI
Type 1: Spontaneous MI
Spontaneous MI related to atherosclerotic plaque rupture, ulceration, ﬁssuring, erosion, or dissection with resulting intraluminal thrombus in $1 of the coronary arteries
leading to decreased myocardial blood ﬂow or distal platelet emboli with ensuing myocyte necrosis. The patient may have underlying severe CAD, but on occasion
nonobstructive or no CAD.
Type 2: MI secondary to ischemic imbalance
In instances of myocardial injury with necrosis where a condition other than CAD contributes to an imbalance between MVO2, e.g., coronary endothelial dysfunction,
coronary artery spasm, coronary embolism, tachy-/bradyarrhythmias, anemia, respiratory failure, hypotension, and hypertension with or without LVH.
Type 3: MI resulting in death when biomarker values are unavailable
Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic electrocardiographic changes or new LBBB, but death occurred before
blood samples could be obtained, before cardiac biomarker could rise, or in rare cases where blood was not collected for cardiac biomarker testing.
Type 4a: MI related to PCI
MI associated with PCI is arbitrarily deﬁned by elevation of cTn values >5  99th percentile URL in patients with normal baseline values (<99th percentile URL) or a rise
of cTn values >20% if baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischemia, (ii) new ischemic
electrocardiographic changes or new LBBB, (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow or no ﬂow or embolization,
or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality is required.
Type 4b: MI related to stent thrombosis
MI associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarker
values with $1 value above the 99th percentile URL.
Type 5: MI related to CABG
MI associated with CABG is arbitrarily deﬁned by elevation of cardiac biomarker values >10  99th percentile URL in patients with normal baseline cTn values (<99th
percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographically documented new graft or new native coronary artery occlusion,
or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; cTn, cardiac troponin; LBBB, left bundle-branch block; LVH, left ventricular hypertrophy; MI, myocardial
infarction; MVO2, myocardial oxygen consumption; PCI, percutaneous coronary intervention; and URL, upper reference limit.
Modiﬁed from Thygesen et al. (21).
TABLE B Pharmacological Therapy in Older Patients With NSTE-ACS
Age-Related
Pharmacological Change Clinical Effect
Dose-Adjustment
Recommendations Additional Precautions
General
principles
 YIn renal function (CrCl*):
drug clearance, water/
electrolyte balance
 SCr unreliable measure of
renal function in older
adults
 Change in body
composition
 [Fat, Ylean body mass/
total water
 YGI absorption
 [Levels renally cleared
drug
 Risk high/low electrolyte
levels
 [Levels hydrophilic agents
 YLevels lipophilic agents
 Longer time to reach
steady-state lipophilic
agents
 Calculate CrCl in all pts—renal-
dose accordingly
 Start at lowest recommended
dose, titrate up slowly
 Avoid interacting drugs
 Consider Ydoses in women,
malnourished, hypovolemic
 Caution fall risk with YBP
agents and diuretics
 Monitor for ADR, especially
delirium
 Frequent monitoring of renal
function/electrolytes
 Minimize polypharmacy—watch
for drug-drug interactions
ASA Hydrophilic; levels [with Ytotal
body water; age-related
[plasma concentration for
similar dose
[Bleeding risk with [age,
dehydration, frailty, diuretics
 Maintenance¼81 mg/d (lowest
possible dose)
[Bleeding with NSAIDs, other AP,
AC, AT; [risk peptic ulcer with
NSAIDs
Nitrates [Sensitivity [Hypotensive response with
Ybaroreceptor response
Lowest dose possible, especially if
hypovolemic
[Risk OH, syncope, falls
ACE inhibitors YFirst-pass metabolism (some)
with Yeffect; enalapril
[effect
May have Yeffect May need [dose [Risk AKI and [Kþ and Yeffect with
NSAIDs; avoid K-sparing diuretics
ARBs No signiﬁcant age-related
changes
No age-related clinical changes None [Risk AKI and [Kþ and Yeffect with
NSAIDs; avoid K-sparing diuretics
Alpha blockers [Sensitivity; YBP with
Ybaroreceptor response
YBP; OH Avoid when possible [Risk OH, falls, syncope, especially
with loop diuretics
Continued on the next page
TABLE B Continued
Age-Related
Pharmacological Change Clinical Effect
Dose-Adjustment
Recommendations Additional Precautions
Beta blockers YMyocardial sensitivity
(Ypostreceptor signaling),
[conduction system
sensitivity
Bradycardia/heart block; YBP
effect vs. younger pts
May need [dose with age Caution conduction system blocks
CCBs
 DHPs
(amlodipine;
nifedipine)
Lipophilic; Yhepatic and overall
clearance; [fat storage;
[sinus node sensitivity;
Ybaroreceptor response to
YBP
YBP more than non–DHP and
with [age; edema
hypotension, bradycardia
Initiate low dose, titrate cautiously Inhibits clopidogrel; [risk OH, falls,
syncope; most potent YBP ﬁrst 3
mo, then less
 Non-DHP
(verapamil;
diltiazem)
YHepatic and overall clearance;
less PR prolongation than
DHP and with [age;
negative inotropy; [SA node
sensitivity and YHR than
DHP and with [age; YAV
conduction with [age;
Ybaroreceptor response to
YBP
YBP more with [age; edema;
[heart block; hypotension;
[bradycardia and
bradyarrhythmias with [age
Initiate low dose, titrate cautiously [Risk OH, falls, syncope; consider
rhythm monitoring
Diuretics YDiuretic/natriuretic response,
YEC space, [drug
concentration if YGFR;
Ybaroreceptor response to
volume shifts
[Sensitivity; [hypotension; risk
hypokalemia/
hypomagnesemia/
hyponatremia; Ydiuretic effect
with YGFR; risk
hypovolemia- Ythirst
May need [doses if YGFR; may need
[dose if cotreating with NSAIDs
 Monitor Naþ, Kþ, Mg2þ levels;
[risk OH/falls;
 With NSAIDs: Ynatriuretic and
diuretic effect, [Kþ, YMg2þ
Heparins
 UFH Hydrophilic; [concentration,
especially if Ylean body
mass or Yplasma proteins;
[levels with [age
[Bleeding risk with age; more
potent anticoagulation per
dose with [age; weight-
based dosing but with
precautions for shift in body
composition
Weight-based 60 U/kg loading
dose þ 12 U/kg/h INF. Suggested
max loading dose: 400 U and
900 U/h INF or 5,000 U loading
dose/1,000 U/h if pt weight
>100 kg
[Bleeding with ASA; [bleeding risk
with other AP, AT, and GP IIb/
IIIa; vigilantly monitor aPTT
 LMWH Cleared renally; more
predictable dose response
than UFH; not dependent on
plasma protein levels;
[levels with Ylean body
mass; [effect with [age
[Bleeding risk with age and
weight and renally dosed
Enoxaparin: Weight-based 1 mg/kg
SC q 12 h; CrCl* <30 mL/min—
avoid or 1 mg/kg SC q 24 h; CrCl
30–60 mL/min: Y75%;
Dalteparin: Use caution in older pts
with low body weight or renal
insufﬁciency
 [Bleed with ASA
 Monitor anti-Xa; [bleeding
with GP IIb/IIIa with [age
Direct Thrombin Inhibitors
 Bivalirudin Cleared renally; more
predictable dose response;
not dependent on plasma
protein levels
Signiﬁcantly less bleeding in
older pts, even with renal
dysfunction vs. UFH þ GP
IIb/IIIa with similar efﬁcacy
CrCl <30 mL/min: 1 mg/kg/h; CrCl:
30 to 60 mL/min—less bleeding
than UFH
Less bleeding than GP IIb/IIIa
inhibitor þ heparin
 Fondaparinux Cleared renally Renal/weight adjust; less
bleeding but similar efﬁcacy
vs. enoxaparin in older pts
with NSTE-ACS, even with
mild to moderate renal
dysfunction
Renal adjustment: CrCl <30—
contraindicated; CrCl 30 to 60—
preferred over enoxaparin
YBleeding vs. enoxaparin; good
safety proﬁle vs. UFH/LMWH
P2Y12 Inhibitors
 Clopidogrel Lipophilic; [HPR; [metabolism;
[fat distribution; [to steady
state ([fat distribution/T1/2)
YAntiplatelet effect in some
older pts
Maintenance: 75 mg (no [response
to higher dose)
YEffect with proton pump inhibitors;
if HPR—may respond to prasugrel
or ticagrelor
 Prasugrel [19% Active metabolite >75 y
of age
[Bleeding risk Avoid in pts $75 y of age or if
weight #60 kg; 10 mg in very
high-risk pts
N/A
 Ticagrelor None known N/A None Reversible
GP IIb/IIIa Inhibitors
 Abciximab N/A  [Bleeding with [age
 [Bleeding risk without
clinical beneﬁt
Not recommended N/A
Continued on the next page
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TABLE B Continued
Age-Related
Pharmacological Change Clinical Effect
Dose-Adjustment
Recommendations Additional Precautions
 Eptiﬁbatide Weight/renally dosed [Bleeding risk Weight-based: 180 mcg/kg loading
dose þ 2 mcg/kg/min INF;
CrCl #50 mL/min: 1.0 mcg/kg/
min INF
Less beneﬁt/more bleeding with
[age
 Tiroﬁban Weight/renally dosed [Bleeding risk Weight-based: 12 mcg/kg loading
dose þ 0.14 mcg/kg/min INF;
CrCl <30 mL/min: 6 mcg/kg
loading dose þ 0.05 mcg/kg/min
INF
In older pts with high bleeding risk,
low-dose INF effective with
Ybleeding
Warfarin [Sensitivity; Y20%–40%
clearance; protein binding;
[inhibition vitamin K-
dependent clotting factors
at same plasma levels with
[age
[Bleeding risk at lower INR;
higher INR/dose with [age;
[risk GI bleeding
 Loading: 4 mg/d  4 d
 Maintain mean dose Y0.4 mg/
w/y of age
Multiple drug interactions,
[frequency of monitoring; ASA
potentiates effect
New Oral AC† N/A N/A Contraindicated if CrCl <15 mL/min If pt taking when admitted, stop—
consider delaying angiogram/PCI
until effect wanes, switch to
UFH/dalteparin/bivalirudin/
fondaparinux; AP and DAPT
[bleeding 2 post-ACS—
consider BMS and radial access.
Avoid GP IIb/IIIa inhibitor if
possible; [thrombotic risk
following discontinuation.
 Rivaroxaban 35% cleared renally; 65%
hepatic (CYP3A4); [levels in
hepatic and/or renal
dysfunction and [age
[Bleeding risk; not reversible CrCl 15–49 mL/min: 15 mg QD;
consider avoiding if CrCl 15–30
mL/min if [bleeding risk; CrCl
>50 mL/min: 20 mg QD
Some drug interactions
 Dabigatran 80% cleared renally; [plasma
level with [age,
especially $75 y
[Bleeding risk; not reversible CrCl 15–30 mL/min: 75 mg BID with
caution; CrCl 30–49 mL/min: 75
mg BID; CrCl >50 mL/min: 150
mg BID
Monitor pt and renal function
frequently; longest for effect to
wane with YCrCl; [risk
dyspepsia, GI bleeding
 Apixaban Hepatically cleared (minor
CYP3A4); dose adjust if
weight #60 kg; highly
protein bound
[Bleeding risk; not reversible CrCl 15–29 mL/min: 2.5 mg BID or
with 2 of the following: age $80
y/weight #60 kg/SCr $1.5 mg/
dL: SCr <1.5: 5 mg BID
[Risk abnormal liver function tests
*CrCl should be calculated for all older pts because SCr level does not accurately reﬂect renal dysfunction: CrCl decreases with age 0.7 mL/min/y.
†These agents are not approved for NSTE-ACS but are included for management of pts with nonvalvular chronic atrial ﬁbrillation.
AC indicates anticoagulants; ACE, angiotensin-converting-enzyme; ACS, acute coronary syndromes; ADR, adverse drug reactions; AKI, acute kidney injury; AP, antiplatelets; aPTT,
activated partial thromboplastin time; ARB, angiotensin receptor blocker; ASA, aspirin; AT, antithrombins; AV, atrioventricular; BID, twice daily; BMS, bare-metal stent; BP, blood
pressure; CCBs, calcium channel blockers; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; DHP, dihydropyridine; EC, extracellular; GFR, glomerular ﬁltration rate; GI,
gastrointestinal; GP, glycoprotein; HPR, high platelet reactivity; HR, heart rate; INF, infusion; INR, international normalized ratio; Kþ, potassium; LMWH, low-molecular-weight heparin;
max, maximum; Mg, magnesium; N/A, not available; NSAIDs, nonsteroidal anti-inﬂammatory drugs; NSTE-ACS, non–ST-elevation acute coronary syndromes; OH, orthostatic hypo-
tension; PCI, percutaneous coronary intervention; pts, patients; QD; once daily; SA, sinoatrial; SC, subcutaneous; SCr, serum creatinine; T1/2, half-life; and UFH, unfractionated heparin.
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TABLE C Age-Related Physiological Changes: Clinical Impact in Older Patients With NSTE-ACS
Age-Related Change Clinical Alteration Clinical Impact in NSTE-ACS
[Central arterial stiffness [SBP/YDBP; [LVH; Ydiastolic function; Ycoronary perfusion
pressure; Yischemia/infarct threshold for tachycardia/
hypertension with and without coronary obstructive
disease; [PA pressure
[Risk end-organ damage (cerebrovascular accident, AKI);
[BP lability; [reinfarction/ischemia; orthostatic hypotension;
[HF; [pulmonary edema
LV diastolic function [LA size; Yearly passive LV ﬁlling; [late LV ﬁlling and
[LV EDP; [PA pressure
[Risk AF; ([pulmonary edema/YCO), [DOE; [pulmonary edema
with [HR/[BP
YResponse to beta-
adrenergic stimulation
YHR/Yinotropic responsiveness to stress; resting systolic LV
function unchanged with age
Hypotension, HF, YHR response
Conduction system changes YSinus node cells; YAV conduction; [LBBB; and [RBBB Difﬁcult to interpret electrocardiographic MI/ischemia; [heart
block; SSS; [SVT, [sensitivity to conduction system drugs
YVolume regulating
hormones
YNa, K, and water regulation—BP lability Altered electrolytes, [sensitivity to ﬂuid therapy/diuretics
Renal changes YGFR (0.8 mL/min/y), YNa/K clearance, normal serum
creatinine despite moderate to severe CKD, altered drug
clearance; Yurine concentrating ability
CrCl or eGFR must be calculated for drug dosing, [sensitivity
to contrast nephropathy, [risk AKI
Fat-muscle redistribution [Third spacing of ﬂuid, may alter drug storage; YVO2max May alter ﬂuid/drug dosing, decreased CO; DOE; early fatigability
YBaroreceptor sensitivity [BP lability Orthostatic hypotension, fall risk
Clotting factor/platelet
function/hemostasis
[Bleeding and clotting risk, [sensitivity to anticoagulants/
antithrombins
[Risk cerebrovascular accident/reinfarction/recurrent ischemia,
bleeding, thrombosis, PE, DVT; may alter drug dosing/
sensitivity;[stent thrombosis
AF indicates atrial ﬁbrillation; AKI, acute kidney injury; AV, atrioventricular; BP, blood pressure; CKD, chronic kidney disease; CO, cardiac output; CrCl, creatinine clearance; DBP,
diastolic blood pressure; DOE, dyspnea on exertion; DVT, deep vein thrombosis; EDP, end-diastolic pressure; eGFR, estimated glomerular ﬁltration rate; GFR, glomerular ﬁltration rate;
HF, heart failure; HR, heart rate; K, potassium; LA, left atrium; LBBB, left bundle-branch block; LV, left ventricular; LVH, left ventricular hypertrophy; MI, myocardial infarction; NA,
nary syndrome; PA, pulmonary artery; PE, pulmonary embolism; RBBB, right bundle-branch
ycardia; and VO2 max, maximum oxygen consumption.
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block, SBP, systolic blood pressure; SSS, sick sinus syndrome; SVT, supraventricular tachTABLE D FREEDOM Trial: Key Outcomes at 2 Years and 5 Years After Randomization
Outcome
2 y 5 y
p Value*
PCI CABG PCI CABG
Number (%)
Primary composite† 121 (13.0) 108 (11.9) 200 (26.6) 146 (18.7) 0.005‡
Death from any cause 62 (6.7) 57 (6.3) 114 (16.3) 83 (10.9) 0.049
MI 62 (6.7) 42 (4.7) 98 (13.9) 48 (6.0) <0.001
Stroke 14 (1.5) 24 (2.7) 20 (2.4) 37 (5.2) 0.03§
Cardiovascular death 9 (0.9) 12 (1.3) 73 (10.9) 52 (6.8) 0.12
*P values were calculated with the log-rank test on the basis of all available follow-up data (i.e., >5 y).
†The primary composite outcome was rate of death from any cause, MI, or stroke.
‡p¼0.006 in the as-treated (non–intention-to-treat) analysis.
§p¼0.16 by the Wald test of the Cox regression estimate for study-group assignment in 1,712 patients after adjustment for average glucose level after procedure.
CABG indicates coronary artery bypass graft; FREEDOM, Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease; MI,
myocardial infarction; and PCI, percutaneous coronary intervention.
Modiﬁed with permission from Farkouh et al. (616).
